✓ Produto localizado
Farmácia
GENÉRICO
Farmácia
Sinvastatina 20 Mg 30 Comprimidos Medley Genérico
GENÉRICO
- GTIN / EAN
- 7896422507844
- NCM
- 30039079
- CEST
- Não informado
- Conteúdo
- Unidade
Dados de produto preservados no idioma original.
Sinvastatina 20 Mg 30 Comprimidos Medley Genérico é fabricado pela GENÉRICO, na categoria Farmácia, com código de barras 7896422507844. Classificado no NCM 30039079 (Outros).
Fonte: SI5 Global · código registrado em Brasil
Classificação fiscal
- NCM
- 30039079Outros
Embalagem
- Tipo
- Unidade
Ficha técnica
- Medicamento
- True
- MarcaPropria
- Não
- NumeroRegistroMS
- 1.8326.0082.007-0
- DescricaoBula
- %0A%3Ch2%3ELaborat%26%23xF3%3Brio%3C%2Fh2%3E%0A%3Cp%3ESun%20Pharmaceutical%20Ind.%20Ltd.%3C%2Fp%3E%0A%3Ch2%3EApresenta%26%23xE7%3B%26%23xE3%3Bo%20SINVASTATINA%3C%2Fh2%3E%0A%3Cp%3ESinvastatina%2020%20e%2040%20mg%20%26%23x2013%3B%20embalagens%20com%2030%2C%20500*%20ou%201000*%20comprimidos%20revestidos.%3Cbr%3E%0A*Embalagens%20hospitalares.%3C%2Fp%3E%0A%3Ch2%3ESINVASTATINA%20%26%23x2013%3B%20Indica%26%23xE7%3B%26%23xF5%3Bes%3C%2Fh2%3E%0A%3Cp%3EPacientes%20sob%20alto%20risco%20de%20doen%26%23xE7%3Ba%20coronariana%20ou%20com%20doen%26%23xE7%3Ba%20coronariana%20(DAC)%3Cbr%3E%0AEm%20pacientes%20sob%20alto%20risco%20de%20doen%26%23xE7%3Ba%20coronariana%20(com%20ou%20sem%20hiperlipidemia)%2C%20isto%20%26%23xE9%3B%2C%20pacientes%20com%20diabetes%2C%20hist%26%23xF3%3Brico%20de%20acidente%20vascular%20cerebral%20(AVC)%20ou%20de%20outra%20doen%26%23xE7%3Ba%20vascular%20cerebral%2C%20de%20doen%26%23xE7%3Ba%20vascular%20perif%26%23xE9%3Brica%20ou%20com%20doen%26%23xE7%3Ba%20coronariana%2C%20a%20sinvastatina%20%26%23xE9%3B%20indicada%20para%3A%3Cbr%3E%0A-reduzir%20o%20risco%20de%20mortalidade%20total%20(por%20todas%20as%20causas)%20por%20meio%20da%20redu%26%23xE7%3B%26%23xE3%3Bo%20de%20mortes%20por%20doen%26%23xE7%3Ba%20coronariana%3B%3Cbr%3E%0A-reduzir%20o%20risco%20dos%20eventos%20vasculares%20maiores%20(um%20composto%20de%20infarto%20do%20mioc%26%23xE1%3Brdio%20n%26%23xE3%3Bo%20fatal%2C%20morte%20por%20doen%26%23xE7%3Ba%20coronariana%2C%20AVC%20ou%20procedimentos%20de%20revasculariza%26%23xE7%3B%26%23xE3%3Bo)%3B%3Cbr%3E%0A-reduzir%20o%20risco%20dos%20eventos%20coronarianos%20maiores%20(um%20composto%20de%20infarto%20do%20mioc%26%23xE1%3Brdio%20n%26%23xE3%3Bo%20fatal%20ou%20mortes%20por%20doen%26%23xE7%3Ba%20coronariana)%3B%3Cbr%3E%0A-reduzir%20o%20risco%20de%20acidente%20vascular%20cerebral%3B%3Cbr%3E%0A-reduzir%20a%20necessidade%20de%20procedimentos%20de%20revasculariza%26%23xE7%3B%26%23xE3%3Bo%20do%20mioc%26%23xE1%3Brdio%20(incluindo%20bypass%20ou%20angioplastia%20coronariana%20transluminal%20percut%26%23xE2%3Bnea)%3B%3Cbr%3E%0A-reduzir%20a%20necessidade%20de%20procedimentos%20de%20revasculariza%26%23xE7%3B%26%23xE3%3Bo%20perif%26%23xE9%3Brica%20e%20outros%2C%20n%26%23xE3%3Bo%20coronarianos%3B%3Cbr%3E%0A-reduzir%20o%20risco%20de%20hospitaliza%26%23xE7%3B%26%23xE3%3Bo%20por%20angina.%3Cbr%3E%0AEm%20pacientes%20com%20diabetes%2C%20sinvastatina%20reduz%20o%20risco%20de%20desenvolvimento%20de%20complica%26%23xE7%3B%26%23xF5%3Bes%20perif%26%23xE9%3Bricas%20macrovasculares%20(um%20composto%20de%20procedimentos%20de%20revasculariza%26%23xE7%3B%26%23xE3%3Bo%20perif%26%23xE9%3Brica%2C%20de%20amputa%26%23xE7%3B%26%23xF5%3Bes%20dos%20membros%20inferiores%20ou%20de%20%26%23xFA%3Blceras%20das%20pernas).%3Cbr%3E%0AEm%20pacientes%20hipercolesterol%26%23xEA%3Bmicos%20com%20doen%26%23xE7%3Ba%20coronariana%2C%20a%20sinvastatina%20retarda%20a%20progress%26%23xE3%3Bo%20da%20aterosclerose%20coronariana%2C%20reduzindo%20inclusive%20o%20desenvolvimento%20de%20novas%20les%26%23xF5%3Bes%20e%20novas%20oclus%26%23xF5%3Bes%20totais.%3C%2Fp%3E%0A%3Cp%3EPacientes%20com%20hiperlipidemia%3Cbr%3E%0A-A%20sinvastatina%20%26%23xE9%3B%20indicada%20como%20adjuvante%20%26%23xE0%3B%20dieta%20para%20reduzir%20os%20n%26%23xED%3Bveis%20elevados%20de%20colesterol%20total%2C%20LDL-colesterol%2Capolipoprote%26%23xED%3Bna%20B%20(apo%20B)%20e%20triglic%26%23xE9%3Brides%20e%20para%20aumentar%20os%20n%26%23xED%3Bveis%20de%20HDL-colesterol%20em%20pacientes%20com%20hipercolesterolemia%20prim%26%23xE1%3Bria%2C%20incluindo%20hipercolesterolemia%20familiar%20heterozig%26%23xF3%3Btica%20(tipo%20IIa%20de%20Fredrickson)%20ou%20hiperlipidemia%20combinada%20(mista)%20(tipo%20IIb%20de%20Fredrickson)%2C%20quando%20a%20resposta%20%26%23xE0%3B%20dieta%20e%20outras%20medidas%20n%26%23xE3%3Bo%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Cp%3ESinvastatina%2020%20mg%20e%2040%20mg%3Cbr%3E%0Afarmacol%26%23xF3%3Bgicas%20for%20inadequada.%20A%20sinvastatina%2C%20portanto%2C%20reduz%20as%20raz%26%23xF5%3Bes%20LDL-colesterol%2FHDL-colesterol%20e%20colesterol%20total%2FHDL-colesterol%3B%3Cbr%3E%0A-A%20sinvastatina%20%26%23xE9%3B%20indicada%20para%20o%20tratamento%20de%20pacientes%20com%20hipertrigliceridemia%20(hiperlipidemia%20tipo%20IV%20de%20Fredrickson)%3B%3Cbr%3E%0A-A%20sinvastatina%20%26%23xE9%3B%20indicada%20para%20o%20tratamento%20de%20pacientes%20com%20disbetalipoproteinemia%20prim%26%23xE1%3Bria%20(hiperlipidemia%20tipo%20III%20de%20Fredrickson)%3B%3Cbr%3E%0A-A%20sinvastatina%20tamb%26%23xE9%3Bm%20%26%23xE9%3B%20indicada%20como%20adjuvante%20%26%23xE0%3B%20dieta%20e%20outras%20medidas%20n%26%23xE3%3Bo%20diet%26%23xE9%3Bticas%20para%20reduzir%20os%20n%26%23xED%3Bveis%20elevados%20de%20colesterol%20total%2C%20LDL-colesterol%20e%20apolipoprote%26%23xED%3Bna%20B%20em%20pacientes%20com%20hipercolesterolemia%20(HoFH)%20familiar%20homozig%26%23xF3%3Btica.%3C%2Fp%3E%0A%3Ch2%3EContra%20indica%26%23xE7%3B%26%23xF5%3Bes%20de%20SINVASTATINA%3C%2Fh2%3E%0A%3Cp%3E-Hipersensibilidade%20a%20qualquer%20componente%20do%20produto%3B%3Cbr%3E%0A-Doen%26%23xE7%3Ba%20hep%26%23xE1%3Btica%20ativa%20ou%20aumentos%20persistentes%20e%20inexplicados%20das%20transaminases%20s%26%23xE9%3Bricas%3B%3C%2Fp%3E%0A%3Cp%3E-Gravidez%20e%20lacta%26%23xE7%3B%26%23xE3%3Bo%20(veja%20o%20item%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Gravidez%20e%20lacta%26%23xE7%3B%26%23xE3%3Bo)%3B%3Cbr%3E%0A-Administra%26%23xE7%3B%26%23xE3%3Bo%20concomitante%20de%20inibidores%20potentes%20do%20CYP3A4%20(por%20exemplo%2C%20itraconazol%2C%20cetoconazol%2C%20posaconazol%2C%20voriconazol%2C%20inibidores%20da%20protease%20do%20HIV%2C%20boceprevir%2C%20telaprevir%2C%20eritromicina%2C%20claritromicina%2C%20telitromicina%2C%20nefazodona%20e%20medicamentos%20contendo%20cobicistate)%20(veja%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise%20e%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS)%3B%3C%2Fp%3E%0A%3Cp%3ESinvastatina%2020%20mg%20e%2040%20mg%3Cbr%3E%0A-Administra%26%23xE7%3B%26%23xE3%3Bo%20concomitante%20de%20genfibrozila%2C%20ciclosporina%20ou%20danazol%20(veja%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise%20e%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS).%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Cp%3EAten%26%23xE7%3B%26%23xE3%3Bo%20diab%26%23xE9%3Bticos%3A%20cont%26%23xE9%3Bm%20a%26%23xE7%3B%26%23xFA%3Bcar%20(lactose%20e%20amido).%3Cbr%3E%0AEste%20medicamento%20deve%20ser%20utilizado%20com%20cautela%20por%20pacientes%20com%20intoler%26%23xE2%3Bncia%20%26%23xE0%3B%20lactose.%20Este%20medicamento%20%26%23xE9%3B%20contraindicado%20para%20uso%20por%20mulheres%20gr%26%23xE1%3Bvidas%20ou%20amamentando.%3C%2Fp%3E%0A%3Cp%3EEste%20medicamento%20n%26%23xE3%3Bo%20deve%20ser%20utilizado%20por%20mulheres%20gr%26%23xE1%3Bvidas%20ou%20que%20possam%20ficar%20gr%26%23xE1%3Bvidas%20durante%20o%20tratamento.%3C%2Fp%3E%0A%3Ch2%3EAdvert%26%23xEA%3Bncias%3C%2Fh2%3E%0A%3Cp%3EMiopatia%2FRabdomi%26%23xF3%3Blise%3A%20a%20sinvastatina%2C%20a%20exemplo%20de%20outros%20inibidores%20da%20HMG-CoA%20redutase%2C%20ocasionalmente%20causa%20miopatia%20que%20se%20manifesta%20como%20dor%2C%20dolorimento%20ou%20fraqueza%20musculares%20e%20creatinina%20quinase%20(CK)%20acima%20de%2010%20vezes%20o%20limite%20superior%20da%20normalidade%20(LSN).%20Algumas%20vezes%2C%20a%20miopatia%20apresenta-se%20como%20rabdomi%26%23xF3%3Blise%2C%20com%20ou%20sem%20insufici%26%23xEA%3Bncia%20renal%20aguda%20secund%26%23xE1%3Bria%20a%20mioglobin%26%23xFA%3Bria%20e%2C%20raramente%2C%20pode%20ser%20fatal.%20O%20risco%20de%20miopatia%20%26%23xE9%3B%20aumentado%20por%20n%26%23xED%3Bveis%20elevados%20de%20atividade%20inibit%26%23xF3%3Bria%20da%20HMG-CoA%20redutase%20no%20plasma%20(isto%20%26%23xE9%3B%2C%20n%26%23xED%3Bveis%20plasm%26%23xE1%3Bticos%20elevados%20de%20sinvastatina%20e%20de%20sinvastatina%20%26%23xE1%3Bcida%20no%20plasma)%2C%20que%20pode%20ser%20devido%2C%20em%20parte%2C%20%26%23xE0%3B%20intera%26%23xE7%3B%26%23xF5%3Bes%20medicamentosas%20que%20interferem%20com%20o%20metabolismo%20da%20sinvastatina%20e%2Fou%20com%20as%20vias%20trasnportadoras%20(veja%20o%20item%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS).%20Os%20fatores%20predisponentes%20para%20miopatia%20incluem%20idade%20avan%26%23xE7%3Bada%20(%3D%26gt%3B%2065%20anos)%2C%20sexo%20feminino%2C%20hipotireoidismo%20n%26%23xE3%3Bo%20controlado%20e%20insufici%26%23xEA%3Bncia%20renal.%3Cbr%3E%0AA%20exemplo%20de%20outros%20inibidores%20da%20HMG-CoA%20redutase%2C%20o%20risco%20de%20miopatia%2Frabdomi%26%23xF3%3Blise%20est%26%23xE1%3B%20relacionado%20%26%23xE0%3B%20dose.%20Em%20um%20banco%20de%20dados%20de%20estudos%20cl%26%23xED%3Bnicos%20no%20qual%2041.413%20pacientes%20foram%20tratados%20com%20sinvastatina%2C%2024.747%20(aproximadamente%2060%25)%20dos%20quais%20foram%20admitidos%20nos%20estudos%20com%20um%20acompanhamento%20mediano%20de%20pelo%20menos%204%20anos%2C%20a%20incid%26%23xEA%3Bncia%20de%20miopatia%20foi%20de%20aproximadamente%200%2C03%25%2C%200%2C08%25%20e%200%2C61%25%20com%2020%2C%2040%20e%2080%20mg%2Fdia%2C%20respectivamente.%20Nesses%20estudos%2C%20os%20pacientes%20foram%20cuidadosamente%20monitorados%20e%20alguns%20medicamentos%20com%20intera%26%23xE7%3B%26%23xE3%3Bo%20foram%20exclu%26%23xED%3Bdos.%3Cbr%3E%0AEm%20um%20estudo%20cl%26%23xED%3Bnico%20no%20qual%20os%20pacientes%20com%20hist%26%23xF3%3Brico%20de%20infarto%20do%20mioc%26%23xE1%3Brdio%20foram%20tratados%20com%20sinvastatina%2080%20mg%2Fdia%20(acompanhamento%20m%26%23xE9%3Bdio%20de%206%2C7%20anos)%2C%20a%20incid%26%23xEA%3Bncia%20de%20miopatia%20foi%20de%20aproximadamente%201%2C0%25%20em%20compara%26%23xE7%3B%26%23xE3%3Bo%20com%200%2C02%25%20para%20os%20pacientes%20tratados%20com%2020%20mg%2Fdia.%20Aproximadamente%20metade%20destes%20casos%20de%20miopatia%20ocorreu%20durante%20o%20primeiro%20ano%20de%20tratamento.%20A%20incid%26%23xEA%3Bncia%20de%20miopatia%20durante%20cada%20ano%20subsequente%20de%20tratamento%20foi%20de%20aproximadamente%200%2C1%25.%3Cbr%3E%0AO%20risco%20de%20miopatia%2C%20incluindo%20rabdomi%26%23xF3%3Blise%2C%20%26%23xE9%3B%20maior%20em%20pacientes%20que%20est%26%23xE3%3Bo%20sendo%20tratados%20com%20sinvastatina%2080%20mg%20quando%20comparado%20com%20outras%20terapias%20%26%23xE0%3B%20base%20de%20estatina%20com%20efic%26%23xE1%3Bcia%20semelhante%20ou%20maior%20na%20redu%26%23xE7%3B%26%23xE3%3Bo%20de%20colesterol%20LDL%20e%20em%20compara%26%23xE7%3B%26%23xE3%3Bo%20com%20doses%20menores%20de%20sinvastatina.%20Portanto%2C%20a%20dose%20de%2080%20mg%20de%20sinvastatina%20deve%20ser%20utilizada%20somente%20em%20pacientes%20que%20est%26%23xE3%3Bo%20tomando%20sinvastatina%2080%20mg%20cronicamente%20(por%2012%20meses%20ou%20mais)%20sem%20evid%26%23xEA%3Bncias%20de%20toxicidade%20muscular%20(veja%20o%20item%208.%20POSOLOGIA%20E%20MODO%20DE%20USAR).%20O%20uso%20de%20sinvastatina%2080%20mg%20n%26%23xE3%3Bo%20deve%20ser%20iniciado%20em%20pacientes%20novos%2C%20incluindo%20os%20pacientes%20que%20j%26%23xE1%3B%20tomam%20doses%20menores%20do%20medicamento.%3Cbr%3E%0ASe%20um%20paciente%20que%20est%26%23xE1%3B%20atualmente%20tolerando%20a%20dose%20de%2080%20mg%20de%20sinvastatina%20precisar%20iniciar%20um%20medicamento%20que%20%26%23xE9%3B%20contraindicado%20ou%20um%20medicamento%20com%20potencial%20de%20intera%26%23xE7%3B%26%23xE3%3Bo%20medicamentosa%20e%20que%20limita%20a%20dose%20m%26%23xE1%3Bxima%20permitida%20de%20sinvastatina%2C%20este%20paciente%20deve%20ser%20mudado%20para%20uma%20estatina%20alternativa%20ou%20regime%20baseado%20em%20estatina%20com%20menor%20potencial%20para%20a%20intera%26%23xE7%3B%26%23xE3%3Bo%20medicamentosa.%20Os%20pacientes%20devem%20ser%20alertados%20sobre%20o%20risco%20aumentado%20de%20miopatia%2C%20incluindo%20rabdomi%26%23xF3%3Blise%2C%20e%20orientados%20a%20relatar%20imediatamente%20qualquer%20dor%2C%20sensibilidade%20ou%20fraqueza%20muscular%20inexplicadas.%20Se%20os%20sintomas%20ocorrerem%2C%20o%20tratamento%20deve%20ser%20interrompido%20imediatamente%20(veja%20os%20itens%208.%20POSOLOGIA%20E%20ADMINISTRA%26%23xC7%3B%26%23xC3%3BO%20e%204.%20CONTRAINDICA%26%23xC7%3B%26%23xD5%3BES).%3Cbr%3E%0ATodos%20os%20pacientes%20que%20iniciam%20tratamento%20com%20sinvastatina%2C%20ou%20cuja%20dose%20de%20sinvastatina%20est%26%23xE1%3B%20sendo%20aumentada%2C%20devem%20ser%20alertados%20sobre%20o%20risco%20de%20miopatia%20e%20orientados%20a%20relatar%20imediatamente%20qualquer%20dor%2C%20sensibilidade%20ou%20fraqueza%20muscular%20inexplicada.%20A%20terapia%20com%20sinvastatina%20deve%20ser%20descontinuada%20imediatamente%20se%20houver%20diagn%26%23xF3%3Bstico%20ou%20suspeita%20de%20miopatia.%20A%20presen%26%23xE7%3Ba%20destes%20sintomas%2C%20bem%20como%20n%26%23xED%3Bvel%20de%20CK%20%26gt%3B10%20vezes%20o%20limite%20normal%20superior%2C%20indica%20miopatia.%20Na%20maioria%20dos%20casos%2C%20quando%20os%20pacientes%20descontinuaram%20imediatamente%20o%20tratamento%2C%20os%20sintomas%20musculares%20e%20os%20aumentos%20de%20CK%20desapareceram%20(veja%20o%20item%209.%20REA%26%23xC7%3B%26%23xD5%3BES%20ADVERSAS).%20Pode-se%20considerar%20determina%26%23xE7%3B%26%23xF5%3Bes%20peri%26%23xF3%3Bdicas%20de%20CK%20para%20pacientes%20que%20iniciam%20terapia%20com%20sinvastatina%20ou%20cuja%20dose%20esteja%20sendo%20aumentada.%20Tamb%26%23xE9%3Bm%20se%20recomenda%20determina%26%23xE7%3B%26%23xF5%3Bes%20peri%26%23xF3%3Bdicas%20de%20CK%20para%20pacientes%20que%20usam%20a%20dose%20de%2080mg%20de%20sinvastatina.%20N%26%23xE3%3Bo%20h%26%23xE1%3B%20nenhuma%20garantia%20de%20que%20esse%20monitoramento%20ir%26%23xE1%3B%20prevenir%20a%20miopatia.%3Cbr%3E%0AMuitos%20dos%20pacientes%20que%20desenvolveram%20rabdomi%26%23xF3%3Blise%20durante%20o%20tratamento%20com%20sinvastatina%20tinham%20hist%26%23xF3%3Bricos%20m%26%23xE9%3Bdicos%20complicados%2C%20incluindo%20insufici%26%23xEA%3Bncia%20renal%2C%20geralmente%20em%20consequ%26%23xEA%3Bncia%20de%20diabetes%20mellitus%20prolongado.%20Tais%20pacientes%20devem%20ser%20cuidadosamente%20monitorados.%20A%20terapia%20com%20sinvastatina%20deve%20ser%20temporariamente%20interrompida%20alguns%20dias%20antes%20de%20cirurgia%20eletiva%20de%20grande%20porte%20e%20quando%20qualquer%20condi%26%23xE7%3B%26%23xE3%3Bo%20cir%26%23xFA%3Brgica%20ou%20m%26%23xE9%3Bdica%20importante%20sobrevenha.%3Cbr%3E%0AEm%20um%20estudo%20cl%26%23xED%3Bnico%20no%20qual%20pacientes%20com%20alto%20risco%20de%20doen%26%23xE7%3Ba%20cardiovascular%20foram%20tratados%20com%20sinvastatina%2040%20mg%2Fdia%20(acompanhamento%20m%26%23xE9%3Bdio%20de%203%2C9%20anos)%2C%20a%20incid%26%23xEA%3Bncia%20de%20miopatia%20foi%20de%20aproximadamente%200%2C05%25%20em%20pacientes%20n%26%23xE3%3Bo-chineses%20(n%20%3D%207.367)%20em%20compara%26%23xE7%3B%26%23xE3%3Bo%20com%200%2C24%25%20em%20pacientes%20chineses%20(n%20%3D%205.468).%20Embora%20a%20%26%23xFA%3Bnica%20popula%26%23xE7%3B%26%23xE3%3Bo%20asi%26%23xE1%3Btica%20avaliada%20neste%20estudo%20cl%26%23xED%3Bnico%20tenha%20sido%20a%20chinesa%2C%20deve-se%20ter%20cautela%20ao%20prescrever%20sinvastatina%20para%20pacientes%20asi%26%23xE1%3Bticos%20e%20a%20menor%20dose%20necess%26%23xE1%3Bria%20deve%20ser%20utilizada.%3C%2Fp%3E%0A%3Cp%3EIntera%26%23xE7%3B%26%23xF5%3Bes%20medicamentosas%3Cbr%3E%0A-O%20risco%20de%20miopatia%2Frabdomi%26%23xF3%3Blise%20%26%23xE9%3B%20aumentado%20pelo%20uso%20concomitante%20de%20sinvastatina%20com%3A%3Cbr%3E%0AMedicamentos%20contraindicados%3Cbr%3E%0A-Inibidores%20potentes%20da%20CYP3A4%3A%20uso%20concomitante%20de%20medicamentos%20conhecidos%20por%20apresentar%20um%20potente%20efeito%20inibit%26%23xF3%3Brio%20sobre%20CYP3A4%20em%20doses%20terap%26%23xEA%3Buticas%20(por%20exemplo%2C%20itraconazol%2C%20cetoconazol%2C%20posaconazol%2C%20voriconazol%2C%20eritromicina%2C%20claritromicina%2C%20telitromicina%2C%20inibidores%20da%20protease%20do%20HIV%2C%20boceprevir%2C%20teloprevir%2C%20nefazodona%20ou%20medicamentos%20contendo%20cobicistate)%20%26%23xE9%3B%20contraindicada.%20Se%20o%20tratamento%20de%20curto%20prazo%20com%20inibidor%20potente%20de%20CYP3A4%20estiver%20indispon%26%23xED%3Bvel%2C%20a%20terapia%20com%20sinvastatina%20deve%20ser%20interrompida%20durante%20o%20tratamento%20(veja%20os%20itens%204.%20CONTRAINDICA%26%23xC7%3B%26%23xD5%3BES%3B%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS%20e%203.%20CARACTER%26%23xCD%3BSTICAS%20FARMACOL%26%23xD3%3BGICAS%2C%20Farmacocin%26%23xE9%3Btica)%3Cbr%3E%0A-Genfibrozila%2C%20ciclosporina%20ou%20danazol%3A%20o%20uso%20concomitante%20desses%20medicamentos%20com%20sinvastatina%20%26%23xE9%3B%20contraindicado%20(veja%20os%20itens%204.%20CONTRAINDICA%26%23xC7%3B%26%23xD5%3BES%3B%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS%20e%203.%20CARACTER%26%23xCD%3BSTICAS%20FARMACOL%26%23xD3%3BGICAS%2C%20Farmacocin%26%23xE9%3Btica).%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Cp%3EOutros%20medicamentos%3A%3Cbr%3E%0A-%26%23xC1%3Bcido%20fus%26%23xED%3Bdico%3A%20pacientes%20tratados%20com%20%26%23xE1%3Bcido%20fus%26%23xED%3Bdico%20concomitantemente%20com%20sinvastatina%20podem%20apresentar%20risco%20aumentado%20de%20miopatia%2Frabdomi%26%23xF3%3Blise%20(veja%20os%20itens%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS%2C%20Outras%20Intera%26%23xE7%3B%26%23xF5%3Bes%20Medicamentosas%20e%203.%20CARACTER%26%23xCD%3BSTICAS%20FARMACOL%26%23xD3%3BGICAS%2C%20Farmacocin%26%23xE9%3Btica).%20A%20coadministra%26%23xE7%3B%26%23xE3%3Bo%20com%20%26%23xE1%3Bcido%20fus%26%23xED%3Bdico%20n%26%23xE3%3Bo%20%26%23xE9%3B%20recomendada.%20Em%20pacientes%20em%20que%20o%20uso%20de%20%26%23xE1%3Bcido%20fus%26%23xED%3Bdico%20sist%26%23xEA%3Bmico%20%26%23xE9%3B%20considerado%20essencial%2C%20a%20sinvastatina%20deve%20ser%20descontinuada%20durante%20todo%20o%20tratamento%20com%20%26%23xE1%3Bcido%20fus%26%23xED%3Bdico.%20Em%20circunst%26%23xE2%3Bncias%20excepcionais%2C%20onde%20o%20uso%20sist%26%23xEA%3Bmico%20prolongado%20do%20%26%23xE1%3Bcido%20fus%26%23xED%3Bdico%20%26%23xE9%3B%20necess%26%23xE1%3Brio%2C%20por%20exemplo%2C%20para%20o%20tratamento%20de%20infec%26%23xE7%3B%26%23xF5%3Bes%20graves%2C%20a%20necessidade%20da%20coadministra%26%23xE7%3B%26%23xE3%3Bo%20de%20sinvastatina%20e%20%26%23xE1%3Bcido%20fus%26%23xED%3Bdico%20deve%20ser%20considerada%20caso%20a%20caso%20e%20sob%20rigorosa%20supervis%26%23xE3%3Bo%20m%26%23xE9%3Bdica.%3Cbr%3E%0A-Outros%20fibratos%3A%20a%20dose%20de%20sinvastatina%20n%26%23xE3%3Bo%20deve%20ser%20maior%20que%2010%20mg%2Fdia%20em%20pacientes%20tratados%20concomitante%20com%20outros%20fibratos%20al%26%23xE9%3Bm%20da%20genfibrozila%20(veja%20o%20item%204.%20CONTRAINDICA%26%23xC7%3B%26%23xD5%3BES)%20ou%20fenofibrato.%20Quando%20sinvastatina%20e%20fenofibrato%20s%26%23xE3%3Bo%20administrados%20concomitantemente%2C%20n%26%23xE3%3Bo%20h%26%23xE1%3B%20nenhuma%20evid%26%23xEA%3Bncia%20de%20que%20o%20risco%20de%20miopatia%20exceda%20a%20soma%20dos%20riscos%20individuais%20de%20cada%20agente.%20Deve-se%20ter%20cautela%20ao%20prescrever%20fenofibrato%20com%20sinvastatina%2C%20uma%20vez%20que%20qualquer%20um%20dos%20agentes%20pode%20causar%20miopatia%20quando%20administrados%20isoladamente.%20A%20adi%26%23xE7%3B%26%23xE3%3Bo%20de%20fibratos%20%26%23xE0%3B%20sinvastatina%20normalmente%20proporciona%20pouca%20redu%26%23xE7%3B%26%23xE3%3Bo%20adicional%20de%20LDL-C%2C%20por%26%23xE9%3Bm%20podem%20ser%20obtidas%20redu%26%23xE7%3B%26%23xF5%3Bes%20adicionais%20de%20TG%20e%20aumentos%20adicionais%20de%20HDL-C.%20As%20combina%26%23xE7%3B%26%23xF5%3Bes%20de%20fibratos%20com%20sinvastatina%20t%26%23xEA%3Bm%20sido%20utilizadas%20sem%20ocorr%26%23xEA%3Bncia%20de%20miopatia%20em%20estudos%20cl%26%23xED%3Bnicos%20de%20pequeno%20porte%2C%20de%20curta%20dura%26%23xE7%3B%26%23xE3%3Bo%20e%20com%20monitoramento%20rigoroso%20(veja%20o%20item%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS).%3Cbr%3E%0A-Amiodarona%3A%20em%20um%20estudo%20cl%26%23xED%3Bnico%2C%20foi%20relatada%20miopatia%20em%206%25%20dos%20pacientes%20que%20receberam%2080%20mg%20de%20sinvastatina%20e%20amiodarona.%20A%20dose%20de%20sinvastatina%20n%26%23xE3%3Bo%20deve%20ser%20maior%20que%2020%20mg%20di%26%23xE1%3Brios%20em%20pacientes%20recebendo%20tratamento%20concomitantemente%20com%20amiodarona%20(veja%20os%20itens%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS%2C%20Outras%20Intera%26%23xE7%3B%26%23xF5%3Bes%20Medicamentosas%20e%208.%20POSOLOGIA%20E%20MODO%20DE%20USAR).%3C%2Fp%3E%0A%3Cp%3E-Bloqueadores%20do%20canal%20de%20c%26%23xE1%3Blcio%3Cbr%3E%0A-Verapamil%20ou%20diltiazem%3A%20em%20um%20estudo%20cl%26%23xED%3Bnico%2C%20os%20pacientes%20em%20tratamento%20concomitante%20com%20sinvastatina%2080%20mg%20e%20diltiazem%20apresentaram%20aumento%20no%20risco%20de%20miopatia.%20A%20dose%20de%20sinvastatina%20n%26%23xE3%3Bo%20deve%20ser%20maior%20que%2020%20mg%20di%26%23xE1%3Brios%20em%20pacientes%20recebendo%20tratamento%20concomitantemente%20com%20veramapil%20ou%20diltiazem%20(veja%20os%20itens%206.%3Cbr%3E%0AINTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS%2C%20Outras%20Intera%26%23xE7%3B%26%23xF5%3Bes%20Medicamentosas%20e%208.%20POSOLOGIA%20E%20MODO%20DE%3Cbr%3E%0AUSAR).%3C%2Fp%3E%0A%3Cp%3E-Anlodipino%3A%20em%20um%20estudo%20cl%26%23xED%3Bnico%2C%20os%20pacientes%20em%20tratamento%20concomitante%20com%20sinvastatina%2080%20mg%20e%20anlodipino%20apresentaram%20um%20risco%20discretamente%20aumentado%20de%20miopatia.%20A%20dose%20de%20sinvastatina%20n%26%23xE3%3Bo%20deve%20exceder%2040%20mg%20di%26%23xE1%3Brios%20em%20pacientes%20recebendo%20concomitantemente%20anlodipino%20(veja%20os%20itens%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS%2C%20Outras%20Intera%26%23xE7%3B%26%23xF5%3Bes%20Medicamentosas%20e%208.%20POSOLOGIA%20E%20MODO%20DE%20USAR).%3C%2Fp%3E%0A%3Cp%3ESinvastatina%2020%20mg%20e%2040%20mg%3Cbr%3E%0A-Lomitapida%3A%20a%20dose%20de%20sinvastatina%20n%26%23xE3%3Bo%20deve%20exceder%2040%20mg%20di%26%23xE1%3Brios%20em%20pacientes%20com%20hipercolesterolemia%20familiar%20homozig%26%23xF3%3Btica%20(HoFH)%20que%20recebam%20concomitantemente%20lomitapida%20(veja%20o%20item%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%3Cbr%3E%0AMEDICAMENTOSAS%2C%20Outras%20Intera%26%23xE7%3B%26%23xF5%3Bes%20Medicamentosas).%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Cp%3E-Inibidores%20moderados%20do%20CYP3A4%3A%20os%20pacientes%20que%20tomam%20outros%20medicamentos%20identificados%20em%20bula%20como%20medicamentos%20com%20efeito%20inibit%26%23xF3%3Brio%20moderado%20sobre%20o%20CYP3A4%20concomitantemente%20com%20sinvastatina%2C%20particularmente%20com%20doses%20mais%20altas%20de%20sinvastatina%2C%20podem%20ter%20maior%20risco%20de%20miopatia.%20Quando%20for%20coadministrada%20sinvastatina%20com%20um%20inibidor%20moderado%20de%20CYP3A4%2C%20um%20ajuste%20da%20dose%20de%20sinvastatina%20pode%20ser%20necess%26%23xE1%3Brio%20(veja%20o%20item%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS%2C%20Outras%20Intera%26%23xE7%3B%26%23xF5%3Bes%20Medicamentosas).%3Cbr%3E%0A-Inibidores%20da%20prote%26%23xED%3Bna%20resistente%20ao%20c%26%23xE2%3Bncer%20de%20mama%20(BCPR)%3A%20a%20administra%26%23xE7%3B%26%23xE3%3Bo%20concomitante%20de%20medicamentos%20inibidores%20da%20BCPR%20(por%20exemplo%2C%20elbasvir%20e%20grazoprevir)%20pode%20levar%20a%20um%20aumento%20das%20concentra%26%23xE7%3B%26%23xF5%3Bes%20plasm%26%23xE1%3Bticas%20da%20sinvastatina%20e%20um%20risco%20aumentado%20de%20miopatia%3B%20portanto%2C%20um%20ajuste%20da%20dose%20de%20sinvastatina%20pode%20ser%20necess%26%23xE1%3Brio.%20A%20coadministra%26%23xE7%3B%26%23xE3%3Bo%20de%20elbasvir%20e%20grazoprevir%20com%20sinvastatina%20n%26%23xE3%3Bo%20foi%20estudada%3B%20no%20entanto%2C%20a%20dose%20de%20sinvastatina%20n%26%23xE3%3Bo%20deve%20exceder%2020%20mg%20por%20dia%20em%20pacientes%20que%20tomam%2C%20concomitantemente%2C%20medicamentos%20contendo%20elbasvir%20ou%20grazoprevir%20(veja%20o%20item%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS%2C%20Outras%20Intera%26%23xE7%3B%26%23xF5%3Bes%20Medicamentosas).%3C%2Fp%3E%0A%3Cp%3E-%26%23xC1%3Bcido%20nicot%26%23xED%3Bnico%20(niacina)%20(%3D%26gt%3B%201%20g%2Fdia)%3A%20casos%20de%20miopatia%2Frabdomi%26%23xF3%3Blise%20foram%20observados%20com%20a%20sinvastatina%20coadministrada%20com%20doses%20modificadoras%20de%20l%26%23xED%3Bpides%20(%26%23x2265%3B%201%20g%2Fdia)%20de%20%26%23xE1%3Bcido%20nicot%26%23xED%3Bnico.%20Em%20um%20estudo%20cl%26%23xED%3Bnico%3Cbr%3E%0A(acompanhamento%20m%26%23xE9%3Bdio%20de%203%2C9%20anos)%20envolvendo%20pacientes%20com%20alto%20risco%20de%20doen%26%23xE7%3Ba%20cardiovascular%20e%20com%20n%26%23xED%3Bveis%20de%20LDL-C%20bem%20controlados%20com%20sinvastatina%2040%20mg%2Fdia%20com%20ou%20sem%20ezetimiba%2010%20mg%2C%20n%26%23xE3%3Bo%20houve%20benef%26%23xED%3Bcio%20incremental%20sobre%20os%20desfechos%20cardiovasculares%20com%20a%20adi%26%23xE7%3B%26%23xE3%3Bo%20de%20doses%20modificadoras%20de%20l%26%23xED%3Bp%26%23xED%3Bdes%20(%26%23x2265%3B%201%20g%2Fdia)%20de%20%26%23xE1%3Bcido%20nicot%26%23xED%3Bnico.%3Cbr%3E%0APortanto%2C%20o%20benef%26%23xED%3Bcio%20do%20uso%20combinado%20de%20sinvastatina%20com%20%26%23xE1%3Bcido%20nicot%26%23xED%3Bnico%20deve%20ser%20cuidadosamente%20ponderado%20contra%20os%20riscos%20potenciais%20da%20combina%26%23xE7%3B%26%23xE3%3Bo.%20Al%26%23xE9%3Bm%20disso%2C%20neste%20estudo%2C%20a%20incid%26%23xEA%3Bncia%20de%20miopatia%20foi%20aproximadamente%200%2C24%25%20em%20pacientes%20chineses%20tratados%20com%20sinvastatina%2040%20mg%20ou%20ezetimiba%2Fsinvastatina%2010%2F40%20mg%20em%20compara%26%23xE7%3B%26%23xE3%3Bo%20com%201%2C24%25%20em%20pacientes%20chineses%20tratados%20com%20sinvastatina%2040%20mg%20ou%20ezetimiba%2Fsinvastatina%2010%2F40%20mg%20coadministradas%20com%20%26%23xE1%3Bcido%20nicot%26%23xED%3Bnico%20de%20libera%26%23xE7%3B%26%23xE3%3Bo%20prolongada%2Flaropipranto%202g%2F40mg.%20Embora%20a%20%26%23xFA%3Bnica%20popula%26%23xE7%3B%26%23xE3%3Bo%20asi%26%23xE1%3Btica%20avaliada%20neste%20estudo%20cl%26%23xED%3Bnico%20tenha%20sido%20a%20de%20chineses%2C%20como%20a%20incid%26%23xEA%3Bncia%20de%20miopatia%20%26%23xE9%3B%20maior%20em%20pacientes%20chineses%20do%20que%20em%20pacientes%20n%26%23xE3%3Bo%20chineses%2C%20a%20coadministra%26%23xE7%3B%26%23xE3%3Bo%20de%20sinvastatina%20com%20doses%20modificadoras%20de%20l%26%23xED%3Bp%26%23xED%3Bdes%20(%26%23x2265%3B%201%20g%2Fdia)%20de%20%26%23xE1%3Bcido%20nicot%26%23xED%3Bnico%20n%26%23xE3%3Bo%20%26%23xE9%3B%20recomendada%20para%20pacientes%20asi%26%23xE1%3Bticos%20(veja%20o%20item%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS%2C%20Outras%20Intera%26%23xE7%3B%26%23xF5%3Bes%20Medicamentosas).%3C%2Fp%3E%0A%3Cp%3EEfeitos%20hep%26%23xE1%3Bticos%3A%3Cbr%3E%0AEm%20estudos%20cl%26%23xED%3Bnicos%2C%20ocorreram%20aumentos%20persistentes%20(acima%20de%20tr%26%23xEA%3Bs%20vezes%20o%20limite%20superior%20da%20normalidade)%20das%20transaminases%20s%26%23xE9%3Bricas%20em%20poucos%20pacientes%20adultos%20que%20receberam%20sinvastatina.%20Quando%20o%20medicamento%20foi%20interrompido%20ou%20descontinuado%2C%20os%20n%26%23xED%3Bveis%20de%20transaminases%20ca%26%23xED%3Bram%20lentamente%20para%20os%20n%26%23xED%3Bveis%20anteriores%20ao%20tratamento.%20Os%20aumentos%20n%26%23xE3%3Bo%20foram%20associados%20%26%23xE0%3B%20icter%26%23xED%3Bcia%20ou%20a%20outros%20sintomas%20ou%20sinais%20cl%26%23xED%3Bnicos.%20N%26%23xE3%3Bo%20houve%20evid%26%23xEA%3Bncia%20de%20hipersensibilidade.%20Alguns%20desses%20pacientes%20apresentavam%20testes%20de%20fun%26%23xE7%3B%26%23xE3%3Bo%20hep%26%23xE1%3Btica%20alterados%20antes%20do%20tratamento%20com%20a%20sinvastatina%20e%2Fou%20consumiam%20quantidades%20consider%26%23xE1%3Bveis%20de%20%26%23xE1%3Blcool.%3Cbr%3E%0ANo%20Estudo%20Escandinavo%20de%20Sobrevida%20com%20Sinvastatina%20(4S)%20(veja%20o%20item%202.%20RESULTADOS%20DE%20EFIC%26%23xC1%3BCIA)%2C%20o%20n%26%23xFA%3Bmero%20de%20pacientes%20com%20transaminases%20elevadas%20(acima%20de%20tr%26%23xEA%3Bs%20vezes%20o%20limite%20superior%20da%20normalidade)%20mais%20de%20uma%20vez%20durante%20o%20estudo%2C%20n%26%23xE3%3Bo%20foi%20significativamente%20diferente%20entre%20os%20grupos%20sinvastatina%20e%20placebo%20(14%20%5B0%2C7%25%5D%20vs.%2012%20%5B0%2C6%25%5D).%20A%20frequ%26%23xEA%3Bncia%20dos%20aumentos%20isolados%20de%20TGP%20(ALT)%20para%20tr%26%23xEA%3Bs%20vezes%20o%20limite%20superior%20da%20normalidade%20foi%20significativamente%20mais%20alta%20no%20grupo%20da%20sinvastatina%20no%20primeiro%20ano%20do%20estudo%20(20%20vs.%208%2C%20p%20%3D%200%2C023)%2C%20mas%20n%26%23xE3%3Bo%20posteriormente.%20O%20aumento%20de%20transaminases%20resultou%20em%20descontinua%26%23xE7%3B%26%23xE3%3Bo%20do%20tratamento%20para%20oito%20pacientes%20do%20grupo%20da%20sinvastatina%20(n%20%3D%202.221)%20e%20para%20cinco%20do%20grupo%20placebo%20(n%20%3D%202.223).%20Dos%201.986%20pacientes%20no%204S%20tratados%20com%20a%20sinvastatina%20cujos%20testes%20de%20fun%26%23xE7%3B%26%23xE3%3Bo%20hep%26%23xE1%3Btica%20eram%20normais%20no%20per%26%23xED%3Bodo%20basal%2C%20somente%20oito%20(0%2C4%25)%20apresentaram%20aumentos%20consecutivos%20%26gt%3B%203%20vezes%20o%20limite%20superior%20da%20normalidade%20de%20enzimas%20hep%26%23xE1%3Bticas%20e%2Fou%20foram%20descontinuados%20por%20aumento%20de%20transaminases%20durante%20os%205%2C4%20anos%20(acompanhamento%20m%26%23xE9%3Bdio)%20do%20estudo.%20A%20dose%20inicial%20de%20sinvastatina%20para%20todos%20os%20pacientes%20do%20estudo%20foi%20de%2020%20mg%3B%2037%25%20foram%20titulados%20para%2040%20mg.%3Cbr%3E%0AEm%20dois%20estudos%20cl%26%23xED%3Bnicos%20controlados%2C%20que%20envolveram%201.105%20pacientes%2C%20a%20incid%26%23xEA%3Bncia%20%26%23x2013%3B%20aos%206%20meses%20%26%23x2013%3B%20de%20aumentos%20persistentes%20de%20transaminases%20considerados%20relacionados%20ao%20medicamento%20foi%20de%200%2C7%25%20e%201%2C8%25%2C%20com%20as%20doses%20de%2040%20mg%20e%2080%20mg%2C%20respectivamente.%3Cbr%3E%0ANo%20estudo%20HPS%20(veja%20o%20item%202.%20RESULTADOS%20DE%20EFIC%26%23xC1%3BCIA)%2C%20no%20qual%2020.536%20pacientes%20foram%20distribu%26%23xED%3Bdos%20de%20modo%20rand%26%23xF4%3Bmico%20para%20receber%2040%20mg%2Fdia%20de%20sinvastatina%20ou%20placebo%2C%20a%20incid%26%23xEA%3Bncia%20de%20transaminases%20elevadas%20(%26gt%3B%203%20vezes%20o%20limite%20superior%20da%20normalidade%2C%20confirmada%20em%20exames%20repetidos)%20foi%20de%200%2C21%25%20(n%20%3D%2021)%20para%20os%20pacientes%20que%20receberam%20sinvastatina%20e%20de%200%2C09%25%20(n%20%3D%209)%20no%20grupo%20placebo.%3Cbr%3E%0ARecomenda-se%20solicitar%20testes%20de%20fun%26%23xE7%3B%26%23xE3%3Bo%20hep%26%23xE1%3Btica%20antes%20de%20iniciar%20o%20tratamento%20e%20posteriormente%2C%20quando%20clinicamente%20indicado.%20Pacientes%20titulados%20para%20doses%20de%2080%20mg%20devem%20realizar%20mais%20um%20teste%20antes%20da%20titula%26%23xE7%3B%26%23xE3%3Bo%2C%203%20meses%20depois%20da%20titula%26%23xE7%3B%26%23xE3%3Bo%20para%20a%20dose%20de%2080%20mg%20e%2C%20a%20seguir%2C%20periodicamente%20(por%20exemplo%2C%20de%206%20em%206%20meses)%20durante%20o%20primeiro%20ano%20de%20Sinvastatina%2020%20mg%20e%2040%20mg%20tratamento.%20Deve-se%20dar%20especial%20aten%26%23xE7%3B%26%23xE3%3Bo%20aos%20pacientes%20que%20apresentarem%20aumento%20de%20transaminases%20s%26%23xE9%3Bricas%20e%2C%20nesses%20pacientes%2C%20as%20avalia%26%23xE7%3B%26%23xF5%3Bes%20laboratoriais%20devem%20ser%20imediatamente%20repetidas%20e%2C%20a%20seguir%2C%20realizadas%20com%20maior%20frequ%26%23xEA%3Bncia.%20Deve-se%20descontinuar%20o%20medicamento%20se%20os%20n%26%23xED%3Bveis%20de%20transaminases%20mostrarem%20evid%26%23xEA%3Bncia%20de%20progress%26%23xE3%3Bo%2C%20particularmente%20se%20aumentarem%20acima%20de%20tr%26%23xEA%3Bs%20vezes%20o%20limite%20superior%20da%20normalidade%20e%20persistirem%20nesse%20patamar.%20Note%20que%20a%20ALT%20pode%20emanar%20do%20m%26%23xFA%3Bsculo%2C%20portanto%2C%20a%20eleva%26%23xE7%3B%26%23xE3%3Bo%20da%20ALT%20com%20CK%20pode%20indicar%20miopatia%20(veja%20o%20item%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise).%3Cbr%3E%0AExistem%20raros%20relatos%20p%26%23xF3%3Bs-comercializa%26%23xE7%3B%26%23xE3%3Bo%20de%20insufici%26%23xEA%3Bncia%20hep%26%23xE1%3Btica%20fatal%20e%20n%26%23xE3%3Bo%20fatal%20em%20pacientes%20que%20tomam%20estatinas%2C%20incluindo%20sinvastatina.%20Se%20ocorrer%20les%26%23xE3%3Bo%20hep%26%23xE1%3Btica%20grave%20com%20sintomas%20cl%26%23xED%3Bnicos%20e%2Fou%20hiperbilirrubinemia%20ou%20icter%26%23xED%3Bcia%20durante%20o%20tratamento%20com%20sinvastatina%2C%20deve-se%20interromper%20imediatamente%20o%20tratamento.%20Se%20uma%20etiologia%20alternativa%20n%26%23xE3%3Bo%20for%20encontrada%2C%20n%26%23xE3%3Bo%20reinicie%20o%20tratamento%20com%20sinvastatina.%3Cbr%3E%0ADeve-se%20utilizar%20o%20medicamento%20com%20cuidado%20em%20pacientes%20que%20consomem%20quantidades%20substanciais%20de%20%26%23xE1%3Blcool%20e%2Fou%20apresentem%20hist%26%23xF3%3Brico%20de%20doen%26%23xE7%3Ba%20hep%26%23xE1%3Btica.%20Hepatopatias%20ativas%20ou%20aumentos%20inexplicados%20de%20transaminases%20constituem%20contraindica%26%23xE7%3B%26%23xF5%3Bes%20para%20o%20uso%20da%20sinvastatina.%3Cbr%3E%0AA%20exemplo%20do%20que%20ocorre%20com%20outros%20agentes%20hipolipemiantes%2C%20foram%20relatados%20aumentos%20moderados%20(abaixo%20de%20tr%26%23xEA%3Bs%20vezes%20o%20limite%20superior%20da%20normalidade)%20das%20transaminases%20s%26%23xE9%3Bricas%20ap%26%23xF3%3Bs%20o%20tratamento%20com%20a%20sinvastatina.%20Essas%20altera%26%23xE7%3B%26%23xF5%3Bes%20ocorreram%20logo%20ap%26%23xF3%3Bs%20o%20in%26%23xED%3Bcio%20do%20tratamento%2C%20foram%20geralmente%20transit%26%23xF3%3Brias%2C%20assintom%26%23xE1%3Bticas%20e%20n%26%23xE3%3Bo%20exigiram%20interrup%26%23xE7%3B%26%23xE3%3Bo%20do%20tratamento.%3C%2Fp%3E%0A%3Cp%3EAvalia%26%23xE7%3B%26%23xF5%3Bes%20oftalmol%26%23xF3%3Bgicas%3A%20%26%23xE9%3B%20esperado%20que%2C%20com%20o%20passar%20do%20tempo%2C%20ocorra%20aumento%20da%20preval%26%23xEA%3Bncia%20de%20opacidade%20do%20cristalino%20como%20resultado%20do%20envelhecimento%2C%20mesmo%20na%20aus%26%23xEA%3Bncia%20de%20qualquer%20tratamento%20medicamentoso.%20Dados%20atuais%20de%20estudos%20cl%26%23xED%3Bnicos%20a%20longo%20prazo%20n%26%23xE3%3Bo%20indicam%20efeito%20adverso%20da%20sinvastatina%20no%20cristalino%20humano.%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Cp%3EGravidez%20e%20Lacta%26%23xE7%3B%26%23xE3%3Bo%3A%20categoria%20de%20Risco%20X.%20Este%20medicamento%20causa%20malforma%26%23xE7%3B%26%23xE3%3Bo%20ao%20beb%26%23xEA%3B%20durante%20a%20gravidez.%20A%20seguran%26%23xE7%3Ba%20em%20mulheres%20gr%26%23xE1%3Bvidas%20n%26%23xE3%3Bo%20foi%20estabelecida.%20N%26%23xE3%3Bo%20foram%20conduzidos%20estudos%20cl%26%23xED%3Bnicos%20controlados%20em%20mulheres%20gr%26%23xE1%3Bvidas.%20H%26%23xE1%3B%20raros%20relatos%20de%20anomalias%20cong%26%23xEA%3Bnitas%20em%20rec%26%23xE9%3Bm-nascidos%20de%20m%26%23xE3%3Bes%20que%20receberam%20inibidores%20de%20HMG-CoAredutase%20durante%20a%20gravidez.%20Entretanto%2C%20em%20uma%20an%26%23xE1%3Blise%20de%20aproximadamente%20200%20gesta%26%23xE7%3B%26%23xF5%3Bes%20acompanhadas%20prospectivamente%20de%20mulheres%20expostas%20a%20sinvastatina%20ou%20a%20outro%20inibidor%20da%20HMG-CoA%20redutase%20estruturalmente%20relacionado%20no%20primeiro%20trimestre%20de%20gravidez%2C%20a%20incid%26%23xEA%3Bncia%20de%20anomalias%20cong%26%23xEA%3Bnitas%20foi%20compar%26%23xE1%3Bvel%20%26%23xE0%3B%20observada%20na%20popula%26%23xE7%3B%26%23xE3%3Bo%20geral.%20Esse%20n%26%23xFA%3Bmero%20de%20gesta%26%23xE7%3B%26%23xF5%3Bes%20foi%20estatisticamente%20suficiente%20para%20excluir%20um%20aumento%20de%20anomalias%20cong%26%23xEA%3Bnitas%202%2C5%20vezes%20ou%20maior%20do%20que%20a%20incid%26%23xEA%3Bncia%20conhecida.%3Cbr%3E%0AEmbora%20n%26%23xE3%3Bo%20haja%20evid%26%23xEA%3Bncia%20de%20que%20a%20incid%26%23xEA%3Bncia%20de%20anomalias%20cong%26%23xEA%3Bnitas%20nos%20descendentes%20de%20pacientes%20expostos%20a%20sinvastatina%20ou%20a%20outro%20inibidor%20da%20HMG-CoA%20redutase%20estruturalmente%20relacionado%20seja%20diferente%20da%20observada%20na%20popula%26%23xE7%3B%26%23xE3%3Bo%20geral%2C%20o%20tratamento%20da%20m%26%23xE3%3Be%20com%20sinvastatina%20pode%20reduzir%20os%20n%26%23xED%3Bveis%20fetais%20de%20mevalonato%2C%20um%20precursor%20da%20bioss%26%23xED%3Bntese%20do%20colesterol.%20A%20aterosclerose%20%26%23xE9%3B%20um%20processo%20cr%26%23xF4%3Bnico%20e%20a%20descontinua%26%23xE7%3B%26%23xE3%3Bo%20dos%20agentes%20hipolipemiantes%20durante%20a%20gravidez%20deve%20ter%20pequeno%20impacto%20sobre%20o%20risco%20a%20longo%20prazo%20associado%20%26%23xE0%3B%20hipercolesterolemia%20prim%26%23xE1%3Bria.%20Por%20essas%20raz%26%23xF5%3Bes%2C%20a%20sinvastatina%20n%26%23xE3%3Bo%20deve%20ser%20usada%20por%20mulheres%20gr%26%23xE1%3Bvidas%2C%20que%20estejam%20tentando%20engravidar%20ou%20que%20possam%20estar%20gr%26%23xE1%3Bvidas.%20O%20tratamento%20com%20sinvastatina%20deve%20ser%20interrompido%20durante%20toda%20a%20gesta%26%23xE7%3B%26%23xE3%3Bo%20ou%20at%26%23xE9%3B%20que%20se%20comprove%20que%20a%20paciente%20n%26%23xE3%3Bo%20est%26%23xE1%3B%20gr%26%23xE1%3Bvida%20(veja%20o%20item%204.%20CONTRAINDICA%26%23xC7%3B%26%23xD5%3BES).%3Cbr%3E%0AN%26%23xE3%3Bo%20se%20sabe%20se%20a%20sinvastatina%20ou%20os%20seus%20metab%26%23xF3%3Blitos%20s%26%23xE3%3Bo%20excretados%20no%20leite%20materno.%20Uma%20vez%20que%20muitos%20f%26%23xE1%3Brmacos%20s%26%23xE3%3Bo%20excretados%20no%20leite%20materno%20e%20podem%20causar%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20graves%2C%20mulheres%20que%20estejam%20recebendo%20sinvastatina%20n%26%23xE3%3Bo%20devem%20amamentar%20(veja%20o%20item%204.%20CONTRAINDICA%26%23xC7%3B%26%23xD5%3BES).%3Cbr%3E%0AIdosos%3A%20a%20efic%26%23xE1%3Bcia%20da%20sinvastatina%20avaliada%20pela%20redu%26%23xE7%3B%26%23xE3%3Bo%20do%20colesterol%20total%20e%20do%20LDL-colesterol%2C%20em%20pacientes%20com%20mais%20de%2065%20anos%20de%20idade%20em%20estudos%20cl%26%23xED%3Bnicos%20controlados%2C%20foi%20semelhante%20%26%23xE0%3B%20observada%20na%20popula%26%23xE7%3B%26%23xE3%3Bo%20geral%20e%20n%26%23xE3%3Bo%20houve%20aumento%20evidente%20na%20frequ%26%23xEA%3Bncia%20global%20de%20achados%20adversos%20cl%26%23xED%3Bnicos%20ou%20laboratoriais.%3Cbr%3E%0ANo%20entanto%2C%20em%20um%20estudo%20cl%26%23xED%3Bnico%20de%20pacientes%20tratados%20com%20sinvastatina%2080%20mg%2Fdia%2C%20pacientes%20%26%23x2265%3B%2065%20anos%20de%20idade%20tiveram%20um%20risco%20aumentado%20de%20miopatia%20em%20compara%26%23xE7%3B%26%23xE3%3Bo%20com%20pacientes%20%26lt%3B%2065%20anos%20de%20idade.%3Cbr%3E%0ACrian%26%23xE7%3Bas%3A%20a%20seguran%26%23xE7%3Ba%20e%20a%20efic%26%23xE1%3Bcia%20em%20crian%26%23xE7%3Bas%20n%26%23xE3%3Bo%20foram%20estabelecidas.%20At%26%23xE9%3B%20o%20momento%2C%20sinvastatina%20n%26%23xE3%3Bo%20%26%23xE9%3B%20recomendada%20para%20uso%20pedi%26%23xE1%3Btrico.%3C%2Fp%3E%0A%3Ch2%3EIntera%26%23xE7%3B%26%23xF5%3Bes%20medicamentosas%20de%20SINVASTATINA%3C%2Fh2%3E%0A%3Cp%3EM%26%23xFA%3Bltiplos%20mecanismos%20podem%20contribuir%20para%20potenciais%20intera%26%23xE7%3B%26%23xF5%3Bes%20com%20os%20inibidores%20da%20HMG-CoA%20redutase.%20F%26%23xE1%3Brmacos%20ou%20fitoter%26%23xE1%3Bpicos%20que%20inibem%20certas%20vias%20enzim%26%23xE1%3Bticas%20(por%20exemplo%20CYP3A4)%20e%2Fou%20transportadoras%20(por%20exemplo%20ATP1B)%20que%20podem%20aumentar%20as%20concentra%26%23xE7%3B%26%23xF5%3Bes%20plasm%26%23xE1%3Bticas%20de%20sinvastatina%20e%20sinvastatina%20%26%23xE1%3Bcida%20e%20podem%20induzir%20a%20um%20risco%20aumentado%20de%20miopatia%2Frabdomiolise.%3C%2Fp%3E%0A%3Cp%3EConsulte%20as%20informa%26%23xE7%3B%26%23xF5%3Bes%20prescritas%20para%20todos%20os%20f%26%23xE1%3Brmacos%20utilizados%20concomitantemente%20para%20obter%20mais%20informa%26%23xE7%3B%26%23xF5%3Bes%20sobre%20suas%20potenciais%20intera%26%23xE7%3B%26%23xF5%3Bes%20com%20sinvastatina%20e%2Fou%20potenciais%20altera%26%23xE7%3B%26%23xF5%3Bes%20enzim%26%23xE1%3Bticas%20ou%20de%20transportadores%20e%20poss%26%23xED%3Bveis%20ajustes%20da%20dose%20e%20dos%20regimes.%3C%2Fp%3E%0A%3Cp%3EMedicamentos%20contraindicados%3Cbr%3E%0AO%20uso%20concomitante%20dos%20seguintes%20medicamentos%20%26%23xE9%3B%20contraindicado%3A%3Cbr%3E%0A-Inibidores%20potentes%20de%20CYP3A4%3A%20a%20sinvastatina%20%26%23xE9%3B%20metabolizada%20pela%20isoenzima%20do%20citocromo%203A4%2C%20mas%20n%26%23xE3%3Bo%20apresenta%20atividade%20inibit%26%23xF3%3Bria%20do%20CYP3A4%2C%20portanto%20n%26%23xE3%3Bo%20se%20espera%20que%20afete%20as%20concentra%26%23xE7%3B%26%23xF5%3Bes%20plasm%26%23xE1%3Bticas%20de%20outros%20f%26%23xE1%3Brmacos%20metabolizados%20pela%20CYP3A4.%20Os%20inibidores%20potentes%20da%20CYP3A4%20aumentam%20o%20risco%20de%20miopatia%20por%20reduzirem%20a%20elimina%26%23xE7%3B%26%23xE3%3Bo%20da%20sinvastatina.%20O%20uso%20concomitante%20de%20medicamentos%20conhecidos%20por%20apresentarem%20um%20potente%20efeito%20inibit%26%23xF3%3Brio%20sobre%20a%20CYP3A4%20(por%20exemplo%2C%20itraconazol%2C%20cetoconazol%2C%20posaconazol%2C%20voriconazol%2C%20eritromicina%2C%20claritromicina%2C%20telitromicina%2C%20inibidores%20da%20protease%20do%20HIV%2C%20boceprevir%2C%20telaprevir%2C%20nefazodona%20e%20medicamentos%20contendo%20cobicistate)%20%26%23xE9%3B%20contraindicado%20(veja%20os%20itens%204.%20CONTRAINDICA%26%23xC7%3B%26%23xD5%3BES%3B%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise%3B%20CARACTER%26%23xCD%3BSTICAS%20FARMACOL%26%23xD3%3BGICAS%2C%20Farmacocin%26%23xE9%3Btica).%3Cbr%3E%0A-Genfibrozila%2C%20ciclosporina%20ou%20danazol%3A%20(veja%20os%20itens%204.CONTRAINDICA%26%23xC7%3B%26%23xD5%3BES%3B%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise%3B%203.%20CARACTER%26%23xCD%3BSTICAS%20FARMACOL%26%23xD3%3BGICAS%2C%20Farmacocin%26%23xE9%3Btica).%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Cp%3EOutras%20intera%26%23xE7%3B%26%23xF5%3Bes%20medicamentosas%3Cbr%3E%0A-Outros%20fibratos%3A%20o%20risco%20de%20miopatia%20%26%23xE9%3B%20aumentado%20pela%20genfibrozila%20(veja%20o%20item%204.%20CONTRAINDICA%26%23xC7%3B%26%23xD5%3BES)%20e%20outros%20fibratos%20(com%20exce%26%23xE7%3B%26%23xE3%3Bo%20do%20fenofibrato)%3B%20estes%20medicamentos%20hipolipemiantes%20podem%20causar%20miopatia%20quando%20administrados%20isoladamente.%20Quando%20a%20sinvastatina%20e%20o%20fenofibrato%20s%26%23xE3%3Bo%20administrados%20concomitantemente%2C%20n%26%23xE3%3Bo%20h%26%23xE1%3B%20nenhuma%20evid%26%23xEA%3Bncia%20de%20que%20o%20risco%20de%20miopatia%20supere%20a%20soma%20dos%20riscos%20individuais%20de%20cada%20agente%20(veja%20os%20itens%204.%20CONTRAINDICA%26%23xC7%3B%26%23xD5%3BES%20e%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise).%3Cbr%3E%0A-%26%23xC1%3Bcido%20fus%26%23xED%3Bdico%3A%20o%20risco%20de%20miopatia%2Frabdomi%26%23xF3%3Blise%20pode%20aumentar%20com%20a%20administra%26%23xE7%3B%26%23xE3%3Bo%20concomitante%20de%20%26%23xE1%3Bcido%20fus%26%23xED%3Bdico%20(veja%20os%20itens%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise%20e%203.%20CARACTER%26%23xCD%3BSTICAS%20FARMACOL%26%23xD3%3BGICAS%2C%20Farmacocin%26%23xE9%3Btica).%3Cbr%3E%0A-Amiodarona%3A%20o%20risco%20de%20miopatia%2Frabdomi%26%23xF3%3Blise%20%26%23xE9%3B%20aumentado%20pela%20administra%26%23xE7%3B%26%23xE3%3Bo%20concomitante%20de%20amiodarona%20com%20sinvastatina%20(veja%20os%20itens%208.%20POSOLOGIA%20E%20MODO%20DE%20USAR%20e%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise).%3Cbr%3E%0A-Bloqueadores%20do%20canal%20de%20c%26%23xE1%3Blcio%3A%20o%20risco%20de%20miopatia%2Frabdomi%26%23xF3%3Blise%20%26%23xE9%3B%20aumentado%20pela%20administra%26%23xE7%3B%26%23xE3%3Bo%20concomitante%20de%20verapamil%2C%20diltiazem%20ou%20anlodipino%20(veja%20os%20itens%208.%20POSOLOGIA%20E%20MODO%20DE%20USAR%3B%20e%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise).%3Cbr%3E%0A-Lomitapida%3A%20o%20risco%20de%20miopatia%2Frabdomi%26%23xF3%3Blise%20pode%20ser%20aumentado%20pela%20administra%26%23xE7%3B%26%23xE3%3Bo%20concomitante%20com%20lomitapida%20(veja%20os%20itens%208.%20POSOLOGIA%20E%20MODO%20DE%20USAR%20e%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise).%3Cbr%3E%0A-Inibidores%20moderados%20da%20CYP3A4%3A%20os%20pacientes%20que%20tomam%20outros%20medicamentos%20conhecidos%20por%20apresentarem%20efeito%20inibit%26%23xF3%3Brio%20moderado%20sobre%20a%20CYP3A4%20concomitantemente%20com%20a%20sinvastatina%2C%20particularmente%20com%20doses%20mais%20altas%20de%20sinvastatina%2C%20podem%20ter%20um%20maior%20risco%20de%20miopatia%20(veja%20o%20item%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise).%3C%2Fp%3E%0A%3Cp%3E-Inibidores%20da%20prote%26%23xED%3Bna%20transportadora%20OATP1B1%3A%20a%20sinvastatina%20%26%23xE1%3Bcida%20%26%23xE9%3B%20um%20substrato%20da%20prote%26%23xED%3Bna%20transportadora%20OATP1B1.%20A%20administra%26%23xE7%3B%26%23xE3%3Bo%20concomitante%20de%20medicamentos%20inibidores%20da%20prote%26%23xED%3Bna%20transportadora%20OATP1B1%20pode%20levar%20ao%20aumento%20da%20concentra%26%23xE7%3B%26%23xE3%3Bo%20plasm%26%23xE1%3Btica%20de%20sinvastatina%20%26%23xE1%3Bcida%20e%20ao%20aumento%20do%20risco%20de%20miopatia%20(veja%20os%20itens%204.%20CONTRAINDICA%26%23xC7%3B%26%23xD5%3BES%20e%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise).%3C%2Fp%3E%0A%3Cp%3E-Inibidores%20da%20prote%26%23xED%3Bna%20resistente%20ao%20c%26%23xE2%3Bncer%20de%20mama%20(BCPR)%3A%20a%20sinvastatina%20%26%23xE9%3B%20um%20substrato%20do%20transportador%20de%20efluxo%20da%20BCPR.%20A%20administra%26%23xE7%3B%26%23xE3%3Bo%20concomitante%20de%20medicamentos%20inibidores%20da%20BCPR%20(por%20exemplo%2C%20elbasvir%20e%20grazoprevir)%20pode%20levar%20a%20um%20aumento%20das%20concentra%26%23xE7%3B%26%23xF5%3Bes%20plasm%26%23xE1%3Bticas%20da%20sinvastatina%20e%20a%20um%20risco%20aumentado%20de%20miopatia.%20Quando%20a%20sinvastatina%20e%20um%20inibidor%20da%20BCPR%20forem%20coadministrados%2C%20um%20ajuste%20da%20dose%20de%20sinvastatina%20poder%26%23xE1%3B%20ser%20necess%26%23xE1%3Brio%20(veja%20os%20itens%208.%20POSOLOGIA%20E%20MODO%20DE%20USAR%3B%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise%20e%203.%20CARACTER%26%23xCD%3BSTICAS%20FARMACOL%26%23xD3%3BGICAS%2C%20Farmacocin%26%23xE9%3Btica).%3C%2Fp%3E%0A%3Cp%3E-%26%23xC1%3Bcido%20nicot%26%23xED%3Bnico%20(Niacina)%20(%26%23x2265%3B%201%20g%2Fdia)%3A%20casos%20de%20miopatia%2Frabdomi%26%23xF3%3Blise%20foram%20observados%20com%20a%20sinvastatina%20coadministrada%20com%20doses%20hipolipemiantes%20(%26%23x2265%3B1%20g%2Fdia)%20de%20%26%23xE1%3Bcido%20nicot%26%23xED%3Bnico%20(veja%20o%20item%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise).%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Cp%3E-Colchicina%3A%20houve%20relatos%20de%20miopatia%20e%20rabdomi%26%23xF3%3Blise%20com%20a%20administra%26%23xE7%3B%26%23xE3%3Bo%20concomitante%20de%20colchicina%20e%20sinvastatina%20em%20pacientes%20com%20insufici%26%23xEA%3Bncia%20renal.%20Aconselha-se%20o%20monitoramento%20de%20pacientes%20que%20tomam%20esta%20combina%26%23xE7%3B%26%23xE3%3Bo.%3C%2Fp%3E%0A%3Cp%3EOutras%20intera%26%23xE7%3B%26%23xF5%3Bes%3Cbr%3E%0AO%20suco%20de%20grapefruit%20cont%26%23xE9%3Bm%20um%20ou%20mais%20componentes%20que%20inibem%20o%20CYP3A4%20e%20podem%20aumentar%20os%20n%26%23xED%3Bveis%20plasm%26%23xE1%3Bticos%20de%20medicamentos%20metabolizados%20por%20este%20sistema%20enzim%26%23xE1%3Btico.%20O%20efeito%20do%20consumo%20t%26%23xED%3Bpico%20(um%20copo%20de%20250%20mL%20diariamente)%20%26%23xE9%3B%20m%26%23xED%3Bnimo%20(aumento%20de%2013%25%20nos%20n%26%23xED%3Bveis%20plasm%26%23xE1%3Bticos%20da%20atividade%20inibit%26%23xF3%3Bria%20da%20HMG-CoA%20redutase%2C%20conforme%20medido%20pela%20%26%23xE1%3Brea%20sob%20a%20curva%20de%20concentra%26%23xE7%3B%26%23xE3%3Bo-tempo)%20e%20sem%20import%26%23xE2%3Bncia%20cl%26%23xED%3Bnica.%20Entretanto%2C%20uma%20vez%20que%20quantidades%20muito%20grandes%20aumentam%20significativamente%20os%20n%26%23xED%3Bveis%20plasm%26%23xE1%3Bticos%20da%20atividade%20inibit%26%23xF3%3Bria%20da%20HMG-CoA%20redutase%20o%20suco%20de%20grapefruit%20deve%20ser%20evitado%20(veja%20o%20item%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise).%3C%2Fp%3E%0A%3Cp%3E-Derivados%20cumar%26%23xED%3Bnicos%3A%20em%20dois%20estudos%20cl%26%23xED%3Bnicos%2C%20um%20que%20envolveu%20volunt%26%23xE1%3Brios%20normais%20e%20outro%2C%20pacientes%20hipercolesterol%26%23xEA%3Bmicos%2C%20a%20sinvastatina%2C%20na%20dose%2020-40%20mg%2Fdia%2C%20potencializou%20discretamente%20o%20efeito%20de%20anticoagulantes%20cumar%26%23xED%3Bnicos%3A%20o%20tempo%20de%20protrombina%2C%20expresso%20como%20INR%20(Raz%26%23xE3%3Bo%20Internacional%20Normalizada)%2C%20aumentou%20em%20rela%26%23xE7%3B%26%23xE3%3Bo%20aos%20valores%20do%20per%26%23xED%3Bodo%20basal%20de%201%2C7%20para%201%2C8%20e%20de%202%2C6%20para%203%2C4%20nos%20estudos%20com%20volunt%26%23xE1%3Brios%20e%20pacientes%2C%20respectivamente.%20O%20tempo%20de%20protrombina%20dos%20pacientes%20que%20estejam%20tomando%20anticoagulantes%20cumar%26%23xED%3Bnicos%20deve%20ser%20determinado%20antes%20de%20se%20iniciar%20o%20tratamento%20com%20a%20sinvastatina%20e%20sempre%20que%20necess%26%23xE1%3Brio%20durante%20a%20fase%20inicial%20do%20tratamento%2C%20para%20assegurar%20que%20n%26%23xE3%3Bo%20ocorra%20nenhuma%20altera%26%23xE7%3B%26%23xE3%3Bo%20significativa.%20Uma%20vez%20estabilizado%2C%20o%20tempo%20de%20protrombina%20poder%26%23xE1%3B%20ser%20monitorizado%20com%20a%20periodicidade%20usualmente%20recomendada%20para%20pacientes%20em%20tratamento%20com%20anticoagulantes%20cumar%26%23xED%3Bnicos.%20O%20mesmo%20procedimento%20deve%20ser%20repetido%20em%20caso%20de%20modifica%26%23xE7%3B%26%23xE3%3Bo%20da%20dose%20ou%20de%20descontinua%26%23xE7%3B%26%23xE3%3Bo%20da%20sinvastatina.%20O%20tratamento%20com%20a%20sinvastatina%20n%26%23xE3%3Bo%20foi%20associado%20a%20sangramento%20ou%20altera%26%23xE7%3B%26%23xF5%3Bes%20do%20tempo%20de%20protrombina%20em%20pacientes%20que%20n%26%23xE3%3Bo%20estavam%20utilizando%20anticoagulantes.%3C%2Fp%3E%0A%3Ch2%3ERea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20%2F%20efeitos%20colaterais%20de%20SINVASTATINA%3C%2Fh2%3E%0A%3Cp%3EA%20sinvastatina%20%26%23xE9%3B%20geralmente%20bem%20tolerada%3B%20a%20maioria%20das%20experi%26%23xEA%3Bncias%20adversas%20foi%20de%20natureza%20leve%20e%20transit%26%23xF3%3Bria.%20Menos%20de%202%25%20dos%20pacientes%20foram%20descontinuados%20dos%20estudos%20cl%26%23xED%3Bnicos%20controlados%20por%20causa%20de%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20atribu%26%23xED%3Bveis%20a%20sinvastatina.%3Cbr%3E%0AAs%20frequ%26%23xEA%3Bncias%20dos%20seguintes%20eventos%20adversos%2C%20que%20foram%20relatados%20durante%20os%20estudos%20cl%26%23xED%3Bnicos%20e%2Fou%20uso%20p%26%23xF3%3Bs-%20comercializa%26%23xE7%3B%26%23xE3%3Bo%2C%20s%26%23xE3%3Bo%20categorizadas%20com%20base%20em%20uma%20avalia%26%23xE7%3B%26%23xE3%3Bo%20de%20suas%20taxas%20de%20incid%26%23xEA%3Bncia%20nos%20amplos%20estudos%20cl%26%23xED%3Bnicos%2C%20prolongados%2C%20controlados%20com%20placebo%20incluindo%20os%20estudos%20HPS%20e%204S%20com%2020.536%20e%204.444%20pacientes%2C%20respectivamente%20(veja%20o%20item%202.%20RESULTADOS%20DE%20EFIC%26%23xC1%3BCIA).%20Para%20o%20HPS%2C%20foram%20registrados%20apenas%20os%20eventos%20adversos%20graves%20bem%20como%20mialgia%2C%20aumento%20de%20transaminases%20s%26%23xE9%3Bricas%20e%20CK.%20Para%20o%204S%2C%20foram%20registrados%20todos%20os%20eventos%20adversos%20listados%20abaixo.%20Se%20as%20taxas%20de%20incid%26%23xEA%3Bncia%20para%20sinvastatina%20fossem%20menores%20ou%20similares%20%26%23xE0%3Bs%20do%20placebo%20nestes%20estudos%2C%20e%20houvesse%20eventos%20de%20relato%20espont%26%23xE2%3Bneo%20razoavelmente%20com%20rela%26%23xE7%3B%26%23xE3%3Bo%20causal%20similar%2C%20esses%20eventos%20adversos%20seriam%20categorizados%20como%20%26%23x201C%3Braros%26%23x201D%3B.%3Cbr%3E%0ANo%20estudo%20HPS%20(veja%20o%20item%202.%20RESULTADOS%20DE%20EFIC%26%23xC1%3BCIA)%20envolvendo%2020.536%20pacientes%20tratados%20com%2040%20mg%2Fdia%20de%20sinvastatina%20(n%20%3D%2010.269)%20ou%20placebo%20(n%20%3D%2010.267)%2C%20os%20perfis%20de%20seguran%26%23xE7%3Ba%20foram%20compar%26%23xE1%3Bveis%20entre%20os%20pacientes%20tratados%20com%20sinvastatina%20e%20os%20pacientes%20que%20receberam%20placebo%20durante%20uma%20m%26%23xE9%3Bdia%20de%205%20anos%20de%20estudo.%20As%20frequ%26%23xEA%3Bncias%20de%20descontinua%26%23xE7%3B%26%23xE3%3Bo%20por%20eventos%20adversos%20foram%20compar%26%23xE1%3Bveis%20(4%2C8%25%20em%20pacientes%20tratados%20com%20sinvastatina%20em%20compara%26%23xE7%3B%26%23xE3%3Bo%20com%205%2C1%25%20em%20pacientes%20que%20receberam%20placebo).%20A%20incid%26%23xEA%3Bncia%20de%20miopatia%20foi%20%26lt%3B%200%2C1%25%20em%20pacientes%20tratados%20com%20sinvastatina%2040mg.%20N%26%23xED%3Bveis%20elevados%20de%20transaminases%20(%26gt%3B%203X%20LSN%20confirmados%20por%20um%20novo%20teste)%20ocorreram%20em%200%2C21%25%20(n%20%3D%2021)%20dos%20pacientes%20tratados%20com%20sinvastatina%20em%20compara%26%23xE7%3B%26%23xE3%3Bo%20com%200%2C09%25%20(n%20%3D%209)%20dos%20pacientes%20que%20receberam%20placebo.%3Cbr%3E%0ANo%20estudo%204S%20(veja%20o%20item%202.%20RESULTADOS%20DE%20EFIC%26%23xC1%3BCIA)%20envolvendo%204.444%20pacientes%20que%20receberam%2020-40mg%2Fdia%20de%20sinvastatina%20(n%20%3D%202.221)%20ou%20placebo%20(n%20%3D%202.223)%2C%20os%20perfis%20de%20seguran%26%23xE7%3Ba%20e%20tolerabilidade%20foram%20compar%26%23xE1%3Bveis%20entre%20os%20grupos%20de%20tratamento%20durante%20a%20mediana%20de%205%2C4%20anos%20do%20estudo.%3Cbr%3E%0AAs%20frequ%26%23xEA%3Bncias%20de%20eventos%20adversos%20s%26%23xE3%3Bo%20classificadas%20de%20acordo%20com%20as%20seguintes%20categorias%3A%20Muito%20comum%20(%26gt%3B%201%2F10)%2C%20Comum%20(%26%23x2265%3B%201%2F100%2C%20%26lt%3B%201%2F10)%2C%20Incomum%20(%26%23x2265%3B%201%2F1000%2C%20%26lt%3B%201%2F100)%2C%20Raro%20(%26%23x2265%3B%201%2F10.000%2C%20%26lt%3B%201%2F1000)%2C%20Muito%20Raro%20(%26lt%3B%201%2F10.000)%2C%20Desconhecido%20(n%26%23xE3%3Bo%20puderam%20ser%20estimados%20a%20partir%20dos%20dados%20dispon%26%23xED%3Bveis).%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Cp%3EDist%26%23xFA%3Brbios%20do%20sangue%20e%20do%20sistema%20linf%26%23xE1%3Btico%3A%3Cbr%3E%0ARaro%3A%20anemia.%3Cbr%3E%0ADist%26%23xFA%3Brbios%20do%20sistema%20nervoso%3A%3Cbr%3E%0ARaro%3A%20cefaleia%2C%20parestesia%2C%20tontura%2C%20neuropatia%20perif%26%23xE9%3Brica.%3Cbr%3E%0AMuito%20raro%3A%20perda%20de%20mem%26%23xF3%3Bria.%3Cbr%3E%0ADist%26%23xFA%3Brbios%20respirat%26%23xF3%3Brios%2C%20tor%26%23xE1%3Bcicos%20e%20do%20mediastino%3A%3Cbr%3E%0ADesconhecido%3A%20doen%26%23xE7%3Ba%20pulmonar%20intersticial.%3Cbr%3E%0ADist%26%23xFA%3Brbios%20gastrintestinais%3A%3Cbr%3E%0ARaro%3A%20constipa%26%23xE7%3B%26%23xE3%3Bo%2C%20dor%20abdominal%2C%20flatul%26%23xEA%3Bncia%2C%20dispepsia%2C%20diarreia%2C%20n%26%23xE1%3Busea%2C%20v%26%23xF4%3Bmito%2C%20pancreatite.%3Cbr%3E%0ADist%26%23xFA%3Brbios%20da%20pele%20e%20do%20tecido%20subcut%26%23xE2%3Bneo%3A%3Cbr%3E%0ARaro%3A%20erup%26%23xE7%3B%26%23xE3%3Bo%20cut%26%23xE2%3Bnea%2C%20prurido%2C%20alopecia.%3Cbr%3E%0ADist%26%23xFA%3Brbios%20musculoesquel%26%23xE9%3Bticos%20e%20do%20tecido%20conjuntivo%3A%3Cbr%3E%0ARaro%3A%20miopatia*%2C%20rabdomi%26%23xF3%3Blise%20(veja%20o%20item%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES)%2C%20mialgia%2C%20c%26%23xE3%3Bibras%20musculares.%20*Em%20um%20estudo%20cl%26%23xED%3Bnico%2C%20a%20miopatia%20ocorreu%20comumente%20em%20pacientes%20tratados%20com%20a%20sinvastatina%2080%20mg%2Fdia%20em%20compara%26%23xE7%3B%26%23xE3%3Bo%20com%20pacientes%20tratados%20com%2020%20mg%2Fdia%20(1%2C0%20%25%20versus%200%2C02%20%25%2C%20respectivamente).%3Cbr%3E%0ADesconhecido%3A%20tendinopatia%2C%20algumas%20vezes%20complicada%20pela%20ruptura%3B%20miopatia%20necrotizante%20imunomediada%20(MNIM).**%3Cbr%3E%0A**Houve%20relatos%20muito%20raros%20de%20miopatia%20necrotizante%20imunomediada%20(MNIM)%2C%20uma%20miopatia%20autoimune%2C%20durante%20ou%20ap%26%23xF3%3Bs%20tratamento%20com%20algumas%20estatinas.%20A%20MNIM%20%26%23xE9%3B%20clinicamente%20caracterizada%20por%3A%20fraqueza%20muscular%20proximal%20persistente%20e%20creatina%20quinase%20s%26%23xE9%3Brica%20elevada%2C%20que%20persistem%20mesmo%20com%20a%20descontinua%26%23xE7%3B%26%23xE3%3Bo%20do%20tratamento%20com%20estatina%3B%20bi%26%23xF3%3Bpsia%20muscular%20mostrando%20miopatia%20necrotizante%20sem%20inflama%26%23xE7%3B%26%23xE3%3Bo%20significativa%3B%20melhoria%20com%20agentes%20imunossupressores%20(veja%20o%20item%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise).%3Cbr%3E%0ADist%26%23xFA%3Brbios%20do%20sistema%20reprodutivo%20e%20da%20mama%3A%3Cbr%3E%0ADesconhecido%3A%20disfun%26%23xE7%3B%26%23xE3%3Bo%20er%26%23xE9%3Btil.%3Cbr%3E%0ADist%26%23xFA%3Brbios%20gerais%20e%20condi%26%23xE7%3B%26%23xF5%3Bes%20no%20local%20de%20administra%26%23xE7%3B%26%23xE3%3Bo%3A%3Cbr%3E%0ARaro%3A%20astenia.%3Cbr%3E%0ADist%26%23xFA%3Brbios%20hepatobiliares%3A%3Cbr%3E%0ARaro%3A%20hepatite%2Ficter%26%23xED%3Bcia%3B%3Cbr%3E%0AMuito%20raro%3A%20insufici%26%23xEA%3Bncia%20hep%26%23xE1%3Btica%20fatal%20e%20n%26%23xE3%3Bo%20fatal.%3Cbr%3E%0ADist%26%23xFA%3Brbios%20psiqui%26%23xE1%3Btricos%3A%3Cbr%3E%0AMuito%20raro%3A%20ins%26%23xF4%3Bnia%3B%3Cbr%3E%0ADesconhecido%3A%20depress%26%23xE3%3Bo.%3Cbr%3E%0AUma%20s%26%23xED%3Bndrome%20aparente%20de%20hipersensibilidade%20tem%20sido%20relatada%20raramente%2C%20a%20qual%20incluiu%20algumas%20das%20caracter%26%23xED%3Bsticas%20a%20seguir%3A%20angioedema%2C%20s%26%23xED%3Bndrome%20semelhante%20a%20l%26%23xFA%3Bpus%2C%20polimialgia%20reum%26%23xE1%3Btica%2C%20dermatomiosite%2C%20vasculite%2C%20trombocitopenia%2C%20eosinofilia%2C%20velocidade%20de%20sedimenta%26%23xE7%3B%26%23xE3%3Bo%20eritrocit%26%23xE1%3Bria%20(VHS)%20aumentada%2C%20artrite%2C%20artralgia%2C%20urtic%26%23xE1%3Bria%2C%20fotossensibilidade%2C%20febre%2C%20rubor%2C%20dispneia%20e%20mal-estar.%3Cbr%3E%0AInvestiga%26%23xE7%3B%26%23xF5%3Bes%3A%3Cbr%3E%0ARaro%3A%20aumentos%20de%20transaminases%20s%26%23xE9%3Bricas%20(alanina%20aminotransferase%2C%20aspartato%20aminotransferase%2C%20%26%23x3B3%3B-glutamil%20transpeptidase)%20(veja%20o%20item%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Efeitos%20hep%26%23xE1%3Bticos)%2C%20n%26%23xED%3Bveis%20elevados%20de%20fosfatase%20alcalina%3B%20aumento%20dos%20n%26%23xED%3Bveis%20s%26%23xE9%3Bricos%20de%20CK%20(veja%20o%20item%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES).%3Cbr%3E%0ADesconhecido%3A%20foi%20reportado%20aumento%20dos%20n%26%23xED%3Bveis%20de%20HbA1c%20e%20glicose%20s%26%23xE9%3Brica%20de%20jejum%20com%20estatinas%2C%20incluindo%20sinvastatina.%3Cbr%3E%0AHouve%20raros%20relatos%20p%26%23xF3%3Bs-comercializa%26%23xE7%3B%26%23xE3%3Bo%20de%20disfun%26%23xE7%3B%26%23xE3%3Bo%20cognitiva%20(por%20exemplo%2C%20perda%20de%20mem%26%23xF3%3Bria%2C%20esquecimento%2C%20amn%26%23xE9%3Bsia%2C%20deteriora%26%23xE7%3B%26%23xE3%3Bo%20da%20mem%26%23xF3%3Bria%2C%20confus%26%23xE3%3Bo)%20associados%20com%20o%20uso%20de%20estatinas%2C%20incluindo%20sinvastatina.%20Os%20relatos%20geralmente%20n%26%23xE3%3Bo%20s%26%23xE3%3Bo%20graves%20e%20s%26%23xE3%3Bo%20revers%26%23xED%3Bveis%20com%20a%20descontinua%26%23xE7%3B%26%23xE3%3Bo%20da%20estatina%2C%20com%20tempos%20vari%26%23xE1%3Bveis%20para%20o%20in%26%23xED%3Bcio%20dos%20sintomas%20(de%201%20dia%20a%20anos)%20e%20resolu%26%23xE7%3B%26%23xE3%3Bo%20dos%20sintomas%20(mediana%20de%203%20semanas).%3Cbr%3E%0AOs%20seguintes%20eventos%20adversos%20adicionais%20foram%20relatados%20com%20algumas%20estatinas%3A%3Cbr%3E%0A-dist%26%23xFA%3Brbios%20do%20sono%2C%20incluindo%20pesadelos%3B%3Cbr%3E%0A-disfun%26%23xE7%3B%26%23xE3%3Bo%20sexual%3B%3Cbr%3E%0A-Diabetes%20mellitus%3A%20frequ%26%23xEA%3Bncia%20depende%20da%20presen%26%23xE7%3Ba%20ou%20aus%26%23xEA%3Bncia%20de%20fatores%20de%20risco%20(glicose%20no%20sangue%20em%20jejum%20%26%23x2265%3B%205%2C6%20mmol%2FL%2C%20IMC%26gt%3B%2030%20kg%2Fm2%2C%20altos%20n%26%23xED%3Bveis%20de%20triglicer%26%23xED%3Bdeos%2C%20hist%26%23xF3%3Brico%20de%20hipertens%26%23xE3%3Bo).%3Cbr%3E%0APopula%26%23xE7%3B%26%23xE3%3Bo%20pedi%26%23xE1%3Btrica%3Cbr%3E%0AEm%20um%20estudo%20de%2048%20semanas%20envolvendo%20crian%26%23xE7%3Bas%20e%20adolescentes%20(meninos%20Tanner%20Stage%20II%20e%20acima%20e%20meninas%20com%20pelo%20menos%20um%20ano%20de%20p%26%23xF3%3Bs-menarca)%20entre%2010-17%20anos%20de%20idade%20com%20hipercolesterolemia%20familiar%20heterozig%26%23xF3%3Btica%20(n%20%3D%20175)%2C%20no%20geral%2C%20o%20perfil%20de%20seguran%26%23xE7%3Ba%20e%20tolerabilidade%20do%20grupo%20tratado%20com%20sinvastatina%20foi%20semelhante%20ao%20do%20grupo%20de%20tratados%20com%20placebo.%20Os%20efeitos%20a%20longo%20prazo%20no%20desenvolvimento%20f%26%23xED%3Bsico%2C%20intelectual%20e%20sexual%20s%26%23xE3%3Bo%20desconhecidos.%20N%26%23xE3%3Bo%20h%26%23xE1%3B%20dados%20suficientes%20dispon%26%23xED%3Bveis%20atualmente%20ap%26%23xF3%3Bs%20um%20ano%20de%20tratamento.%3C%2Fp%3E%0A%3Cp%3EEm%20casos%20de%20eventos%20adversos%2C%20notifique%20ao%20Sistema%20de%20Notifica%26%23xE7%3B%26%23xF5%3Bes%20em%20Vigil%26%23xE2%3Bncia%20Sanit%26%23xE1%3Bria%20%26%23x2013%3B%20NOTIVISA%2C%20dispon%26%23xED%3Bvel%20em%20www.anvisa.gov.br%2Fhotsite%2Fnotivisa%2Findex.htm%2C%20ou%20para%20a%20Vigil%26%23xE2%3Bncia%20Sanit%26%23xE1%3Bria%20Estadual%20ou%20Municipal.%3C%2Fp%3E%0A%3Ch2%3ESINVASTATINA%20%26%23x2013%3B%20Posologia%3C%2Fh2%3E%0A%3Cp%3EA%20varia%26%23xE7%3B%26%23xE3%3Bo%20posol%26%23xF3%3Bgica%20de%20sinvastatina%20%26%23xE9%3B%20de%205-80%20mg%2Fdia%2C%20administrados%20em%20dose%20%26%23xFA%3Bnica%2C%20%26%23xE0%3B%20noite.%20Ajustes%20posol%26%23xF3%3Bgicos%2C%20se%20necess%26%23xE1%3Brios%2C%20devem%20ser%20feitos%20a%20intervalos%20n%26%23xE3%3Bo%20inferiores%20a%204%20semanas.%3Cbr%3E%0ADevido%20ao%20aumento%20do%20risco%20de%20miopatia%2C%20incluindo%20rabdomi%26%23xF3%3Blise%2C%20particularmente%20durante%20o%20primeiro%20ano%20de%20tratamento%2C%20o%20uso%20da%20dose%2080%20mg%20de%20sinvastatina%20deve%20ser%20restrito%20a%20pacientes%20que%20est%26%23xE3%3Bo%20tomando%20sinvastatina%2080%20mg%20de%20forma%20cont%26%23xED%3Bnua%20(por%2012%20meses%20ou%20mais)%2C%20sem%20evid%26%23xEA%3Bncias%20de%20toxicidade%20muscular%20(veja%20o%20item%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise).%20O%20uso%20de%20sinvastatina%2080%20mg%20n%26%23xE3%3Bo%20deve%20ser%20iniciado%20em%20pacientes%20novos%2C%20incluindo%20que%20j%26%23xE1%3B%20tomam%20doses%20menores%20do%20medicamento.%3Cbr%3E%0APacientes%20que%20est%26%23xE3%3Bo%20atualmente%20tolerando%20a%20dose%20de%2080%20mg%20de%20sinvastatina%20e%20que%20precisam%20iniciar%20um%20medicamento%20que%20%26%23xE9%3B%20contraindicado%20ou%20um%20medicamento%20com%20potencial%20de%20intera%26%23xE7%3B%26%23xE3%3Bo%20medicamentosa%20com%20a%20sinvastativa%20e%20que%20limita%20a%20sua%20dose%20m%26%23xE1%3Bxima%20permitida%2C%20devem%20ser%20mudados%20para%20uma%20estatina%20alternativa%20ou%20regime%20baseado%20em%20estatina%20com%20menor%20potencial%20de%20intera%26%23xE7%3B%26%23xE3%3Bo%20medicamentosa.%3Cbr%3E%0ADevido%20ao%20aumento%20do%20risco%20de%20miopatia%2C%20incluindo%20a%20rabdomi%26%23xF3%3Blise%2C%20associado%20com%20a%20dose%20de%2080%20mg%20de%20sinvastatina%2C%20pacientes%20incapazes%20de%20alcan%26%23xE7%3Bar%20as%20suas%20metas%20de%20colesterol%20LDL%2C%20utilizando%20a%20dose%20de%2040%20mg%20de%20sinvastatina%20n%26%23xE3%3Bo%20devem%20ser%20titulado%20para%20a%20dose%20de%2080%20mg%2C%20mas%20devem%20ser%20colocados%20em%20tratamento(s)%20alternativo(s)%20para%20redu%26%23xE7%3B%26%23xE3%3Bo%20de%20colesterol%20LDL%2C%20que%20proporcione%20redu%26%23xE7%3B%26%23xE3%3Bo%20mais%20intensiva%20do%20colesterol%20LDL.%3C%2Fp%3E%0A%3Cp%3EPacientes%20sob%20alto%20risco%20de%20doen%26%23xE7%3Ba%20coronariana%20ou%20com%20doen%26%23xE7%3Ba%20coronariana%3Cbr%3E%0AA%20dose%20inicial%20usual%20de%20sinvastatina%20%26%23xE9%3B%20de%2040%20mg%2Fdia%2C%20administrada%20em%20dose%20%26%23xFA%3Bnica%2C%20%26%23xE0%3B%20noite%2C%20para%20os%20pacientes%20sob%20alto%20risco%20de%20doen%26%23xE7%3Ba%20coronariana%20(com%20ou%20sem%20hiperlipidemia)%2C%20isto%20%26%23xE9%3B%2C%20pacientes%20com%20diabetes%2C%20hist%26%23xF3%3Brico%20de%20AVC%20ou%20de%20outra%20doen%26%23xE7%3Ba%20vascular%20cerebral%2C%20doen%26%23xE7%3Ba%20vascular%20perif%26%23xE9%3Brica%20ou%20doen%26%23xE7%3Ba%20coronariana.%20O%20tratamento%20pode%20ser%20iniciado%20simultaneamente%20%26%23xE0%3B%20dieta%20e%20aos%20exerc%26%23xED%3Bcios.%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Cp%3EPacientes%20com%20hiperlipidemia%20(n%26%23xE3%3Bo%20inclu%26%23xED%3Bdos%20nas%20categorias%20de%20risco%20j%26%23xE1%3B%20descritas)%3Cbr%3E%0AO%20paciente%20deve%20iniciar%20dieta-padr%26%23xE3%3Bo%20redutora%20de%20colesterol%20antes%20de%20receber%20sinvastatina%2C%20a%20qual%20dever%26%23xE1%3B%20ser%20mantida%20durante%20o%20tratamento%20com%20sinvastatina.%3Cbr%3E%0AA%20dose%20inicial%20usual%20%26%23xE9%3B%20de%2020%20mg%2Fdia%2C%20administrada%20em%20dose%20%26%23xFA%3Bnica%2C%20%26%23xE0%3B%20noite.%20Pacientes%20que%20necessitem%20de%20redu%26%23xE7%3B%26%23xE3%3Bo%20mais%20acentuada%20do%20LDL-C%20(mais%20de%2045%25)%20podem%20iniciar%20o%20tratamento%20com%20a%20dose%20de%2040%20mg%2Fdia%2C%20administrada%20em%20dose%20%26%23xFA%3Bnica%2C%3Cbr%3E%0A%26%23xE0%3Bnoite.%20Pacientes%20com%20hipercolesterolemia%20leve%20a%20moderada%20podem%20iniciar%20o%20tratamento%20com%20a%20dose%20de%2010%20mg%20de%20sinvastatina.%20Ajustes%20posol%26%23xF3%3Bgicos%2C%20se%20necess%26%23xE1%3Brios%2C%20devem%20ser%20feitos%20conforme%20especificado%20acima.%3C%2Fp%3E%0A%3Cp%3EPacientes%20com%20hipercolesterolemia%20familiar%20homozig%26%23xF3%3Btica%3Cbr%3E%0ACom%20base%20nos%20resultados%20de%20um%20estudo%20cl%26%23xED%3Bnico%20controlado%2C%20a%20posologia%20recomendada%20para%20pacientes%20com%20hipercolesterolemia%20familiar%20homozig%26%23xF3%3Btica%20%26%23xE9%3B%20de%2040%20mg%2Fdia%2C%20%26%23xE0%3B%20noite.%20Para%20esses%20pacientes%2C%20sinvastatina%20deve%20ser%20adjuvante%20de%20outros%20tratamentos%20hipolipemiantes%20(por%20exemplo%2C%20af%26%23xE9%3Brese%20de%20LDL)%20ou%20deve%20ser%20utilizado%20quando%20tais%20tratamentos%20n%26%23xE3%3Bo%20estiverem%20dispon%26%23xED%3Bveis%20(veja%20os%20itens%204.%20CONTRAINDICA%26%23xC7%3B%26%23xD5%3BES%20e%205.ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise%3B%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS).%3Cbr%3E%0ASe%20sinvastatina%20for%20utilizada%20concomitantemente%20com%20lomitapida%2C%20a%20dose%20di%26%23xE1%3Bria%20de%20sinvastatina%20n%26%23xE3%3Bo%20deve%20exceder%2040%20mg%20(veja%20os%20itens%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise%20e%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS).%3C%2Fp%3E%0A%3Cp%3ETerapia%20concomitante%3Cbr%3E%0AA%20sinvastatina%20%26%23xE9%3B%20eficaz%20isoladamente%20ou%20em%20combina%26%23xE7%3B%26%23xE3%3Bo%20com%20os%20sequestrantes%20de%20%26%23xE1%3Bcidos%20biliares.%3Cbr%3E%0ASe%20a%20sinvastatina%20for%20utilizada%20concomitantemente%20com%20fibratos%20diferentes%20de%20genfibrozila%20(veja%20o%20item%204.%20CONTRAINDICA%26%23xC7%3B%26%23xD5%3BES)%20ou%20fenofibrato%2C%20a%20dose%20de%20sinvastatina%20n%26%23xE3%3Bo%20deve%20ser%20maior%20do%20que%2010%20mg%2Fdia.%20Se%20a%20sinvastatina%20for%20utilizada%20concomitantemente%20com%20amiodarona%2C%20verapamil%2C%20diltiazem%20ou%20medicamentos%20que%20contenham%20elbasvir%20ou%20grazoprevir%20aa%20dose%20de%20sinvastatina%20n%26%23xE3%3Bo%20deve%20ser%20maior%20do%20que%2020%20mg%2Fdia.%20Em%20pacientes%20tomando%20anlodipino%20concomitantemente%20com%20sinvastatina%2C%20a%20dose%20de%20sinvastatina%20n%26%23xE3%3Bo%20deve%20exceder%2040%20mg%2Fdia%20(veja%20os%20itens%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise%3B%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS).%3C%2Fp%3E%0A%3Cp%3EPosologia%20na%20insufici%26%23xEA%3Bncia%20renal%3Cbr%3E%0AUma%20vez%20que%20a%20excre%26%23xE7%3B%26%23xE3%3Bo%20renal%20de%20sinvastatina%20n%26%23xE3%3Bo%20%26%23xE9%3B%20significativa%2C%20n%26%23xE3%3Bo%20devem%20ser%20necess%26%23xE1%3Brias%20modifica%26%23xE7%3B%26%23xF5%3Bes%20posol%26%23xF3%3Bgicas%20para%20pacientes%20com%20insufici%26%23xEA%3Bncia%20renal%20moderada.%3Cbr%3E%0APara%20pacientes%20com%20insufici%26%23xEA%3Bncia%20renal%20grave%20(depura%26%23xE7%3B%26%23xE3%3Bo%20plasm%26%23xE1%3Btica%20de%20creatinina%20%26lt%3B%2030%20mL%2Fmin)%2C%20deve-se%20avaliar%20cuidadosamente%20o%20uso%20de%20doses%20maiores%20do%20que%2010%20mg%2Fdia%3B%20se%20forem%20extremamente%20necess%26%23xE1%3Brias%2C%20dever%26%23xE3%3Bo%20ser%20administradas%20com%20cautela%20(veja%20o%20item%203.%20CARACTER%26%23xCD%3BSTICAS%20FARMACOL%26%23xD3%3BGICAS).%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Cp%3EEste%20medicamento%20n%26%23xE3%3Bo%20deve%20ser%20partido%20ou%20mastigado.%3C%2Fp%3E%0A%3Ch2%3ESuper%20dosagem%3C%2Fh2%3E%0A%3Cp%3EForam%20relatados%20poucos%20casos%20de%20superdose%3B%20a%20dose%20m%26%23xE1%3Bxima%20ingerida%20foi%20de%203%2C6%20g.%20Todos%20os%20pacientes%20recuperaram-se%20sem%20sequelas.%20N%26%23xE3%3Bo%20h%26%23xE1%3B%20tratamento%20espec%26%23xED%3Bfico%20para%20a%20superdose%3B%20nesses%20casos%2C%20devem%20ser%20adotadas%20medidas%20sintom%26%23xE1%3Bticas%20e%20de%20suporte.%3C%2Fp%3E%0A%3Cp%3EEm%20caso%20de%20intoxica%26%23xE7%3B%26%23xE3%3Bo%20ligue%20para%200800%20722%206001%2C%20se%20voc%26%23xEA%3B%20precisar%20de%20mais%20orienta%26%23xE7%3B%26%23xF5%3Bes.%3C%2Fp%3E%0A%3Ch2%3ECaracteristicas%20farmalogicas%3C%2Fh2%3E%0A%3Cp%3EA%20sinvastatina%20%26%23xE9%3B%20um%20agente%20redutor%20do%20colesterol%20derivado%20sinteticamente%20de%20um%20produto%20de%20fermenta%26%23xE7%3B%26%23xE3%3Bo%20do%20Aspergillus%20terreus.%3Cbr%3E%0AAp%26%23xF3%3Bs%20a%20ingest%26%23xE3%3Bo%2C%20sinvastatina%2C%20uma%20lactona%20inativa%2C%20%26%23xE9%3B%20hidrolisado%20ao%20%26%23x3B2%3B-hidroxi%26%23xE1%3Bcido%20correspondente.%20Esse%20%26%23xE9%3B%20o%20principal%20metab%26%23xF3%3Blito%20e%20%26%23xE9%3B%20um%20inibidor%20da%203-hidr%26%23xF3%3Bxi-3-metilglutaril-coenzima%20A%20(HMG-CoA)%20redutase%2C%20uma%20enzima%20que%20catalisa%20um%20passo%20precoce%20e%20limitante%20da%20taxa%20de%20bioss%26%23xED%3Bntese%20do%20colesterol.%20Estudos%20cl%26%23xED%3Bnicos%20mostram%20que%20sinvastatina%20%26%23xE9%3B%20altamente%20eficaz%20para%20reduzir%20as%20concentra%26%23xE7%3B%26%23xF5%3Bes%20plasm%26%23xE1%3Bticas%20do%20colesterol%20total%2C%20do%20LDL-colesterol%2C%20dos%20triglic%26%23xE9%3Brides%20e%20do%20VLDL-%20colesterol%20e%20para%20aumentar%20o%20HDL-colesterol%20nas%20formas%20familiar%20heterozig%26%23xF3%3Btica%20e%20n%26%23xE3%3Bo%20familiar%20de%20hipercolesterolemia%20e%20na%20hiperlipidemia%20mista%2C%20quando%20o%20colesterol%20elevado%20for%20preocupante%20e%20a%20dieta%20apenas%20for%20insuficiente.%20Observam-se%20respostas%20acentuadas%20em%20duas%20semanas%20e%20respostas%20terap%26%23xEA%3Buticas%20m%26%23xE1%3Bximas%20ocorrem%20em%204%20a%206%20semanas.%20A%20resposta%20mant%26%23xE9%3Bm-se%20com%20a%20continuidade%20do%20tratamento.%20Quando%20o%20tratamento%20com%20sinvastatina%20%26%23xE9%3B%20interrompido%2C%20os%20n%26%23xED%3Bveis%20de%20colesterol%20e%20l%26%23xED%3Bpides%20voltam%20aos%20n%26%23xED%3Bveis%20anteriores%20ao%20tratamento.%3Cbr%3E%0AA%20forma%20ativa%20da%20sinvastatina%20%26%23xE9%3B%20um%20inibidor%20espec%26%23xED%3Bfico%20da%20HMG-CoA%20redutase%2C%20enzima%20que%20catalisa%20a%20convers%26%23xE3%3Bo%20da%20HMG-CoA%20a%20mevalonato.%20Em%20virtude%20de%20essa%20convers%26%23xE3%3Bo%20ser%20um%20passo%20inicial%20da%20bioss%26%23xED%3Bntese%20do%20colesterol%2C%20n%26%23xE3%3Bo%20se%20espera%20que%20o%20tratamento%20com%20sinvastatina%20provoque%20ac%26%23xFA%3Bmulo%20de%20ester%26%23xF3%3Bis%20potencialmente%20t%26%23xF3%3Bxicos.%20Al%26%23xE9%3Bm%20disso%2C%20a%20HMG-CoA%20%26%23xE9%3B%20tamb%26%23xE9%3Bm%20rapidamente%20metabolizada%20de%20volta%20a%20acetil-CoA%2C%20a%20qual%20participa%20de%20muitos%20processos%20de%20bioss%26%23xED%3Bntese%20no%20organismo.%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Cp%3EFarmacocin%26%23xE9%3Btica%3Cbr%3E%0AAbsor%26%23xE7%3B%26%23xE3%3Bo%3A%20demonstrou-se%20que%20a%20biodisponibilidade%20do%20beta-hidroxi%26%23xE1%3Bcido%20para%20a%20circula%26%23xE7%3B%26%23xE3%3Bo%20sist%26%23xEA%3Bmica%20ap%26%23xF3%3Bs%20uma%20dose%20oral%20de%20sinvastatina%20foi%20menor%20do%20que%205%25%20da%20dose%2C%20o%20que%20%26%23xE9%3B%20compat%26%23xED%3Bvel%20com%20a%20ampla%20extra%26%23xE7%3B%26%23xE3%3Bo%20hep%26%23xE1%3Btica%20de%20primeira%20passagem.%20Os%20principais%20metab%26%23xF3%3Blitos%20da%20sinvastatina%20presentes%20no%20plasma%20humano%20s%26%23xE3%3Bo%20o%20%26%23x3B2%3B-hidroxi%26%23xE1%3Bcido%20e%20quatro%20metab%26%23xF3%3Blitos%20ativos%20adicionais.%3Cbr%3E%0AEm%20jejum%2C%20o%20perfil%20plasm%26%23xE1%3Btico%20dos%20inibidores%20total%20e%20ativo%20n%26%23xE3%3Bo%20foi%20afetado%20quando%20a%20sinvastatina%20foi%20administrada%20imediatamente%20antes%20de%20uma%20refei%26%23xE7%3B%26%23xE3%3Bo-teste.%3C%2Fp%3E%0A%3Cp%3EDistribui%26%23xE7%3B%26%23xE3%3Bo%3A%20a%20sinvastatina%20e%20o%20beta-hidroxi%26%23xE1%3Bcido%20ligam-se%20%26%23xE0%3Bs%20prote%26%23xED%3Bnas%20plasm%26%23xE1%3Bticas%20humanas%20(95%25).%3Cbr%3E%0AA%20farmacocin%26%23xE9%3Btica%20de%20doses%20%26%23xFA%3Bnica%20e%20m%26%23xFA%3Bltipla%20de%20sinvastatina%20n%26%23xE3%3Bo%20mostrou%20ac%26%23xFA%3Bmulo%20do%20medicamento%20ap%26%23xF3%3Bs%20a%20administra%26%23xE7%3B%26%23xE3%3Bo%20m%26%23xFA%3Bltipla.%20Em%20todos%20os%20estudos%20de%20farmacocin%26%23xE9%3Btica%20acima%2C%20a%20concentra%26%23xE7%3B%26%23xE3%3Bo%20plasm%26%23xE1%3Btica%20m%26%23xE1%3Bxima%20dos%20inibidores%20ocorreu%201%2C3%20a%202%2C4%20horas%20ap%26%23xF3%3Bs%20a%20dose.%3C%2Fp%3E%0A%3Cp%3EMetabolismo%3A%20a%20sinvastatina%20%26%23xE9%3B%20uma%20lactona%20inativa%20que%20%26%23xE9%3B%20rapidamente%20hidrolisada%20in%20vivo%20para%20o%20%26%23x3B2%3B-hidroxi%26%23xE1%3Bcidocorrespondente%2C%20um%20potente%20inibidor%20da%20HMG-CoA%20redutase.%20A%20hidr%26%23xF3%3Blise%20ocorre%20principalmente%20no%20f%26%23xED%3Bgado%3B%20a%20velocidade%20de%20hidr%26%23xF3%3Blise%20no%20plasma%20humano%20%26%23xE9%3B%20muito%20lenta.%3Cbr%3E%0AA%20sinvastatina%20%26%23xE9%3B%20bem%20absorvida%20em%20humanos%20e%20passa%20por%20ampla%20extra%26%23xE7%3B%26%23xE3%3Bo%20hep%26%23xE1%3Btica%20de%20primeira%20passagem.%20A%20extra%26%23xE7%3B%26%23xE3%3Bo%20no%20f%26%23xED%3Bgado%20depende%20do%20fluxo%20sangu%26%23xED%3Bneo%20hep%26%23xE1%3Btico.%20O%20f%26%23xED%3Bgado%20%26%23xE9%3B%20o%20principal%20local%20de%20a%26%23xE7%3B%26%23xE3%3Bo%2C%20com%20excre%26%23xE7%3B%26%23xE3%3Bo%20posterior%20dos%20equivalentes%20do%20f%26%23xE1%3Brmaco%20na%20bile.%20Consequentemente%2C%20a%20disponibilidade%20do%20f%26%23xE1%3Brmaco%20ativo%20na%20circula%26%23xE7%3B%26%23xE3%3Bo%20sist%26%23xEA%3Bmica%20%26%23xE9%3B%20baixa.%20Ap%26%23xF3%3Bs%20uma%20inje%26%23xE7%3B%26%23xE3%3Bo%20intravenosa%20do%20metab%26%23xF3%3Blito%20beta-hidroxi%26%23xE1%3Bcido%2C%20sua%20meia-vida%20m%26%23xE9%3Bdia%20%26%23xE9%3B%20de%201%2C9%20hora.%3C%2Fp%3E%0A%3Cp%3EElimina%26%23xE7%3B%26%23xE3%3Bo%3A%20ap%26%23xF3%3Bs%20uma%20dose%20oral%20de%20sinvastatina%20radioativa%20em%20humanos%2C%2013%25%20da%20radioatividade%20foi%20excretada%20na%20urina%20e%2060%25%20nas%20fezes%20em%2096%20horas.%20A%20quantidade%20recuperada%20nas%20fezes%20representa%20os%20equivalentes%20do%20f%26%23xE1%3Brmaco%20absorvido%20excretados%20na%20bile%2C%20assim%20como%20o%20f%26%23xE1%3Brmaco%20n%26%23xE3%3Bo%20absorvido.%20Ap%26%23xF3%3Bs%20uma%20inje%26%23xE7%3B%26%23xE3%3Bo%20intravenosa%20do%20metab%26%23xF3%3Blito%20%26%23x3B2%3B-hidroxi%26%23xE1%3Bcido%2Capenas%200%2C3%25%20da%20dose%20IV%2C%20em%20m%26%23xE9%3Bdia%2C%20foi%20excretada%20na%20urina%20como%20inibidores.%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Ch2%3EResultados%20de%20eficacia%3C%2Fh2%3E%0A%3Cp%3ENo%20Estudo%20Escandinavo%20de%20Sobrevida%20com%20sinvastatina%20(4S)%2C%20o%20efeito%20do%20tratamento%20com%20sinvastatina%20na%20mortalidade%20por%20todas%20as%20causas%20foi%20avaliado%20em%204.444%20pacientes%20com%20doen%26%23xE7%3Ba%20coronariana%20(DAC)%20e%20colesterol%20total%20no%20per%26%23xED%3Bodo%20basal%20entre%20212-309%20mg%2FdL%20(5%2C5-8%2C0%20mmol%2FL)%20durante%20um%20per%26%23xED%3Bodo%20mediano%20de%205%2C4%20anos.%20Nesse%20estudo%20multic%26%23xEA%3Bntrico%2C%20rand%26%23xF4%3Bmico%2C%20duplo-cego%20e%20controlado%20com%20placebo%2C%20sinvastatina%20reduziu%20em%2030%25%20o%20risco%20de%20morte%3B%20em%2042%25%20o%20risco%20de%20morte%20por%20DAC%3B%20e%20em%2037%25%20o%20risco%20de%20infarto%20do%20mioc%26%23xE1%3Brdio%20n%26%23xE3%3Bo%20fatal%20comprovado%20no%20hospital.%20Al%26%23xE9%3Bm%20disso%2C%20sinvastatina%20reduziu%20em%2037%25%20o%20risco%20de%20procedimentos%20para%20revasculariza%26%23xE7%3B%26%23xE3%3Bo%20do%20mioc%26%23xE1%3Brdio%20(bypass%20da%20art%26%23xE9%3Bria%20coronariana%20ou%20angioplastia%20coronariana%20transluminal%20percut%26%23xE2%3Bnea).%20Em%20pacientes%20com%20diabetes%20mellitus%2C%20o%20risco%20de%20um%20evento%20coronariano%20importante%20foi%20reduzido%20em%2055%25.%20Al%26%23xE9%3Bm%20disso%2C%20sinvastatina%20reduziu%20significativamente%20o%20risco%20de%20eventos%20vasculares%20cerebrais%20fatais%20e%20n%26%23xE3%3Bo%20fatais%20(AVC%20e%20ataques%20isqu%26%23xEA%3Bmicos%20transit%26%23xF3%3Brios)%20em%2028%25.%3Cbr%3E%0ANo%20Estudo%20de%20Prote%26%23xE7%3B%26%23xE3%3Bo%20do%20Cora%26%23xE7%3B%26%23xE3%3Bo%20(HPS%20%26%23x2013%3B%20Heart%20Protection%20Study)%2C%20os%20efeitos%20do%20tratamento%20com%20sinvastatina%20durante%20um%20per%26%23xED%3Bodo%20de%20acompanhamento%20de%205%20anos%2C%20em%20m%26%23xE9%3Bdia%2C%20foram%20avaliados%20em%2020.536%20pacientes%20com%20ou%20sem%20hiperlipidemia%20e%20alto%20risco%20de%20eventos%20coronarianos%2C%20em%20decorr%26%23xEA%3Bncia%20de%20diabetes%2C%20antecedentes%20de%20acidente%20vascular%20cerebral%20(AVC)%20ou%20outra%20doen%26%23xE7%3Ba%20vascular%20cerebral%2C%20doen%26%23xE7%3Ba%20vascular%20perif%26%23xE9%3Brica%20ou%20doen%26%23xE7%3Ba%20coronariana.%20No%20per%26%23xED%3Bodo%20basal%2C%2033%25%20apresentavam%20n%26%23xED%3Bveis%20de%20LDL%20inferiores%20a%20116%20mg%2FdL%3B%2025%25%2C%20entre%20116%20mg%2FdL%20e%20135%20mg%2FdL%20e%2042%25%2C%20superiores%20a%20135%20mg%2FdL.%3Cbr%3E%0ANesse%20estudo%20multic%26%23xEA%3Bntrico%2C%20rand%26%23xF4%3Bmico%2C%20duplo-cego%20e%20controlado%20com%20placebo%2C%20sinvastatina%2040%20mg%2Fdia%20comparado%20ao%20placebo%20reduziu%20o%20risco%20de%20mortalidade%20por%20todas%20as%20causas%20em%2013%25%2C%20em%20consequ%26%23xEA%3Bncia%20da%20redu%26%23xE7%3B%26%23xE3%3Bo%20de%20mortes%20por%20doen%26%23xE7%3Ba%20coronariana%20(18%25).%20A%20sinvastatina%20tamb%26%23xE9%3Bm%20diminuiu%20o%20risco%20de%20eventos%20coronarianos%20maiores%20(um%20desfecho%20composto%20de%20IM%20n%26%23xE3%3Bo%20fatal%20ou%20mortes%20de%20origem%20coronariana)%20em%2027%25.%20A%20sinvastatina%20reduziu%20a%20necessidade%20de%20procedimentos%20de%20revasculariza%26%23xE7%3B%26%23xE3%3Bo%20coronariana%20(incluindo%20bypass%20ou%20angioplastia%20coronariana%20transluminal%20percut%26%23xE2%3Bnea)%20e%20procedimentos%20de%20revasculariza%26%23xE7%3B%26%23xE3%3Bo%20perif%26%23xE9%3Brica%20e%20outros%20procedimentos%20de%20revasculariza%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20coronarianos%2C%20em%2030%25%20e%2016%25%2C%20respectivamente.%20A%20sinvastatina%20reduziu%20o%20risco%20de%20AVC%20em%2025%25.%20Al%26%23xE9%3Bm%20disso%2C%20sinvastatina%20reduziu%20o%20risco%20de%20hospitaliza%26%23xE7%3B%26%23xE3%3Bo%20por%20angina%20em%2017%25.%20Os%20riscos%20de%20eventos%20coronarianos%20e%20vasculares%20maiores%20(um%20desfecho%20composto%20que%20incluiu%20os%20eventos%20coronarianos%20relevantes%2C%20AVC%20ou%20procedimentos%20de%20revasculariza%26%23xE7%3B%26%23xE3%3Bo)%20foram%20reduzidos%20em%20cerca%20de%2025%25%20em%20pacientes%20com%20ou%20sem%20doen%26%23xE7%3Ba%20coronariana%2C%20incluindo%20pacientes%20com%20diabetes%20e%20pacientes%20com%20doen%26%23xE7%3Ba%20perif%26%23xE9%3Brica%20ou%20vascular%20cerebral.%20Al%26%23xE9%3Bm%20disso%2C%20no%20subgrupo%20de%20pacientes%20com%20diabetes%2C%20sinvastatina%20reduziu%20o%20risco%20do%20desenvolvimento%20de%20complica%26%23xE7%3B%26%23xF5%3Bes%20macrovasculares%2C%20incluindo%20procedimentos%20de%20revasculariza%26%23xE7%3B%26%23xE3%3Bo%20perif%26%23xE9%3Brica%20(cirurgia%20ou%20angioplastia)%2C%20amputa%26%23xE7%3B%26%23xE3%3Bo%20de%20membros%20inferiores%20ou%20%26%23xFA%3Blceras%20nas%20pernas%20em%2021%25.%20As%20redu%26%23xE7%3B%26%23xF5%3Bes%20de%20risco%20produzidas%20por%20sinvastatina%20nos%20eventos%20maiores%2C%20vasculares%20e%20coronarianos%2C%20foram%20evidentes%20e%20consistentes%20independentemente%20da%20idade%20e%20do%20sexo%20do%20paciente%2C%20dos%20n%26%23xED%3Bveis%20de%20LDL-C%2C%20HDL-C%2C%20TG%2C%20apolipoprote%26%23xED%3Bna%20A-I%20ou%20apolipoprote%26%23xED%3Bna%20B%20no%20per%26%23xED%3Bodo%20basal%2C%20da%20presen%26%23xE7%3Ba%20ou%20aus%26%23xEA%3Bncia%20de%20hipertens%26%23xE3%3Bo%2C%20dos%20n%26%23xED%3Bveis%20de%20creatinina%20at%26%23xE9%3B%20o%20limite%20para%20inclus%26%23xE3%3Bo%20de%202%2C3%20mg%2FdL%2C%20da%20presen%26%23xE7%3Ba%20ou%20aus%26%23xEA%3Bncia%20de%20medica%26%23xE7%3B%26%23xF5%3Bes%20cardiovasculares%20(aspirina%2C%20betabloqueadores%2C%20inibidores%20da%20enzima%20conversora%20de%20angiotensina%20%5BECA%5D%20ou%20bloqueadores%20dos%20canais%20de%20c%26%23xE1%3Blcio)%20no%20per%26%23xED%3Bodo%20basal%2C%20de%20tabagismo%2C%20de%20ingest%26%23xE3%3Bo%20de%20%26%23xE1%3Blcool%20ou%20de%20obesidade.%20Ao%20final%20de%205%20anos%2C%2032%25%20dos%20pacientes%20no%20grupo%20placebo%20estavam%20tomando%20uma%20estatina%20(fora%20do%20protocolo%20do%20estudo)%3B%20portanto%2C%20as%20redu%26%23xE7%3B%26%23xF5%3Bes%20de%20risco%20observadas%20subestimam%20o%20real%20efeito%20da%20sinvastatina.%3Cbr%3E%0AEm%20estudo%20cl%26%23xED%3Bnico%20multic%26%23xEA%3Bntrico%2C%20controlado%20com%20placebo%2C%20que%20utilizou%20angiografia%20coronariana%20quantitativa%20e%20envolveu%20404%20pacientes%2C%20sinvastatina%20retardou%20a%20progress%26%23xE3%3Bo%20da%20aterosclerose%20coronariana%20e%20reduziu%20o%20desenvolvimento%20de%20novas%20les%26%23xF5%3Bes%20e%20de%20novas%20oclus%26%23xF5%3Bes%20totais%2C%20ao%20passo%20que%20as%20les%26%23xF5%3Bes%20ateroscler%26%23xF3%3Bticas%20coronarianas%20pioraram%20de%20forma%20constante%20ao%20longo%20de%20um%20per%26%23xED%3Bodo%20de%204%20anos%20em%20pacientes%20que%20receberam%20tratamento-padr%26%23xE3%3Bo.%3Cbr%3E%0AAs%20an%26%23xE1%3Blises%20de%20subgrupo%20de%20dois%20estudos%20que%20inclu%26%23xED%3Bram%20147%20pacientes%20com%20hipertrigliceridemia%20(hiperlipidemia%20tipo%20IV%20de%20Fredrickson)%20demonstraram%20que%2020%20a%2080%20mg%2Fdia%20de%20sinvastatina%20reduziu%20os%20n%26%23xED%3Bveis%20de%20triglic%26%23xE9%3Brides%20em%2021%25%20a%2039%25%20(placebo%3A%2011%25%20a%2013%25)%2C%20de%20LDL-colesterol%20em%2023%25%20a%2035%25%20(placebo%3A%20%2B1%25%20a%20%2B3%25)%20e%20do%20colesterol%20n%26%23xE3%3Bo%20HDL%2C%20em%2026%25%20a%2043%25%20(placebo%3A%20%2B1%25%20a%20%2B3%25)%20e%20aumentou%20o%20HDL-C%20em%209%25%20a%2014%25%20(placebo%3A%203%25).%3Cbr%3E%0AEm%20outra%20an%26%23xE1%3Blise%20de%20subgrupo%20de%20sete%20pacientes%20com%20disbetalipoproteinemia%20(hiperlipidemia%20tipo%20III%20de%20Fredrickson)%2C%20a%20dose%20de%2080%20mg%2Fdia%20de%20sinvastatina%20reduziu%20os%20n%26%23xED%3Bveis%20de%20LDL-C%2C%20inclusive%20das%20lipoprote%26%23xED%3Bnas%20de%20densidade%20intermedi%26%23xE1%3Bria%20(IDL)%20em%2051%25%20(placebo%3A%208%25)%20e%20de%20VLDL-colesterol%20%2B%20IDL%20em%2060%25%20(placebo%3A%204%25).%3C%2Fp%3E%0A%3Ch2%3EUsos%20em%20idosos%2C%20crian%26%23xE7%3Bas%20e%20em%20outros%20grupos%20de%20risco%3C%2Fh2%3E%0A%3Cp%3EInforma%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20dispon%26%23xED%3Bvel%20para%20esta%20bula.%3C%2Fp%3E%0A%3Ch2%3EArmazenagem%3C%2Fh2%3E%0A%3Cp%3EConservar%20em%20temperatura%20ambiente%20(entre%2015%20e%2030%26%23xB0%3BC).%20Proteger%20da%20luz%20e%20umidade.%3Cbr%3E%0APrazo%20de%20validade%3A%2024%20meses%20ap%26%23xF3%3Bs%20a%20data%20de%20fabrica%26%23xE7%3B%26%23xE3%3Bo%20impressa%20na%20embalagem.%3C%2Fp%3E%0A%3Cp%3EN%26%23xFA%3Bmero%20de%20lote%20e%20datas%20de%20fabrica%26%23xE7%3B%26%23xE3%3Bo%20e%20validade%3A%20vide%20embalagem.%3Cbr%3E%0AN%26%23xE3%3Bo%20use%20medicamento%20com%20o%20prazo%20de%20validade%20vencido.%20Guarde-o%20em%20sua%20embalagem%20original.%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Cp%3EApar%26%23xEA%3Bncia%3A%3C%2Fp%3E%0A%3Cp%3EPara%2020%20mg%20comprimidos%20revestidos%20com%20formato%20oval%20de%20colora%26%23xE7%3B%26%23xE3%3Bo%20p%26%23xEA%3Bssego%2C%20gravados%20com%20%26%23x201C%3BSST%26%23x201D%3B%20em%20uma%20das%20faces%20e%20%26%23x201C%3B20%26%23x201D%3B%20na%20outra%20face.%3Cbr%3E%0APara%2040%20mg%20comprimidos%20revestidos%20com%20formato%20oval%2C%20de%20colora%26%23xE7%3B%26%23xE3%3Bo%20rosa%2C%20gravados%20com%20%26%23x201C%3BSST%26%23x201D%3B%20em%20uma%20das%20faces%20e%20%26%23x201C%3B40%26%23x201D%3B%20na%20outra%20face.%3C%2Fp%3E%0A%3Cp%3EAntes%20de%20usar%2C%20observe%20o%20aspecto%20do%20medicamento.%3Cbr%3E%0ATodo%20medicamento%20deve%20ser%20mantido%20fora%20do%20alcance%20das%20crian%26%23xE7%3Bas.%3C%2Fp%3E%0A%3Ch2%3EDizeres%20legais%3C%2Fh2%3E%0A%3Cp%3EReg.%20MS.%3A%201.2352.0048%3Cbr%3E%0AFarm.%20Resp.%3A%20Adriana%20M.%20C.%20Cardoso%3Cbr%3E%0ACRF%20%26%23x2013%3B%20RJ%20N%26%23xB0%3B%206750%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Cp%3EFabricado%20por%3A%20Sun%20Pharmaceutical%20Ind.%20Ltd.%3Cbr%3E%0AIndustrial%20Area%203%20A.B.%20Road%2C%20Dewas%2C%3Cbr%3E%0A455%20001%2C%20Madhya%20Pradesh%20%26%23x2013%3B%20India%3C%2Fp%3E%0A%3Cp%3EImportado%20e%20Registrado%20por%20%3A%20Ranbaxy%20Farmac%26%23xEA%3Butica%20Ltda.%3Cbr%3E%0AAv.%20Eug%26%23xEA%3Bnio%20Borges%2C%201.060%3Cbr%3E%0AArsenal%20%26%23x2013%3B%20S%26%23xE3%3Bo%20Gon%26%23xE7%3Balo%20%26%23x2013%3B%20RJ%3Cbr%3E%0ACEP%3A%2024751-000%3Cbr%3E%0ACNPJ%3A%2073.663.650%2F0001-90%3C%2Fp%3E%0A%3Ch2%3ESINVASTATINA%20%26%23x2013%3B%20Bula%20para%20o%20paciente%3C%2Fh2%3E%0A%3Cp%3E1.%20INDICA%26%23xC7%3B%26%23xD5%3BES%3Cbr%3E%0APacientes%20sob%20alto%20risco%20de%20doen%26%23xE7%3Ba%20coronariana%20ou%20com%20doen%26%23xE7%3Ba%20coronariana%20(DAC)%3Cbr%3E%0AEm%20pacientes%20sob%20alto%20risco%20de%20doen%26%23xE7%3Ba%20coronariana%20(com%20ou%20sem%20hiperlipidemia)%2C%20isto%20%26%23xE9%3B%2C%20pacientes%20com%20diabetes%2C%20hist%26%23xF3%3Brico%20de%20acidente%20vascular%20cerebral%20(AVC)%20ou%20de%20outra%20doen%26%23xE7%3Ba%20vascular%20cerebral%2C%20de%20doen%26%23xE7%3Ba%20vascular%20perif%26%23xE9%3Brica%20ou%20com%20doen%26%23xE7%3Ba%20coronariana%2C%20a%20sinvastatina%20%26%23xE9%3B%20indicada%20para%3A%3Cbr%3E%0A-reduzir%20o%20risco%20de%20mortalidade%20total%20(por%20todas%20as%20causas)%20por%20meio%20da%20redu%26%23xE7%3B%26%23xE3%3Bo%20de%20mortes%20por%20doen%26%23xE7%3Ba%20coronariana%3B%3Cbr%3E%0A-reduzir%20o%20risco%20dos%20eventos%20vasculares%20maiores%20(um%20composto%20de%20infarto%20do%20mioc%26%23xE1%3Brdio%20n%26%23xE3%3Bo%20fatal%2C%20morte%20por%20doen%26%23xE7%3Ba%20coronariana%2C%20AVC%20ou%20procedimentos%20de%20revasculariza%26%23xE7%3B%26%23xE3%3Bo)%3B%3Cbr%3E%0A-reduzir%20o%20risco%20dos%20eventos%20coronarianos%20maiores%20(um%20composto%20de%20infarto%20do%20mioc%26%23xE1%3Brdio%20n%26%23xE3%3Bo%20fatal%20ou%20mortes%20por%20doen%26%23xE7%3Ba%20coronariana)%3B%3Cbr%3E%0A-reduzir%20o%20risco%20de%20acidente%20vascular%20cerebral%3B%3Cbr%3E%0A-reduzir%20a%20necessidade%20de%20procedimentos%20de%20revasculariza%26%23xE7%3B%26%23xE3%3Bo%20do%20mioc%26%23xE1%3Brdio%20(incluindo%20bypass%20ou%20angioplastia%20coronariana%20transluminal%20percut%26%23xE2%3Bnea)%3B%3Cbr%3E%0A-reduzir%20a%20necessidade%20de%20procedimentos%20de%20revasculariza%26%23xE7%3B%26%23xE3%3Bo%20perif%26%23xE9%3Brica%20e%20outros%2C%20n%26%23xE3%3Bo%20coronarianos%3B%3Cbr%3E%0A-reduzir%20o%20risco%20de%20hospitaliza%26%23xE7%3B%26%23xE3%3Bo%20por%20angina.%3Cbr%3E%0AEm%20pacientes%20com%20diabetes%2C%20sinvastatina%20reduz%20o%20risco%20de%20desenvolvimento%20de%20complica%26%23xE7%3B%26%23xF5%3Bes%20perif%26%23xE9%3Bricas%20macrovasculares%20(um%20composto%20de%20procedimentos%20de%20revasculariza%26%23xE7%3B%26%23xE3%3Bo%20perif%26%23xE9%3Brica%2C%20de%20amputa%26%23xE7%3B%26%23xF5%3Bes%20dos%20membros%20inferiores%20ou%20de%20%26%23xFA%3Blceras%20das%20pernas).%3Cbr%3E%0AEm%20pacientes%20hipercolesterol%26%23xEA%3Bmicos%20com%20doen%26%23xE7%3Ba%20coronariana%2C%20a%20sinvastatina%20retarda%20a%20progress%26%23xE3%3Bo%20da%20aterosclerose%20coronariana%2C%20reduzindo%20inclusive%20o%20desenvolvimento%20de%20novas%20les%26%23xF5%3Bes%20e%20novas%20oclus%26%23xF5%3Bes%20totais.%3C%2Fp%3E%0A%3Cp%3EPacientes%20com%20hiperlipidemia%3Cbr%3E%0A-A%20sinvastatina%20%26%23xE9%3B%20indicada%20como%20adjuvante%20%26%23xE0%3B%20dieta%20para%20reduzir%20os%20n%26%23xED%3Bveis%20elevados%20de%20colesterol%20total%2C%20LDL-colesterol%2Capolipoprote%26%23xED%3Bna%20B%20(apo%20B)%20e%20triglic%26%23xE9%3Brides%20e%20para%20aumentar%20os%20n%26%23xED%3Bveis%20de%20HDL-colesterol%20em%20pacientes%20com%20hipercolesterolemia%20prim%26%23xE1%3Bria%2C%20incluindo%20hipercolesterolemia%20familiar%20heterozig%26%23xF3%3Btica%20(tipo%20IIa%20de%20Fredrickson)%20ou%20hiperlipidemia%20combinada%20(mista)%20(tipo%20IIb%20de%20Fredrickson)%2C%20quando%20a%20resposta%20%26%23xE0%3B%20dieta%20e%20outras%20medidas%20n%26%23xE3%3Bo%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Cp%3ESinvastatina%2020%20mg%20e%2040%20mg%3Cbr%3E%0Afarmacol%26%23xF3%3Bgicas%20for%20inadequada.%20A%20sinvastatina%2C%20portanto%2C%20reduz%20as%20raz%26%23xF5%3Bes%20LDL-colesterol%2FHDL-colesterol%20e%20colesterol%20total%2FHDL-colesterol%3B%3Cbr%3E%0A-A%20sinvastatina%20%26%23xE9%3B%20indicada%20para%20o%20tratamento%20de%20pacientes%20com%20hipertrigliceridemia%20(hiperlipidemia%20tipo%20IV%20de%20Fredrickson)%3B%3Cbr%3E%0A-A%20sinvastatina%20%26%23xE9%3B%20indicada%20para%20o%20tratamento%20de%20pacientes%20com%20disbetalipoproteinemia%20prim%26%23xE1%3Bria%20(hiperlipidemia%20tipo%20III%20de%20Fredrickson)%3B%3Cbr%3E%0A-A%20sinvastatina%20tamb%26%23xE9%3Bm%20%26%23xE9%3B%20indicada%20como%20adjuvante%20%26%23xE0%3B%20dieta%20e%20outras%20medidas%20n%26%23xE3%3Bo%20diet%26%23xE9%3Bticas%20para%20reduzir%20os%20n%26%23xED%3Bveis%20elevados%20de%20colesterol%20total%2C%20LDL-colesterol%20e%20apolipoprote%26%23xED%3Bna%20B%20em%20pacientes%20com%20hipercolesterolemia%20(HoFH)%20familiar%20homozig%26%23xF3%3Btica.%3C%2Fp%3E%0A%3Cp%3E2.%20RESULTADOS%20DE%20EFIC%26%23xC1%3BCIA%3Cbr%3E%0ANo%20Estudo%20Escandinavo%20de%20Sobrevida%20com%20sinvastatina%20(4S)%2C%20o%20efeito%20do%20tratamento%20com%20sinvastatina%20na%20mortalidade%20por%20todas%20as%20causas%20foi%20avaliado%20em%204.444%20pacientes%20com%20doen%26%23xE7%3Ba%20coronariana%20(DAC)%20e%20colesterol%20total%20no%20per%26%23xED%3Bodo%20basal%20entre%20212-309%20mg%2FdL%20(5%2C5-8%2C0%20mmol%2FL)%20durante%20um%20per%26%23xED%3Bodo%20mediano%20de%205%2C4%20anos.%20Nesse%20estudo%20multic%26%23xEA%3Bntrico%2C%20rand%26%23xF4%3Bmico%2C%20duplo-cego%20e%20controlado%20com%20placebo%2C%20sinvastatina%20reduziu%20em%2030%25%20o%20risco%20de%20morte%3B%20em%2042%25%20o%20risco%20de%20morte%20por%20DAC%3B%20e%20em%2037%25%20o%20risco%20de%20infarto%20do%20mioc%26%23xE1%3Brdio%20n%26%23xE3%3Bo%20fatal%20comprovado%20no%20hospital.%20Al%26%23xE9%3Bm%20disso%2C%20sinvastatina%20reduziu%20em%2037%25%20o%20risco%20de%20procedimentos%20para%20revasculariza%26%23xE7%3B%26%23xE3%3Bo%20do%20mioc%26%23xE1%3Brdio%20(bypass%20da%20art%26%23xE9%3Bria%20coronariana%20ou%20angioplastia%20coronariana%20transluminal%20percut%26%23xE2%3Bnea).%20Em%20pacientes%20com%20diabetes%20mellitus%2C%20o%20risco%20de%20um%20evento%20coronariano%20importante%20foi%20reduzido%20em%2055%25.%20Al%26%23xE9%3Bm%20disso%2C%20sinvastatina%20reduziu%20significativamente%20o%20risco%20de%20eventos%20vasculares%20cerebrais%20fatais%20e%20n%26%23xE3%3Bo%20fatais%20(AVC%20e%20ataques%20isqu%26%23xEA%3Bmicos%20transit%26%23xF3%3Brios)%20em%2028%25.%3Cbr%3E%0ANo%20Estudo%20de%20Prote%26%23xE7%3B%26%23xE3%3Bo%20do%20Cora%26%23xE7%3B%26%23xE3%3Bo%20(HPS%20%26%23x2013%3B%20Heart%20Protection%20Study)%2C%20os%20efeitos%20do%20tratamento%20com%20sinvastatina%20durante%20um%20per%26%23xED%3Bodo%20de%20acompanhamento%20de%205%20anos%2C%20em%20m%26%23xE9%3Bdia%2C%20foram%20avaliados%20em%2020.536%20pacientes%20com%20ou%20sem%20hiperlipidemia%20e%20alto%20risco%20de%20eventos%20coronarianos%2C%20em%20decorr%26%23xEA%3Bncia%20de%20diabetes%2C%20antecedentes%20de%20acidente%20vascular%20cerebral%20(AVC)%20ou%20outra%20doen%26%23xE7%3Ba%20vascular%20cerebral%2C%20doen%26%23xE7%3Ba%20vascular%20perif%26%23xE9%3Brica%20ou%20doen%26%23xE7%3Ba%20coronariana.%20No%20per%26%23xED%3Bodo%20basal%2C%2033%25%20apresentavam%20n%26%23xED%3Bveis%20de%20LDL%20inferiores%20a%20116%20mg%2FdL%3B%2025%25%2C%20entre%20116%20mg%2FdL%20e%20135%20mg%2FdL%20e%2042%25%2C%20superiores%20a%20135%20mg%2FdL.%3Cbr%3E%0ANesse%20estudo%20multic%26%23xEA%3Bntrico%2C%20rand%26%23xF4%3Bmico%2C%20duplo-cego%20e%20controlado%20com%20placebo%2C%20sinvastatina%2040%20mg%2Fdia%20comparado%20ao%20placebo%20reduziu%20o%20risco%20de%20mortalidade%20por%20todas%20as%20causas%20em%2013%25%2C%20em%20consequ%26%23xEA%3Bncia%20da%20redu%26%23xE7%3B%26%23xE3%3Bo%20de%20mortes%20por%20doen%26%23xE7%3Ba%20coronariana%20(18%25).%20A%20sinvastatina%20tamb%26%23xE9%3Bm%20diminuiu%20o%20risco%20de%20eventos%20coronarianos%20maiores%20(um%20desfecho%20composto%20de%20IM%20n%26%23xE3%3Bo%20fatal%20ou%20mortes%20de%20origem%20coronariana)%20em%2027%25.%20A%20sinvastatina%20reduziu%20a%20necessidade%20de%20procedimentos%20de%20revasculariza%26%23xE7%3B%26%23xE3%3Bo%20coronariana%20(incluindo%20bypass%20ou%20angioplastia%20coronariana%20transluminal%20percut%26%23xE2%3Bnea)%20e%20procedimentos%20de%20revasculariza%26%23xE7%3B%26%23xE3%3Bo%20perif%26%23xE9%3Brica%20e%20outros%20procedimentos%20de%20revasculariza%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20coronarianos%2C%20em%2030%25%20e%2016%25%2C%20respectivamente.%20A%20sinvastatina%20reduziu%20o%20risco%20de%20AVC%20em%2025%25.%20Al%26%23xE9%3Bm%20disso%2C%20sinvastatina%20reduziu%20o%20risco%20de%20hospitaliza%26%23xE7%3B%26%23xE3%3Bo%20por%20angina%20em%2017%25.%20Os%20riscos%20de%20eventos%20coronarianos%20e%20vasculares%20maiores%20(um%20desfecho%20composto%20que%20incluiu%20os%20eventos%20coronarianos%20relevantes%2C%20AVC%20ou%20procedimentos%20de%20revasculariza%26%23xE7%3B%26%23xE3%3Bo)%20foram%20reduzidos%20em%20cerca%20de%2025%25%20em%20pacientes%20com%20ou%20sem%20doen%26%23xE7%3Ba%20coronariana%2C%20incluindo%20pacientes%20com%20diabetes%20e%20pacientes%20com%20doen%26%23xE7%3Ba%20perif%26%23xE9%3Brica%20ou%20vascular%20cerebral.%20Al%26%23xE9%3Bm%20disso%2C%20no%20subgrupo%20de%20pacientes%20com%20diabetes%2C%20sinvastatina%20reduziu%20o%20risco%20do%20desenvolvimento%20de%20complica%26%23xE7%3B%26%23xF5%3Bes%20macrovasculares%2C%20incluindo%20procedimentos%20de%20revasculariza%26%23xE7%3B%26%23xE3%3Bo%20perif%26%23xE9%3Brica%20(cirurgia%20ou%20angioplastia)%2C%20amputa%26%23xE7%3B%26%23xE3%3Bo%20de%20membros%20inferiores%20ou%20%26%23xFA%3Blceras%20nas%20pernas%20em%2021%25.%20As%20redu%26%23xE7%3B%26%23xF5%3Bes%20de%20risco%20produzidas%20por%20sinvastatina%20nos%20eventos%20maiores%2C%20vasculares%20e%20coronarianos%2C%20foram%20evidentes%20e%20consistentes%20independentemente%20da%20idade%20e%20do%20sexo%20do%20paciente%2C%20dos%20n%26%23xED%3Bveis%20de%20LDL-C%2C%20HDL-C%2C%20TG%2C%20apolipoprote%26%23xED%3Bna%20A-I%20ou%20apolipoprote%26%23xED%3Bna%20B%20no%20per%26%23xED%3Bodo%20basal%2C%20da%20presen%26%23xE7%3Ba%20ou%20aus%26%23xEA%3Bncia%20de%20hipertens%26%23xE3%3Bo%2C%20dos%20n%26%23xED%3Bveis%20de%20creatinina%20at%26%23xE9%3B%20o%20limite%20para%20inclus%26%23xE3%3Bo%20de%202%2C3%20mg%2FdL%2C%20da%20presen%26%23xE7%3Ba%20ou%20aus%26%23xEA%3Bncia%20de%20medica%26%23xE7%3B%26%23xF5%3Bes%20cardiovasculares%20(aspirina%2C%20betabloqueadores%2C%20inibidores%20da%20enzima%20conversora%20de%20angiotensina%20%5BECA%5D%20ou%20bloqueadores%20dos%20canais%20de%20c%26%23xE1%3Blcio)%20no%20per%26%23xED%3Bodo%20basal%2C%20de%20tabagismo%2C%20de%20ingest%26%23xE3%3Bo%20de%20%26%23xE1%3Blcool%20ou%20de%20obesidade.%20Ao%20final%20de%205%20anos%2C%2032%25%20dos%20pacientes%20no%20grupo%20placebo%20estavam%20tomando%20uma%20estatina%20(fora%20do%20protocolo%20do%20estudo)%3B%20portanto%2C%20as%20redu%26%23xE7%3B%26%23xF5%3Bes%20de%20risco%20observadas%20subestimam%20o%20real%20efeito%20da%20sinvastatina.%3Cbr%3E%0AEm%20estudo%20cl%26%23xED%3Bnico%20multic%26%23xEA%3Bntrico%2C%20controlado%20com%20placebo%2C%20que%20utilizou%20angiografia%20coronariana%20quantitativa%20e%20envolveu%20404%20pacientes%2C%20sinvastatina%20retardou%20a%20progress%26%23xE3%3Bo%20da%20aterosclerose%20coronariana%20e%20reduziu%20o%20desenvolvimento%20de%20novas%20les%26%23xF5%3Bes%20e%20de%20novas%20oclus%26%23xF5%3Bes%20totais%2C%20ao%20passo%20que%20as%20les%26%23xF5%3Bes%20ateroscler%26%23xF3%3Bticas%20coronarianas%20pioraram%20de%20forma%20constante%20ao%20longo%20de%20um%20per%26%23xED%3Bodo%20de%204%20anos%20em%20pacientes%20que%20receberam%20tratamento-padr%26%23xE3%3Bo.%3Cbr%3E%0AAs%20an%26%23xE1%3Blises%20de%20subgrupo%20de%20dois%20estudos%20que%20inclu%26%23xED%3Bram%20147%20pacientes%20com%20hipertrigliceridemia%20(hiperlipidemia%20tipo%20IV%20de%20Fredrickson)%20demonstraram%20que%2020%20a%2080%20mg%2Fdia%20de%20sinvastatina%20reduziu%20os%20n%26%23xED%3Bveis%20de%20triglic%26%23xE9%3Brides%20em%2021%25%20a%2039%25%20(placebo%3A%2011%25%20a%2013%25)%2C%20de%20LDL-colesterol%20em%2023%25%20a%2035%25%20(placebo%3A%20%2B1%25%20a%20%2B3%25)%20e%20do%20colesterol%20n%26%23xE3%3Bo%20HDL%2C%20em%2026%25%20a%2043%25%20(placebo%3A%20%2B1%25%20a%20%2B3%25)%20e%20aumentou%20o%20HDL-C%20em%209%25%20a%2014%25%20(placebo%3A%203%25).%3Cbr%3E%0AEm%20outra%20an%26%23xE1%3Blise%20de%20subgrupo%20de%20sete%20pacientes%20com%20disbetalipoproteinemia%20(hiperlipidemia%20tipo%20III%20de%20Fredrickson)%2C%20a%20dose%20de%2080%20mg%2Fdia%20de%20sinvastatina%20reduziu%20os%20n%26%23xED%3Bveis%20de%20LDL-C%2C%20inclusive%20das%20lipoprote%26%23xED%3Bnas%20de%20densidade%20intermedi%26%23xE1%3Bria%20(IDL)%20em%2051%25%20(placebo%3A%208%25)%20e%20de%20VLDL-colesterol%20%2B%20IDL%20em%2060%25%20(placebo%3A%204%25).%3C%2Fp%3E%0A%3Cp%3E3.%20CARACTER%26%23xCD%3BSTICAS%20FARMACOL%26%23xD3%3BGICAS%3C%2Fp%3E%0A%3Cp%3EA%20sinvastatina%20%26%23xE9%3B%20um%20agente%20redutor%20do%20colesterol%20derivado%20sinteticamente%20de%20um%20produto%20de%20fermenta%26%23xE7%3B%26%23xE3%3Bo%20do%20Aspergillus%20terreus.%3Cbr%3E%0AAp%26%23xF3%3Bs%20a%20ingest%26%23xE3%3Bo%2C%20sinvastatina%2C%20uma%20lactona%20inativa%2C%20%26%23xE9%3B%20hidrolisado%20ao%20%26%23x3B2%3B-hidroxi%26%23xE1%3Bcido%20correspondente.%20Esse%20%26%23xE9%3B%20o%20principal%20metab%26%23xF3%3Blito%20e%20%26%23xE9%3B%20um%20inibidor%20da%203-hidr%26%23xF3%3Bxi-3-metilglutaril-coenzima%20A%20(HMG-CoA)%20redutase%2C%20uma%20enzima%20que%20catalisa%20um%20passo%20precoce%20e%20limitante%20da%20taxa%20de%20bioss%26%23xED%3Bntese%20do%20colesterol.%20Estudos%20cl%26%23xED%3Bnicos%20mostram%20que%20sinvastatina%20%26%23xE9%3B%20altamente%20eficaz%20para%20reduzir%20as%20concentra%26%23xE7%3B%26%23xF5%3Bes%20plasm%26%23xE1%3Bticas%20do%20colesterol%20total%2C%20do%20LDL-colesterol%2C%20dos%20triglic%26%23xE9%3Brides%20e%20do%20VLDL-%20colesterol%20e%20para%20aumentar%20o%20HDL-colesterol%20nas%20formas%20familiar%20heterozig%26%23xF3%3Btica%20e%20n%26%23xE3%3Bo%20familiar%20de%20hipercolesterolemia%20e%20na%20hiperlipidemia%20mista%2C%20quando%20o%20colesterol%20elevado%20for%20preocupante%20e%20a%20dieta%20apenas%20for%20insuficiente.%20Observam-se%20respostas%20acentuadas%20em%20duas%20semanas%20e%20respostas%20terap%26%23xEA%3Buticas%20m%26%23xE1%3Bximas%20ocorrem%20em%204%20a%206%20semanas.%20A%20resposta%20mant%26%23xE9%3Bm-se%20com%20a%20continuidade%20do%20tratamento.%20Quando%20o%20tratamento%20com%20sinvastatina%20%26%23xE9%3B%20interrompido%2C%20os%20n%26%23xED%3Bveis%20de%20colesterol%20e%20l%26%23xED%3Bpides%20voltam%20aos%20n%26%23xED%3Bveis%20anteriores%20ao%20tratamento.%3Cbr%3E%0AA%20forma%20ativa%20da%20sinvastatina%20%26%23xE9%3B%20um%20inibidor%20espec%26%23xED%3Bfico%20da%20HMG-CoA%20redutase%2C%20enzima%20que%20catalisa%20a%20convers%26%23xE3%3Bo%20da%20HMG-CoA%20a%20mevalonato.%20Em%20virtude%20de%20essa%20convers%26%23xE3%3Bo%20ser%20um%20passo%20inicial%20da%20bioss%26%23xED%3Bntese%20do%20colesterol%2C%20n%26%23xE3%3Bo%20se%20espera%20que%20o%20tratamento%20com%20sinvastatina%20provoque%20ac%26%23xFA%3Bmulo%20de%20ester%26%23xF3%3Bis%20potencialmente%20t%26%23xF3%3Bxicos.%20Al%26%23xE9%3Bm%20disso%2C%20a%20HMG-CoA%20%26%23xE9%3B%20tamb%26%23xE9%3Bm%20rapidamente%20metabolizada%20de%20volta%20a%20acetil-CoA%2C%20a%20qual%20participa%20de%20muitos%20processos%20de%20bioss%26%23xED%3Bntese%20no%20organismo.%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Cp%3EFarmacocin%26%23xE9%3Btica%3Cbr%3E%0AAbsor%26%23xE7%3B%26%23xE3%3Bo%3A%20demonstrou-se%20que%20a%20biodisponibilidade%20do%20beta-hidroxi%26%23xE1%3Bcido%20para%20a%20circula%26%23xE7%3B%26%23xE3%3Bo%20sist%26%23xEA%3Bmica%20ap%26%23xF3%3Bs%20uma%20dose%20oral%20de%20sinvastatina%20foi%20menor%20do%20que%205%25%20da%20dose%2C%20o%20que%20%26%23xE9%3B%20compat%26%23xED%3Bvel%20com%20a%20ampla%20extra%26%23xE7%3B%26%23xE3%3Bo%20hep%26%23xE1%3Btica%20de%20primeira%20passagem.%20Os%20principais%20metab%26%23xF3%3Blitos%20da%20sinvastatina%20presentes%20no%20plasma%20humano%20s%26%23xE3%3Bo%20o%20%26%23x3B2%3B-hidroxi%26%23xE1%3Bcido%20e%20quatro%20metab%26%23xF3%3Blitos%20ativos%20adicionais.%3Cbr%3E%0AEm%20jejum%2C%20o%20perfil%20plasm%26%23xE1%3Btico%20dos%20inibidores%20total%20e%20ativo%20n%26%23xE3%3Bo%20foi%20afetado%20quando%20a%20sinvastatina%20foi%20administrada%20imediatamente%20antes%20de%20uma%20refei%26%23xE7%3B%26%23xE3%3Bo-teste.%3C%2Fp%3E%0A%3Cp%3EDistribui%26%23xE7%3B%26%23xE3%3Bo%3A%20a%20sinvastatina%20e%20o%20beta-hidroxi%26%23xE1%3Bcido%20ligam-se%20%26%23xE0%3Bs%20prote%26%23xED%3Bnas%20plasm%26%23xE1%3Bticas%20humanas%20(95%25).%3Cbr%3E%0AA%20farmacocin%26%23xE9%3Btica%20de%20doses%20%26%23xFA%3Bnica%20e%20m%26%23xFA%3Bltipla%20de%20sinvastatina%20n%26%23xE3%3Bo%20mostrou%20ac%26%23xFA%3Bmulo%20do%20medicamento%20ap%26%23xF3%3Bs%20a%20administra%26%23xE7%3B%26%23xE3%3Bo%20m%26%23xFA%3Bltipla.%20Em%20todos%20os%20estudos%20de%20farmacocin%26%23xE9%3Btica%20acima%2C%20a%20concentra%26%23xE7%3B%26%23xE3%3Bo%20plasm%26%23xE1%3Btica%20m%26%23xE1%3Bxima%20dos%20inibidores%20ocorreu%201%2C3%20a%202%2C4%20horas%20ap%26%23xF3%3Bs%20a%20dose.%3C%2Fp%3E%0A%3Cp%3EMetabolismo%3A%20a%20sinvastatina%20%26%23xE9%3B%20uma%20lactona%20inativa%20que%20%26%23xE9%3B%20rapidamente%20hidrolisada%20in%20vivo%20para%20o%20%26%23x3B2%3B-hidroxi%26%23xE1%3Bcidocorrespondente%2C%20um%20potente%20inibidor%20da%20HMG-CoA%20redutase.%20A%20hidr%26%23xF3%3Blise%20ocorre%20principalmente%20no%20f%26%23xED%3Bgado%3B%20a%20velocidade%20de%20hidr%26%23xF3%3Blise%20no%20plasma%20humano%20%26%23xE9%3B%20muito%20lenta.%3Cbr%3E%0AA%20sinvastatina%20%26%23xE9%3B%20bem%20absorvida%20em%20humanos%20e%20passa%20por%20ampla%20extra%26%23xE7%3B%26%23xE3%3Bo%20hep%26%23xE1%3Btica%20de%20primeira%20passagem.%20A%20extra%26%23xE7%3B%26%23xE3%3Bo%20no%20f%26%23xED%3Bgado%20depende%20do%20fluxo%20sangu%26%23xED%3Bneo%20hep%26%23xE1%3Btico.%20O%20f%26%23xED%3Bgado%20%26%23xE9%3B%20o%20principal%20local%20de%20a%26%23xE7%3B%26%23xE3%3Bo%2C%20com%20excre%26%23xE7%3B%26%23xE3%3Bo%20posterior%20dos%20equivalentes%20do%20f%26%23xE1%3Brmaco%20na%20bile.%20Consequentemente%2C%20a%20disponibilidade%20do%20f%26%23xE1%3Brmaco%20ativo%20na%20circula%26%23xE7%3B%26%23xE3%3Bo%20sist%26%23xEA%3Bmica%20%26%23xE9%3B%20baixa.%20Ap%26%23xF3%3Bs%20uma%20inje%26%23xE7%3B%26%23xE3%3Bo%20intravenosa%20do%20metab%26%23xF3%3Blito%20beta-hidroxi%26%23xE1%3Bcido%2C%20sua%20meia-vida%20m%26%23xE9%3Bdia%20%26%23xE9%3B%20de%201%2C9%20hora.%3C%2Fp%3E%0A%3Cp%3EElimina%26%23xE7%3B%26%23xE3%3Bo%3A%20ap%26%23xF3%3Bs%20uma%20dose%20oral%20de%20sinvastatina%20radioativa%20em%20humanos%2C%2013%25%20da%20radioatividade%20foi%20excretada%20na%20urina%20e%2060%25%20nas%20fezes%20em%2096%20horas.%20A%20quantidade%20recuperada%20nas%20fezes%20representa%20os%20equivalentes%20do%20f%26%23xE1%3Brmaco%20absorvido%20excretados%20na%20bile%2C%20assim%20como%20o%20f%26%23xE1%3Brmaco%20n%26%23xE3%3Bo%20absorvido.%20Ap%26%23xF3%3Bs%20uma%20inje%26%23xE7%3B%26%23xE3%3Bo%20intravenosa%20do%20metab%26%23xF3%3Blito%20%26%23x3B2%3B-hidroxi%26%23xE1%3Bcido%2Capenas%200%2C3%25%20da%20dose%20IV%2C%20em%20m%26%23xE9%3Bdia%2C%20foi%20excretada%20na%20urina%20como%20inibidores.%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Cp%3E4.%20CONTRAINDICA%26%23xC7%3B%26%23xD5%3BES%3Cbr%3E%0A-Hipersensibilidade%20a%20qualquer%20componente%20do%20produto%3B%3Cbr%3E%0A-Doen%26%23xE7%3Ba%20hep%26%23xE1%3Btica%20ativa%20ou%20aumentos%20persistentes%20e%20inexplicados%20das%20transaminases%20s%26%23xE9%3Bricas%3B%3C%2Fp%3E%0A%3Cp%3E-Gravidez%20e%20lacta%26%23xE7%3B%26%23xE3%3Bo%20(veja%20o%20item%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Gravidez%20e%20lacta%26%23xE7%3B%26%23xE3%3Bo)%3B%3Cbr%3E%0A-Administra%26%23xE7%3B%26%23xE3%3Bo%20concomitante%20de%20inibidores%20potentes%20do%20CYP3A4%20(por%20exemplo%2C%20itraconazol%2C%20cetoconazol%2C%20posaconazol%2C%20voriconazol%2C%20inibidores%20da%20protease%20do%20HIV%2C%20boceprevir%2C%20telaprevir%2C%20eritromicina%2C%20claritromicina%2C%20telitromicina%2C%20nefazodona%20e%20medicamentos%20contendo%20cobicistate)%20(veja%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise%20e%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS)%3B%3C%2Fp%3E%0A%3Cp%3ESinvastatina%2020%20mg%20e%2040%20mg%3Cbr%3E%0A-Administra%26%23xE7%3B%26%23xE3%3Bo%20concomitante%20de%20genfibrozila%2C%20ciclosporina%20ou%20danazol%20(veja%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise%20e%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS).%3C%2Fp%3E%0A%3Cp%3EAten%26%23xE7%3B%26%23xE3%3Bo%20diab%26%23xE9%3Bticos%3A%20cont%26%23xE9%3Bm%20a%26%23xE7%3B%26%23xFA%3Bcar%20(lactose%20e%20amido).%3Cbr%3E%0AEste%20medicamento%20deve%20ser%20utilizado%20com%20cautela%20por%20pacientes%20com%20intoler%26%23xE2%3Bncia%20%26%23xE0%3B%20lactose.%20Este%20medicamento%20%26%23xE9%3B%20contraindicado%20para%20uso%20por%20mulheres%20gr%26%23xE1%3Bvidas%20ou%20amamentando.%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Cp%3EEste%20medicamento%20n%26%23xE3%3Bo%20deve%20ser%20utilizado%20por%20mulheres%20gr%26%23xE1%3Bvidas%20ou%20que%20possam%20ficar%20gr%26%23xE1%3Bvidas%20durante%20o%20tratamento.%3C%2Fp%3E%0A%3Cp%3E5.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%3C%2Fp%3E%0A%3Cp%3EMiopatia%2FRabdomi%26%23xF3%3Blise%3A%20a%20sinvastatina%2C%20a%20exemplo%20de%20outros%20inibidores%20da%20HMG-CoA%20redutase%2C%20ocasionalmente%20causa%20miopatia%20que%20se%20manifesta%20como%20dor%2C%20dolorimento%20ou%20fraqueza%20musculares%20e%20creatinina%20quinase%20(CK)%20acima%20de%2010%20vezes%20o%20limite%20superior%20da%20normalidade%20(LSN).%20Algumas%20vezes%2C%20a%20miopatia%20apresenta-se%20como%20rabdomi%26%23xF3%3Blise%2C%20com%20ou%20sem%20insufici%26%23xEA%3Bncia%20renal%20aguda%20secund%26%23xE1%3Bria%20a%20mioglobin%26%23xFA%3Bria%20e%2C%20raramente%2C%20pode%20ser%20fatal.%20O%20risco%20de%20miopatia%20%26%23xE9%3B%20aumentado%20por%20n%26%23xED%3Bveis%20elevados%20de%20atividade%20inibit%26%23xF3%3Bria%20da%20HMG-CoA%20redutase%20no%20plasma%20(isto%20%26%23xE9%3B%2C%20n%26%23xED%3Bveis%20plasm%26%23xE1%3Bticos%20elevados%20de%20sinvastatina%20e%20de%20sinvastatina%20%26%23xE1%3Bcida%20no%20plasma)%2C%20que%20pode%20ser%20devido%2C%20em%20parte%2C%20%26%23xE0%3B%20intera%26%23xE7%3B%26%23xF5%3Bes%20medicamentosas%20que%20interferem%20com%20o%20metabolismo%20da%20sinvastatina%20e%2Fou%20com%20as%20vias%20trasnportadoras%20(veja%20o%20item%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS).%20Os%20fatores%20predisponentes%20para%20miopatia%20incluem%20idade%20avan%26%23xE7%3Bada%20(%3D%26gt%3B%2065%20anos)%2C%20sexo%20feminino%2C%20hipotireoidismo%20n%26%23xE3%3Bo%20controlado%20e%20insufici%26%23xEA%3Bncia%20renal.%3Cbr%3E%0AA%20exemplo%20de%20outros%20inibidores%20da%20HMG-CoA%20redutase%2C%20o%20risco%20de%20miopatia%2Frabdomi%26%23xF3%3Blise%20est%26%23xE1%3B%20relacionado%20%26%23xE0%3B%20dose.%20Em%20um%20banco%20de%20dados%20de%20estudos%20cl%26%23xED%3Bnicos%20no%20qual%2041.413%20pacientes%20foram%20tratados%20com%20sinvastatina%2C%2024.747%20(aproximadamente%2060%25)%20dos%20quais%20foram%20admitidos%20nos%20estudos%20com%20um%20acompanhamento%20mediano%20de%20pelo%20menos%204%20anos%2C%20a%20incid%26%23xEA%3Bncia%20de%20miopatia%20foi%20de%20aproximadamente%200%2C03%25%2C%200%2C08%25%20e%200%2C61%25%20com%2020%2C%2040%20e%2080%20mg%2Fdia%2C%20respectivamente.%20Nesses%20estudos%2C%20os%20pacientes%20foram%20cuidadosamente%20monitorados%20e%20alguns%20medicamentos%20com%20intera%26%23xE7%3B%26%23xE3%3Bo%20foram%20exclu%26%23xED%3Bdos.%3Cbr%3E%0AEm%20um%20estudo%20cl%26%23xED%3Bnico%20no%20qual%20os%20pacientes%20com%20hist%26%23xF3%3Brico%20de%20infarto%20do%20mioc%26%23xE1%3Brdio%20foram%20tratados%20com%20sinvastatina%2080%20mg%2Fdia%20(acompanhamento%20m%26%23xE9%3Bdio%20de%206%2C7%20anos)%2C%20a%20incid%26%23xEA%3Bncia%20de%20miopatia%20foi%20de%20aproximadamente%201%2C0%25%20em%20compara%26%23xE7%3B%26%23xE3%3Bo%20com%200%2C02%25%20para%20os%20pacientes%20tratados%20com%2020%20mg%2Fdia.%20Aproximadamente%20metade%20destes%20casos%20de%20miopatia%20ocorreu%20durante%20o%20primeiro%20ano%20de%20tratamento.%20A%20incid%26%23xEA%3Bncia%20de%20miopatia%20durante%20cada%20ano%20subsequente%20de%20tratamento%20foi%20de%20aproximadamente%200%2C1%25.%3Cbr%3E%0AO%20risco%20de%20miopatia%2C%20incluindo%20rabdomi%26%23xF3%3Blise%2C%20%26%23xE9%3B%20maior%20em%20pacientes%20que%20est%26%23xE3%3Bo%20sendo%20tratados%20com%20sinvastatina%2080%20mg%20quando%20comparado%20com%20outras%20terapias%20%26%23xE0%3B%20base%20de%20estatina%20com%20efic%26%23xE1%3Bcia%20semelhante%20ou%20maior%20na%20redu%26%23xE7%3B%26%23xE3%3Bo%20de%20colesterol%20LDL%20e%20em%20compara%26%23xE7%3B%26%23xE3%3Bo%20com%20doses%20menores%20de%20sinvastatina.%20Portanto%2C%20a%20dose%20de%2080%20mg%20de%20sinvastatina%20deve%20ser%20utilizada%20somente%20em%20pacientes%20que%20est%26%23xE3%3Bo%20tomando%20sinvastatina%2080%20mg%20cronicamente%20(por%2012%20meses%20ou%20mais)%20sem%20evid%26%23xEA%3Bncias%20de%20toxicidade%20muscular%20(veja%20o%20item%208.%20POSOLOGIA%20E%20MODO%20DE%20USAR).%20O%20uso%20de%20sinvastatina%2080%20mg%20n%26%23xE3%3Bo%20deve%20ser%20iniciado%20em%20pacientes%20novos%2C%20incluindo%20os%20pacientes%20que%20j%26%23xE1%3B%20tomam%20doses%20menores%20do%20medicamento.%3Cbr%3E%0ASe%20um%20paciente%20que%20est%26%23xE1%3B%20atualmente%20tolerando%20a%20dose%20de%2080%20mg%20de%20sinvastatina%20precisar%20iniciar%20um%20medicamento%20que%20%26%23xE9%3B%20contraindicado%20ou%20um%20medicamento%20com%20potencial%20de%20intera%26%23xE7%3B%26%23xE3%3Bo%20medicamentosa%20e%20que%20limita%20a%20dose%20m%26%23xE1%3Bxima%20permitida%20de%20sinvastatina%2C%20este%20paciente%20deve%20ser%20mudado%20para%20uma%20estatina%20alternativa%20ou%20regime%20baseado%20em%20estatina%20com%20menor%20potencial%20para%20a%20intera%26%23xE7%3B%26%23xE3%3Bo%20medicamentosa.%20Os%20pacientes%20devem%20ser%20alertados%20sobre%20o%20risco%20aumentado%20de%20miopatia%2C%20incluindo%20rabdomi%26%23xF3%3Blise%2C%20e%20orientados%20a%20relatar%20imediatamente%20qualquer%20dor%2C%20sensibilidade%20ou%20fraqueza%20muscular%20inexplicadas.%20Se%20os%20sintomas%20ocorrerem%2C%20o%20tratamento%20deve%20ser%20interrompido%20imediatamente%20(veja%20os%20itens%208.%20POSOLOGIA%20E%20ADMINISTRA%26%23xC7%3B%26%23xC3%3BO%20e%204.%3Cbr%3E%0ACONTRAINDICA%26%23xC7%3B%26%23xD5%3BES).%3Cbr%3E%0ATodos%20os%20pacientes%20que%20iniciam%20tratamento%20com%20sinvastatina%2C%20ou%20cuja%20dose%20de%20sinvastatina%20est%26%23xE1%3B%20sendo%20aumentada%2C%20devem%20ser%20alertados%20sobre%20o%20risco%20de%20miopatia%20e%20orientados%20a%20relatar%20imediatamente%20qualquer%20dor%2C%20sensibilidade%20ou%20fraqueza%20muscular%20inexplicada.%20A%20terapia%20com%20sinvastatina%20deve%20ser%20descontinuada%20imediatamente%20se%20houver%20diagn%26%23xF3%3Bstico%20ou%20suspeita%20de%20miopatia.%20A%20presen%26%23xE7%3Ba%20destes%20sintomas%2C%20bem%20como%20n%26%23xED%3Bvel%20de%20CK%20%26gt%3B10%20vezes%20o%20limite%20normal%20superior%2C%20indica%20miopatia.%20Na%20maioria%20dos%20casos%2C%20quando%20os%20pacientes%20descontinuaram%20imediatamente%20o%20tratamento%2C%20os%20sintomas%20musculares%20e%20os%20aumentos%20de%20CK%20desapareceram%20(veja%20o%20item%209.%20REA%26%23xC7%3B%26%23xD5%3BES%20ADVERSAS).%20Pode-se%20considerar%20determina%26%23xE7%3B%26%23xF5%3Bes%20peri%26%23xF3%3Bdicas%20de%20CK%20para%20pacientes%20que%20iniciam%20terapia%20com%20sinvastatina%20ou%20cuja%20dose%20esteja%20sendo%20aumentada.%20Tamb%26%23xE9%3Bm%20se%20recomenda%20determina%26%23xE7%3B%26%23xF5%3Bes%20peri%26%23xF3%3Bdicas%20de%20CK%20para%20pacientes%20que%20usam%20a%20dose%20de%2080mg%20de%20sinvastatina.%20N%26%23xE3%3Bo%20h%26%23xE1%3B%20nenhuma%20garantia%20de%20que%20esse%20monitoramento%20ir%26%23xE1%3B%20prevenir%20a%20miopatia.%3Cbr%3E%0AMuitos%20dos%20pacientes%20que%20desenvolveram%20rabdomi%26%23xF3%3Blise%20durante%20o%20tratamento%20com%20sinvastatina%20tinham%20hist%26%23xF3%3Bricos%20m%26%23xE9%3Bdicos%20complicados%2C%20incluindo%20insufici%26%23xEA%3Bncia%20renal%2C%20geralmente%20em%20consequ%26%23xEA%3Bncia%20de%20diabetes%20mellitus%20prolongado.%20Tais%20pacientes%20devem%20ser%20cuidadosamente%20monitorados.%20A%20terapia%20com%20sinvastatina%20deve%20ser%20temporariamente%20interrompida%20alguns%20dias%20antes%20de%20cirurgia%20eletiva%20de%20grande%20porte%20e%20quando%20qualquer%20condi%26%23xE7%3B%26%23xE3%3Bo%20cir%26%23xFA%3Brgica%20ou%20m%26%23xE9%3Bdica%20importante%20sobrevenha.%3Cbr%3E%0AEm%20um%20estudo%20cl%26%23xED%3Bnico%20no%20qual%20pacientes%20com%20alto%20risco%20de%20doen%26%23xE7%3Ba%20cardiovascular%20foram%20tratados%20com%20sinvastatina%2040%20mg%2Fdia%20(acompanhamento%20m%26%23xE9%3Bdio%20de%203%2C9%20anos)%2C%20a%20incid%26%23xEA%3Bncia%20de%20miopatia%20foi%20de%20aproximadamente%200%2C05%25%20em%20pacientes%20n%26%23xE3%3Bo-chineses%20(n%20%3D%207.367)%20em%20compara%26%23xE7%3B%26%23xE3%3Bo%20com%200%2C24%25%20em%20pacientes%20chineses%20(n%20%3D%205.468).%20Embora%20a%20%26%23xFA%3Bnica%20popula%26%23xE7%3B%26%23xE3%3Bo%20asi%26%23xE1%3Btica%20avaliada%20neste%20estudo%20cl%26%23xED%3Bnico%20tenha%20sido%20a%20chinesa%2C%20deve-se%20ter%20cautela%20ao%20prescrever%20sinvastatina%20para%20pacientes%20asi%26%23xE1%3Bticos%20e%20a%20menor%20dose%20necess%26%23xE1%3Bria%20deve%20ser%20utilizada.%3C%2Fp%3E%0A%3Cp%3EIntera%26%23xE7%3B%26%23xF5%3Bes%20medicamentosas%3Cbr%3E%0A-O%20risco%20de%20miopatia%2Frabdomi%26%23xF3%3Blise%20%26%23xE9%3B%20aumentado%20pelo%20uso%20concomitante%20de%20sinvastatina%20com%3A%3Cbr%3E%0AMedicamentos%20contraindicados%3Cbr%3E%0A-Inibidores%20potentes%20da%20CYP3A4%3A%20uso%20concomitante%20de%20medicamentos%20conhecidos%20por%20apresentar%20um%20potente%20efeito%20inibit%26%23xF3%3Brio%20sobre%20CYP3A4%20em%20doses%20terap%26%23xEA%3Buticas%20(por%20exemplo%2C%20itraconazol%2C%20cetoconazol%2C%20posaconazol%2C%20voriconazol%2C%20eritromicina%2C%20claritromicina%2C%20telitromicina%2C%20inibidores%20da%20protease%20do%20HIV%2C%20boceprevir%2C%20teloprevir%2C%20nefazodona%20ou%20medicamentos%20contendo%20cobicistate)%20%26%23xE9%3B%20contraindicada.%20Se%20o%20tratamento%20de%20curto%20prazo%20com%20inibidor%20potente%20de%20CYP3A4%20estiver%20indispon%26%23xED%3Bvel%2C%20a%20terapia%20com%20sinvastatina%20deve%20ser%20interrompida%20durante%20o%20tratamento%20(veja%20os%20itens%204.%20CONTRAINDICA%26%23xC7%3B%26%23xD5%3BES%3B%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS%20e%203.%20CARACTER%26%23xCD%3BSTICAS%20FARMACOL%26%23xD3%3BGICAS%2C%20Farmacocin%26%23xE9%3Btica)%3Cbr%3E%0A-Genfibrozila%2C%20ciclosporina%20ou%20danazol%3A%20o%20uso%20concomitante%20desses%20medicamentos%20com%20sinvastatina%20%26%23xE9%3B%20contraindicado%20(veja%20os%20itens%204.%20CONTRAINDICA%26%23xC7%3B%26%23xD5%3BES%3B%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS%20e%203.%20CARACTER%26%23xCD%3BSTICAS%20FARMACOL%26%23xD3%3BGICAS%2C%20Farmacocin%26%23xE9%3Btica).%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Cp%3EOutros%20medicamentos%3A%3Cbr%3E%0A-%26%23xC1%3Bcido%20fus%26%23xED%3Bdico%3A%20pacientes%20tratados%20com%20%26%23xE1%3Bcido%20fus%26%23xED%3Bdico%20concomitantemente%20com%20sinvastatina%20podem%20apresentar%20risco%20aumentado%20de%20miopatia%2Frabdomi%26%23xF3%3Blise%20(veja%20os%20itens%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS%2C%20Outras%20Intera%26%23xE7%3B%26%23xF5%3Bes%20Medicamentosas%20e%203.%20CARACTER%26%23xCD%3BSTICAS%20FARMACOL%26%23xD3%3BGICAS%2C%20Farmacocin%26%23xE9%3Btica).%20A%20coadministra%26%23xE7%3B%26%23xE3%3Bo%20com%20%26%23xE1%3Bcido%20fus%26%23xED%3Bdico%20n%26%23xE3%3Bo%20%26%23xE9%3B%20recomendada.%20Em%20pacientes%20em%20que%20o%20uso%20de%20%26%23xE1%3Bcido%20fus%26%23xED%3Bdico%20sist%26%23xEA%3Bmico%20%26%23xE9%3B%20considerado%20essencial%2C%20a%20sinvastatina%20deve%20ser%20descontinuada%20durante%20todo%20o%20tratamento%20com%20%26%23xE1%3Bcido%20fus%26%23xED%3Bdico.%20Em%20circunst%26%23xE2%3Bncias%20excepcionais%2C%20onde%20o%20uso%20sist%26%23xEA%3Bmico%20prolongado%20do%20%26%23xE1%3Bcido%20fus%26%23xED%3Bdico%20%26%23xE9%3B%20necess%26%23xE1%3Brio%2C%20por%20exemplo%2C%20para%20o%20tratamento%20de%20infec%26%23xE7%3B%26%23xF5%3Bes%20graves%2C%20a%20necessidade%20da%20coadministra%26%23xE7%3B%26%23xE3%3Bo%20de%20sinvastatina%20e%20%26%23xE1%3Bcido%20fus%26%23xED%3Bdico%20deve%20ser%20considerada%20caso%20a%20caso%20e%20sob%20rigorosa%20supervis%26%23xE3%3Bo%20m%26%23xE9%3Bdica.%3Cbr%3E%0A-Outros%20fibratos%3A%20a%20dose%20de%20sinvastatina%20n%26%23xE3%3Bo%20deve%20ser%20maior%20que%2010%20mg%2Fdia%20em%20pacientes%20tratados%20concomitante%20com%20outros%20fibratos%20al%26%23xE9%3Bm%20da%20genfibrozila%20(veja%20o%20item%204.%20CONTRAINDICA%26%23xC7%3B%26%23xD5%3BES)%20ou%20fenofibrato.%20Quando%20sinvastatina%20e%20fenofibrato%20s%26%23xE3%3Bo%20administrados%20concomitantemente%2C%20n%26%23xE3%3Bo%20h%26%23xE1%3B%20nenhuma%20evid%26%23xEA%3Bncia%20de%20que%20o%20risco%20de%20miopatia%20exceda%20a%20soma%20dos%20riscos%20individuais%20de%20cada%20agente.%20Deve-se%20ter%20cautela%20ao%20prescrever%20fenofibrato%20com%20sinvastatina%2C%20uma%20vez%20que%20qualquer%20um%20dos%20agentes%20pode%20causar%20miopatia%20quando%20administrados%20isoladamente.%20A%20adi%26%23xE7%3B%26%23xE3%3Bo%20de%20fibratos%20%26%23xE0%3B%20sinvastatina%20normalmente%20proporciona%20pouca%20redu%26%23xE7%3B%26%23xE3%3Bo%20adicional%20de%20LDL-C%2C%20por%26%23xE9%3Bm%20podem%20ser%20obtidas%20redu%26%23xE7%3B%26%23xF5%3Bes%20adicionais%20de%20TG%20e%20aumentos%20adicionais%20de%20HDL-C.%20As%20combina%26%23xE7%3B%26%23xF5%3Bes%20de%20fibratos%20com%20sinvastatina%20t%26%23xEA%3Bm%20sido%20utilizadas%20sem%20ocorr%26%23xEA%3Bncia%20de%20miopatia%20em%20estudos%20cl%26%23xED%3Bnicos%20de%20pequeno%20porte%2C%20de%20curta%20dura%26%23xE7%3B%26%23xE3%3Bo%20e%20com%20monitoramento%20rigoroso%20(veja%20o%20item%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS).%3Cbr%3E%0A-Amiodarona%3A%20em%20um%20estudo%20cl%26%23xED%3Bnico%2C%20foi%20relatada%20miopatia%20em%206%25%20dos%20pacientes%20que%20receberam%2080%20mg%20de%20sinvastatina%20e%20amiodarona.%20A%20dose%20de%20sinvastatina%20n%26%23xE3%3Bo%20deve%20ser%20maior%20que%2020%20mg%20di%26%23xE1%3Brios%20em%20pacientes%20recebendo%20tratamento%20concomitantemente%20com%20amiodarona%20(veja%20os%20itens%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS%2C%20Outras%20Intera%26%23xE7%3B%26%23xF5%3Bes%20Medicamentosas%20e%208.%20POSOLOGIA%20E%20MODO%20DE%20USAR).%3C%2Fp%3E%0A%3Cp%3E-Bloqueadores%20do%20canal%20de%20c%26%23xE1%3Blcio%3Cbr%3E%0A-Verapamil%20ou%20diltiazem%3A%20em%20um%20estudo%20cl%26%23xED%3Bnico%2C%20os%20pacientes%20em%20tratamento%20concomitante%20com%20sinvastatina%2080%20mg%20e%20diltiazem%20apresentaram%20aumento%20no%20risco%20de%20miopatia.%20A%20dose%20de%20sinvastatina%20n%26%23xE3%3Bo%20deve%20ser%20maior%20que%2020%20mg%20di%26%23xE1%3Brios%20em%20pacientes%20recebendo%20tratamento%20concomitantemente%20com%20veramapil%20ou%20diltiazem%20(veja%20os%20itens%206.%3Cbr%3E%0AINTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS%2C%20Outras%20Intera%26%23xE7%3B%26%23xF5%3Bes%20Medicamentosas%20e%208.%20POSOLOGIA%20E%20MODO%20DE%3Cbr%3E%0AUSAR).%3C%2Fp%3E%0A%3Cp%3E-Anlodipino%3A%20em%20um%20estudo%20cl%26%23xED%3Bnico%2C%20os%20pacientes%20em%20tratamento%20concomitante%20com%20sinvastatina%2080%20mg%20e%20anlodipino%20apresentaram%20um%20risco%20discretamente%20aumentado%20de%20miopatia.%20A%20dose%20de%20sinvastatina%20n%26%23xE3%3Bo%20deve%20exceder%2040%20mg%20di%26%23xE1%3Brios%20em%20pacientes%20recebendo%20concomitantemente%20anlodipino%20(veja%20os%20itens%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS%2C%20Outras%20Intera%26%23xE7%3B%26%23xF5%3Bes%20Medicamentosas%20e%208.%20POSOLOGIA%20E%20MODO%20DE%20USAR).%3C%2Fp%3E%0A%3Cp%3ESinvastatina%2020%20mg%20e%2040%20mg%3Cbr%3E%0A-Lomitapida%3A%20a%20dose%20de%20sinvastatina%20n%26%23xE3%3Bo%20deve%20exceder%2040%20mg%20di%26%23xE1%3Brios%20em%20pacientes%20com%20hipercolesterolemia%20familiar%20homozig%26%23xF3%3Btica%20(HoFH)%20que%20recebam%20concomitantemente%20lomitapida%20(veja%20o%20item%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%3Cbr%3E%0AMEDICAMENTOSAS%2C%20Outras%20Intera%26%23xE7%3B%26%23xF5%3Bes%20Medicamentosas).%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Cp%3E-Inibidores%20moderados%20do%20CYP3A4%3A%20os%20pacientes%20que%20tomam%20outros%20medicamentos%20identificados%20em%20bula%20como%20medicamentos%20com%20efeito%20inibit%26%23xF3%3Brio%20moderado%20sobre%20o%20CYP3A4%20concomitantemente%20com%20sinvastatina%2C%20particularmente%20com%20doses%20mais%20altas%20de%20sinvastatina%2C%20podem%20ter%20maior%20risco%20de%20miopatia.%20Quando%20for%20coadministrada%20sinvastatina%20com%20um%20inibidor%20moderado%20de%20CYP3A4%2C%20um%20ajuste%20da%20dose%20de%20sinvastatina%20pode%20ser%20necess%26%23xE1%3Brio%20(veja%20o%20item%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS%2C%20Outras%20Intera%26%23xE7%3B%26%23xF5%3Bes%20Medicamentosas).%3Cbr%3E%0A-Inibidores%20da%20prote%26%23xED%3Bna%20resistente%20ao%20c%26%23xE2%3Bncer%20de%20mama%20(BCPR)%3A%20a%20administra%26%23xE7%3B%26%23xE3%3Bo%20concomitante%20de%20medicamentos%20inibidores%20da%20BCPR%20(por%20exemplo%2C%20elbasvir%20e%20grazoprevir)%20pode%20levar%20a%20um%20aumento%20das%20concentra%26%23xE7%3B%26%23xF5%3Bes%20plasm%26%23xE1%3Bticas%20da%20sinvastatina%20e%20um%20risco%20aumentado%20de%20miopatia%3B%20portanto%2C%20um%20ajuste%20da%20dose%20de%20sinvastatina%20pode%20ser%20necess%26%23xE1%3Brio.%20A%20coadministra%26%23xE7%3B%26%23xE3%3Bo%20de%20elbasvir%20e%20grazoprevir%20com%20sinvastatina%20n%26%23xE3%3Bo%20foi%20estudada%3B%20no%20entanto%2C%20a%20dose%20de%20sinvastatina%20n%26%23xE3%3Bo%20deve%20exceder%2020%20mg%20por%20dia%20em%20pacientes%20que%20tomam%2C%20concomitantemente%2C%20medicamentos%20contendo%20elbasvir%20ou%20grazoprevir%20(veja%20o%20item%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS%2C%20Outras%20Intera%26%23xE7%3B%26%23xF5%3Bes%20Medicamentosas).%3C%2Fp%3E%0A%3Cp%3E-%26%23xC1%3Bcido%20nicot%26%23xED%3Bnico%20(niacina)%20(%3D%26gt%3B%201%20g%2Fdia)%3A%20casos%20de%20miopatia%2Frabdomi%26%23xF3%3Blise%20foram%20observados%20com%20a%20sinvastatina%20coadministrada%20com%20doses%20modificadoras%20de%20l%26%23xED%3Bpides%20(%26%23x2265%3B%201%20g%2Fdia)%20de%20%26%23xE1%3Bcido%20nicot%26%23xED%3Bnico.%20Em%20um%20estudo%20cl%26%23xED%3Bnico%3Cbr%3E%0A(acompanhamento%20m%26%23xE9%3Bdio%20de%203%2C9%20anos)%20envolvendo%20pacientes%20com%20alto%20risco%20de%20doen%26%23xE7%3Ba%20cardiovascular%20e%20com%20n%26%23xED%3Bveis%20de%20LDL-C%20bem%20controlados%20com%20sinvastatina%2040%20mg%2Fdia%20com%20ou%20sem%20ezetimiba%2010%20mg%2C%20n%26%23xE3%3Bo%20houve%20benef%26%23xED%3Bcio%20incremental%20sobre%20os%20desfechos%20cardiovasculares%20com%20a%20adi%26%23xE7%3B%26%23xE3%3Bo%20de%20doses%20modificadoras%20de%20l%26%23xED%3Bp%26%23xED%3Bdes%20(%26%23x2265%3B%201%20g%2Fdia)%20de%20%26%23xE1%3Bcido%20nicot%26%23xED%3Bnico.%3Cbr%3E%0APortanto%2C%20o%20benef%26%23xED%3Bcio%20do%20uso%20combinado%20de%20sinvastatina%20com%20%26%23xE1%3Bcido%20nicot%26%23xED%3Bnico%20deve%20ser%20cuidadosamente%20ponderado%20contra%20os%20riscos%20potenciais%20da%20combina%26%23xE7%3B%26%23xE3%3Bo.%20Al%26%23xE9%3Bm%20disso%2C%20neste%20estudo%2C%20a%20incid%26%23xEA%3Bncia%20de%20miopatia%20foi%20aproximadamente%200%2C24%25%20em%20pacientes%20chineses%20tratados%20com%20sinvastatina%2040%20mg%20ou%20ezetimiba%2Fsinvastatina%2010%2F40%20mg%20em%20compara%26%23xE7%3B%26%23xE3%3Bo%20com%201%2C24%25%20em%20pacientes%20chineses%20tratados%20com%20sinvastatina%2040%20mg%20ou%20ezetimiba%2Fsinvastatina%2010%2F40%20mg%20coadministradas%20com%20%26%23xE1%3Bcido%20nicot%26%23xED%3Bnico%20de%20libera%26%23xE7%3B%26%23xE3%3Bo%20prolongada%2Flaropipranto%202g%2F40mg.%20Embora%20a%20%26%23xFA%3Bnica%20popula%26%23xE7%3B%26%23xE3%3Bo%20asi%26%23xE1%3Btica%20avaliada%20neste%20estudo%20cl%26%23xED%3Bnico%20tenha%20sido%20a%20de%20chineses%2C%20como%20a%20incid%26%23xEA%3Bncia%20de%20miopatia%20%26%23xE9%3B%20maior%20em%20pacientes%20chineses%20do%20que%20em%20pacientes%20n%26%23xE3%3Bo%20chineses%2C%20a%20coadministra%26%23xE7%3B%26%23xE3%3Bo%20de%20sinvastatina%20com%20doses%20modificadoras%20de%20l%26%23xED%3Bp%26%23xED%3Bdes%20(%26%23x2265%3B%201%20g%2Fdia)%20de%20%26%23xE1%3Bcido%20nicot%26%23xED%3Bnico%20n%26%23xE3%3Bo%20%26%23xE9%3B%20recomendada%20para%20pacientes%20asi%26%23xE1%3Bticos%20(veja%20o%20item%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS%2C%20Outras%20Intera%26%23xE7%3B%26%23xF5%3Bes%20Medicamentosas).%3C%2Fp%3E%0A%3Cp%3EEfeitos%20hep%26%23xE1%3Bticos%3A%3Cbr%3E%0AEm%20estudos%20cl%26%23xED%3Bnicos%2C%20ocorreram%20aumentos%20persistentes%20(acima%20de%20tr%26%23xEA%3Bs%20vezes%20o%20limite%20superior%20da%20normalidade)%20das%20transaminases%20s%26%23xE9%3Bricas%20em%20poucos%20pacientes%20adultos%20que%20receberam%20sinvastatina.%20Quando%20o%20medicamento%20foi%20interrompido%20ou%20descontinuado%2C%20os%20n%26%23xED%3Bveis%20de%20transaminases%20ca%26%23xED%3Bram%20lentamente%20para%20os%20n%26%23xED%3Bveis%20anteriores%20ao%20tratamento.%20Os%20aumentos%20n%26%23xE3%3Bo%20foram%20associados%20%26%23xE0%3B%20icter%26%23xED%3Bcia%20ou%20a%20outros%20sintomas%20ou%20sinais%20cl%26%23xED%3Bnicos.%20N%26%23xE3%3Bo%20houve%20evid%26%23xEA%3Bncia%20de%20hipersensibilidade.%20Alguns%20desses%20pacientes%20apresentavam%20testes%20de%20fun%26%23xE7%3B%26%23xE3%3Bo%20hep%26%23xE1%3Btica%20alterados%20antes%20do%20tratamento%20com%20a%20sinvastatina%20e%2Fou%20consumiam%20quantidades%20consider%26%23xE1%3Bveis%20de%20%26%23xE1%3Blcool.%3Cbr%3E%0ANo%20Estudo%20Escandinavo%20de%20Sobrevida%20com%20Sinvastatina%20(4S)%20(veja%20o%20item%202.%20RESULTADOS%20DE%20EFIC%26%23xC1%3BCIA)%2C%20o%20n%26%23xFA%3Bmero%20de%20pacientes%20com%20transaminases%20elevadas%20(acima%20de%20tr%26%23xEA%3Bs%20vezes%20o%20limite%20superior%20da%20normalidade)%20mais%20de%20uma%20vez%20durante%20o%20estudo%2C%20n%26%23xE3%3Bo%20foi%20significativamente%20diferente%20entre%20os%20grupos%20sinvastatina%20e%20placebo%20(14%20%5B0%2C7%25%5D%20vs.%2012%20%5B0%2C6%25%5D).%20A%20frequ%26%23xEA%3Bncia%20dos%20aumentos%20isolados%20de%20TGP%20(ALT)%20para%20tr%26%23xEA%3Bs%20vezes%20o%20limite%20superior%20da%20normalidade%20foi%20significativamente%20mais%20alta%20no%20grupo%20da%20sinvastatina%20no%20primeiro%20ano%20do%20estudo%20(20%20vs.%208%2C%20p%20%3D%200%2C023)%2C%20mas%20n%26%23xE3%3Bo%20posteriormente.%20O%20aumento%20de%20transaminases%20resultou%20em%20descontinua%26%23xE7%3B%26%23xE3%3Bo%20do%20tratamento%20para%20oito%20pacientes%20do%20grupo%20da%20sinvastatina%20(n%20%3D%202.221)%20e%20para%20cinco%20do%20grupo%20placebo%20(n%20%3D%202.223).%20Dos%201.986%20pacientes%20no%204S%20tratados%20com%20a%20sinvastatina%20cujos%20testes%20de%20fun%26%23xE7%3B%26%23xE3%3Bo%20hep%26%23xE1%3Btica%20eram%20normais%20no%20per%26%23xED%3Bodo%20basal%2C%20somente%20oito%20(0%2C4%25)%20apresentaram%20aumentos%20consecutivos%20%26gt%3B%203%20vezes%20o%20limite%20superior%20da%20normalidade%20de%20enzimas%20hep%26%23xE1%3Bticas%20e%2Fou%20foram%20descontinuados%20por%20aumento%20de%20transaminases%20durante%20os%205%2C4%20anos%20(acompanhamento%20m%26%23xE9%3Bdio)%20do%20estudo.%20A%20dose%20inicial%20de%20sinvastatina%20para%20todos%20os%20pacientes%20do%20estudo%20foi%20de%2020%20mg%3B%2037%25%20foram%20titulados%20para%2040%20mg.%3Cbr%3E%0AEm%20dois%20estudos%20cl%26%23xED%3Bnicos%20controlados%2C%20que%20envolveram%201.105%20pacientes%2C%20a%20incid%26%23xEA%3Bncia%20%26%23x2013%3B%20aos%206%20meses%20%26%23x2013%3B%20de%20aumentos%20persistentes%20de%20transaminases%20considerados%20relacionados%20ao%20medicamento%20foi%20de%200%2C7%25%20e%201%2C8%25%2C%20com%20as%20doses%20de%2040%20mg%20e%2080%20mg%2C%20respectivamente.%3Cbr%3E%0ANo%20estudo%20HPS%20(veja%20o%20item%202.%20RESULTADOS%20DE%20EFIC%26%23xC1%3BCIA)%2C%20no%20qual%2020.536%20pacientes%20foram%20distribu%26%23xED%3Bdos%20de%20modo%20rand%26%23xF4%3Bmico%20para%20receber%2040%20mg%2Fdia%20de%20sinvastatina%20ou%20placebo%2C%20a%20incid%26%23xEA%3Bncia%20de%20transaminases%20elevadas%20(%26gt%3B%203%20vezes%20o%20limite%20superior%20da%20normalidade%2C%20confirmada%20em%20exames%20repetidos)%20foi%20de%200%2C21%25%20(n%20%3D%2021)%20para%20os%20pacientes%20que%20receberam%20sinvastatina%20e%20de%200%2C09%25%20(n%20%3D%209)%20no%20grupo%20placebo.%3Cbr%3E%0ARecomenda-se%20solicitar%20testes%20de%20fun%26%23xE7%3B%26%23xE3%3Bo%20hep%26%23xE1%3Btica%20antes%20de%20iniciar%20o%20tratamento%20e%20posteriormente%2C%20quando%20clinicamente%20indicado.%20Pacientes%20titulados%20para%20doses%20de%2080%20mg%20devem%20realizar%20mais%20um%20teste%20antes%20da%20titula%26%23xE7%3B%26%23xE3%3Bo%2C%203%20meses%20depois%20da%20titula%26%23xE7%3B%26%23xE3%3Bo%20para%20a%20dose%20de%2080%20mg%20e%2C%20a%20seguir%2C%20periodicamente%20(por%20exemplo%2C%20de%206%20em%206%20meses)%20durante%20o%20primeiro%20ano%20de%20Sinvastatina%2020%20mg%20e%2040%20mg%20tratamento.%20Deve-se%20dar%20especial%20aten%26%23xE7%3B%26%23xE3%3Bo%20aos%20pacientes%20que%20apresentarem%20aumento%20de%20transaminases%20s%26%23xE9%3Bricas%20e%2C%20nesses%20pacientes%2C%20as%20avalia%26%23xE7%3B%26%23xF5%3Bes%20laboratoriais%20devem%20ser%20imediatamente%20repetidas%20e%2C%20a%20seguir%2C%20realizadas%20com%20maior%20frequ%26%23xEA%3Bncia.%20Deve-se%20descontinuar%20o%20medicamento%20se%20os%20n%26%23xED%3Bveis%20de%20transaminases%20mostrarem%20evid%26%23xEA%3Bncia%20de%20progress%26%23xE3%3Bo%2C%20particularmente%20se%20aumentarem%20acima%20de%20tr%26%23xEA%3Bs%20vezes%20o%20limite%20superior%20da%20normalidade%20e%20persistirem%20nesse%20patamar.%20Note%20que%20a%20ALT%20pode%20emanar%20do%20m%26%23xFA%3Bsculo%2C%20portanto%2C%20a%20eleva%26%23xE7%3B%26%23xE3%3Bo%20da%20ALT%20com%20CK%20pode%20indicar%20miopatia%20(veja%20o%20item%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise).%3Cbr%3E%0AExistem%20raros%20relatos%20p%26%23xF3%3Bs-comercializa%26%23xE7%3B%26%23xE3%3Bo%20de%20insufici%26%23xEA%3Bncia%20hep%26%23xE1%3Btica%20fatal%20e%20n%26%23xE3%3Bo%20fatal%20em%20pacientes%20que%20tomam%20estatinas%2C%20incluindo%20sinvastatina.%20Se%20ocorrer%20les%26%23xE3%3Bo%20hep%26%23xE1%3Btica%20grave%20com%20sintomas%20cl%26%23xED%3Bnicos%20e%2Fou%20hiperbilirrubinemia%20ou%20icter%26%23xED%3Bcia%20durante%20o%20tratamento%20com%20sinvastatina%2C%20deve-se%20interromper%20imediatamente%20o%20tratamento.%20Se%20uma%20etiologia%20alternativa%20n%26%23xE3%3Bo%20for%20encontrada%2C%20n%26%23xE3%3Bo%20reinicie%20o%20tratamento%20com%20sinvastatina.%3Cbr%3E%0ADeve-se%20utilizar%20o%20medicamento%20com%20cuidado%20em%20pacientes%20que%20consomem%20quantidades%20substanciais%20de%20%26%23xE1%3Blcool%20e%2Fou%20apresentem%20hist%26%23xF3%3Brico%20de%20doen%26%23xE7%3Ba%20hep%26%23xE1%3Btica.%20Hepatopatias%20ativas%20ou%20aumentos%20inexplicados%20de%20transaminases%20constituem%20contraindica%26%23xE7%3B%26%23xF5%3Bes%20para%20o%20uso%20da%20sinvastatina.%3Cbr%3E%0AA%20exemplo%20do%20que%20ocorre%20com%20outros%20agentes%20hipolipemiantes%2C%20foram%20relatados%20aumentos%20moderados%20(abaixo%20de%20tr%26%23xEA%3Bs%20vezes%20o%20limite%20superior%20da%20normalidade)%20das%20transaminases%20s%26%23xE9%3Bricas%20ap%26%23xF3%3Bs%20o%20tratamento%20com%20a%20sinvastatina.%20Essas%20altera%26%23xE7%3B%26%23xF5%3Bes%20ocorreram%20logo%20ap%26%23xF3%3Bs%20o%20in%26%23xED%3Bcio%20do%20tratamento%2C%20foram%20geralmente%20transit%26%23xF3%3Brias%2C%20assintom%26%23xE1%3Bticas%20e%20n%26%23xE3%3Bo%20exigiram%20interrup%26%23xE7%3B%26%23xE3%3Bo%20do%20tratamento.%3C%2Fp%3E%0A%3Cp%3EAvalia%26%23xE7%3B%26%23xF5%3Bes%20oftalmol%26%23xF3%3Bgicas%3A%20%26%23xE9%3B%20esperado%20que%2C%20com%20o%20passar%20do%20tempo%2C%20ocorra%20aumento%20da%20preval%26%23xEA%3Bncia%20de%20opacidade%20do%20cristalino%20como%20resultado%20do%20envelhecimento%2C%20mesmo%20na%20aus%26%23xEA%3Bncia%20de%20qualquer%20tratamento%20medicamentoso.%20Dados%20atuais%20de%20estudos%20cl%26%23xED%3Bnicos%20a%20longo%20prazo%20n%26%23xE3%3Bo%20indicam%20efeito%20adverso%20da%20sinvastatina%20no%20cristalino%20humano.%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Cp%3EGravidez%20e%20Lacta%26%23xE7%3B%26%23xE3%3Bo%3A%20categoria%20de%20Risco%20X.%20Este%20medicamento%20causa%20malforma%26%23xE7%3B%26%23xE3%3Bo%20ao%20beb%26%23xEA%3B%20durante%20a%20gravidez.%20A%20seguran%26%23xE7%3Ba%20em%20mulheres%20gr%26%23xE1%3Bvidas%20n%26%23xE3%3Bo%20foi%20estabelecida.%20N%26%23xE3%3Bo%20foram%20conduzidos%20estudos%20cl%26%23xED%3Bnicos%20controlados%20em%20mulheres%20gr%26%23xE1%3Bvidas.%20H%26%23xE1%3B%20raros%20relatos%20de%20anomalias%20cong%26%23xEA%3Bnitas%20em%20rec%26%23xE9%3Bm-nascidos%20de%20m%26%23xE3%3Bes%20que%20receberam%20inibidores%20de%20HMG-CoAredutase%20durante%20a%20gravidez.%20Entretanto%2C%20em%20uma%20an%26%23xE1%3Blise%20de%20aproximadamente%20200%20gesta%26%23xE7%3B%26%23xF5%3Bes%20acompanhadas%20prospectivamente%20de%20mulheres%20expostas%20a%20sinvastatina%20ou%20a%20outro%20inibidor%20da%20HMG-CoA%20redutase%20estruturalmente%20relacionado%20no%20primeiro%20trimestre%20de%20gravidez%2C%20a%20incid%26%23xEA%3Bncia%20de%20anomalias%20cong%26%23xEA%3Bnitas%20foi%20compar%26%23xE1%3Bvel%20%26%23xE0%3B%20observada%20na%20popula%26%23xE7%3B%26%23xE3%3Bo%20geral.%20Esse%20n%26%23xFA%3Bmero%20de%20gesta%26%23xE7%3B%26%23xF5%3Bes%20foi%20estatisticamente%20suficiente%20para%20excluir%20um%20aumento%20de%20anomalias%20cong%26%23xEA%3Bnitas%202%2C5%20vezes%20ou%20maior%20do%20que%20a%20incid%26%23xEA%3Bncia%20conhecida.%3Cbr%3E%0AEmbora%20n%26%23xE3%3Bo%20haja%20evid%26%23xEA%3Bncia%20de%20que%20a%20incid%26%23xEA%3Bncia%20de%20anomalias%20cong%26%23xEA%3Bnitas%20nos%20descendentes%20de%20pacientes%20expostos%20a%20sinvastatina%20ou%20a%20outro%20inibidor%20da%20HMG-CoA%20redutase%20estruturalmente%20relacionado%20seja%20diferente%20da%20observada%20na%20popula%26%23xE7%3B%26%23xE3%3Bo%20geral%2C%20o%20tratamento%20da%20m%26%23xE3%3Be%20com%20sinvastatina%20pode%20reduzir%20os%20n%26%23xED%3Bveis%20fetais%20de%20mevalonato%2C%20um%20precursor%20da%20bioss%26%23xED%3Bntese%20do%20colesterol.%20A%20aterosclerose%20%26%23xE9%3B%20um%20processo%20cr%26%23xF4%3Bnico%20e%20a%20descontinua%26%23xE7%3B%26%23xE3%3Bo%20dos%20agentes%20hipolipemiantes%20durante%20a%20gravidez%20deve%20ter%20pequeno%20impacto%20sobre%20o%20risco%20a%20longo%20prazo%20associado%20%26%23xE0%3B%20hipercolesterolemia%20prim%26%23xE1%3Bria.%20Por%20essas%20raz%26%23xF5%3Bes%2C%20a%20sinvastatina%20n%26%23xE3%3Bo%20deve%20ser%20usada%20por%20mulheres%20gr%26%23xE1%3Bvidas%2C%20que%20estejam%20tentando%20engravidar%20ou%20que%20possam%20estar%20gr%26%23xE1%3Bvidas.%20O%20tratamento%20com%20sinvastatina%20deve%20ser%20interrompido%20durante%20toda%20a%20gesta%26%23xE7%3B%26%23xE3%3Bo%20ou%20at%26%23xE9%3B%20que%20se%20comprove%20que%20a%20paciente%20n%26%23xE3%3Bo%20est%26%23xE1%3B%20gr%26%23xE1%3Bvida%20(veja%20o%20item%204.%20CONTRAINDICA%26%23xC7%3B%26%23xD5%3BES).%3Cbr%3E%0AN%26%23xE3%3Bo%20se%20sabe%20se%20a%20sinvastatina%20ou%20os%20seus%20metab%26%23xF3%3Blitos%20s%26%23xE3%3Bo%20excretados%20no%20leite%20materno.%20Uma%20vez%20que%20muitos%20f%26%23xE1%3Brmacos%20s%26%23xE3%3Bo%20excretados%20no%20leite%20materno%20e%20podem%20causar%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20graves%2C%20mulheres%20que%20estejam%20recebendo%20sinvastatina%20n%26%23xE3%3Bo%20devem%20amamentar%20(veja%20o%20item%204.%20CONTRAINDICA%26%23xC7%3B%26%23xD5%3BES).%3Cbr%3E%0AIdosos%3A%20a%20efic%26%23xE1%3Bcia%20da%20sinvastatina%20avaliada%20pela%20redu%26%23xE7%3B%26%23xE3%3Bo%20do%20colesterol%20total%20e%20do%20LDL-colesterol%2C%20em%20pacientes%20com%20mais%20de%2065%20anos%20de%20idade%20em%20estudos%20cl%26%23xED%3Bnicos%20controlados%2C%20foi%20semelhante%20%26%23xE0%3B%20observada%20na%20popula%26%23xE7%3B%26%23xE3%3Bo%20geral%20e%20n%26%23xE3%3Bo%20houve%20aumento%20evidente%20na%20frequ%26%23xEA%3Bncia%20global%20de%20achados%20adversos%20cl%26%23xED%3Bnicos%20ou%20laboratoriais.%3Cbr%3E%0ANo%20entanto%2C%20em%20um%20estudo%20cl%26%23xED%3Bnico%20de%20pacientes%20tratados%20com%20sinvastatina%2080%20mg%2Fdia%2C%20pacientes%20%26%23x2265%3B%2065%20anos%20de%20idade%20tiveram%20um%20risco%20aumentado%20de%20miopatia%20em%20compara%26%23xE7%3B%26%23xE3%3Bo%20com%20pacientes%20%26lt%3B%2065%20anos%20de%20idade.%3Cbr%3E%0ACrian%26%23xE7%3Bas%3A%20a%20seguran%26%23xE7%3Ba%20e%20a%20efic%26%23xE1%3Bcia%20em%20crian%26%23xE7%3Bas%20n%26%23xE3%3Bo%20foram%20estabelecidas.%20At%26%23xE9%3B%20o%20momento%2C%20sinvastatina%20n%26%23xE3%3Bo%20%26%23xE9%3B%20recomendada%20para%20uso%20pedi%26%23xE1%3Btrico.%3C%2Fp%3E%0A%3Cp%3E6.%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS%3C%2Fp%3E%0A%3Cp%3EM%26%23xFA%3Bltiplos%20mecanismos%20podem%20contribuir%20para%20potenciais%20intera%26%23xE7%3B%26%23xF5%3Bes%20com%20os%20inibidores%20da%20HMG-CoA%20redutase.%20F%26%23xE1%3Brmacos%20ou%20fitoter%26%23xE1%3Bpicos%20que%20inibem%20certas%20vias%20enzim%26%23xE1%3Bticas%20(por%20exemplo%20CYP3A4)%20e%2Fou%20transportadoras%20(por%20exemplo%20ATP1B)%20que%20podem%20aumentar%20as%20concentra%26%23xE7%3B%26%23xF5%3Bes%20plasm%26%23xE1%3Bticas%20de%20sinvastatina%20e%20sinvastatina%20%26%23xE1%3Bcida%20e%20podem%20induzir%20a%20um%20risco%20aumentado%20de%20miopatia%2Frabdomiolise.%3C%2Fp%3E%0A%3Cp%3EConsulte%20as%20informa%26%23xE7%3B%26%23xF5%3Bes%20prescritas%20para%20todos%20os%20f%26%23xE1%3Brmacos%20utilizados%20concomitantemente%20para%20obter%20mais%20informa%26%23xE7%3B%26%23xF5%3Bes%20sobre%20suas%20potenciais%20intera%26%23xE7%3B%26%23xF5%3Bes%20com%20sinvastatina%20e%2Fou%20potenciais%20altera%26%23xE7%3B%26%23xF5%3Bes%20enzim%26%23xE1%3Bticas%20ou%20de%20transportadores%20e%20poss%26%23xED%3Bveis%20ajustes%20da%20dose%20e%20dos%20regimes.%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Cp%3EMedicamentos%20contraindicados%3Cbr%3E%0AO%20uso%20concomitante%20dos%20seguintes%20medicamentos%20%26%23xE9%3B%20contraindicado%3A%3Cbr%3E%0A-Inibidores%20potentes%20de%20CYP3A4%3A%20a%20sinvastatina%20%26%23xE9%3B%20metabolizada%20pela%20isoenzima%20do%20citocromo%203A4%2C%20mas%20n%26%23xE3%3Bo%20apresenta%20atividade%20inibit%26%23xF3%3Bria%20do%20CYP3A4%2C%20portanto%20n%26%23xE3%3Bo%20se%20espera%20que%20afete%20as%20concentra%26%23xE7%3B%26%23xF5%3Bes%20plasm%26%23xE1%3Bticas%20de%20outros%20f%26%23xE1%3Brmacos%20metabolizados%20pela%20CYP3A4.%20Os%20inibidores%20potentes%20da%20CYP3A4%20aumentam%20o%20risco%20de%20miopatia%20por%20reduzirem%20a%20elimina%26%23xE7%3B%26%23xE3%3Bo%20da%20sinvastatina.%20O%20uso%20concomitante%20de%20medicamentos%20conhecidos%20por%20apresentarem%20um%20potente%20efeito%20inibit%26%23xF3%3Brio%20sobre%20a%20CYP3A4%20(por%20exemplo%2C%20itraconazol%2C%20cetoconazol%2C%20posaconazol%2C%20voriconazol%2C%20eritromicina%2C%20claritromicina%2C%20telitromicina%2C%20inibidores%20da%20protease%20do%20HIV%2C%20boceprevir%2C%20telaprevir%2C%20nefazodona%20e%20medicamentos%20contendo%20cobicistate)%20%26%23xE9%3B%20contraindicado%20(veja%20os%20itens%204.%20CONTRAINDICA%26%23xC7%3B%26%23xD5%3BES%3B%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise%3B%20CARACTER%26%23xCD%3BSTICAS%20FARMACOL%26%23xD3%3BGICAS%2C%20Farmacocin%26%23xE9%3Btica).%3Cbr%3E%0A-Genfibrozila%2C%20ciclosporina%20ou%20danazol%3A%20(veja%20os%20itens%204.CONTRAINDICA%26%23xC7%3B%26%23xD5%3BES%3B%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise%3B%203.%20CARACTER%26%23xCD%3BSTICAS%20FARMACOL%26%23xD3%3BGICAS%2C%20Farmacocin%26%23xE9%3Btica).%3C%2Fp%3E%0A%3Cp%3EOutras%20intera%26%23xE7%3B%26%23xF5%3Bes%20medicamentosas%3Cbr%3E%0A-Outros%20fibratos%3A%20o%20risco%20de%20miopatia%20%26%23xE9%3B%20aumentado%20pela%20genfibrozila%20(veja%20o%20item%204.%20CONTRAINDICA%26%23xC7%3B%26%23xD5%3BES)%20e%20outros%20fibratos%20(com%20exce%26%23xE7%3B%26%23xE3%3Bo%20do%20fenofibrato)%3B%20estes%20medicamentos%20hipolipemiantes%20podem%20causar%20miopatia%20quando%20administrados%20isoladamente.%20Quando%20a%20sinvastatina%20e%20o%20fenofibrato%20s%26%23xE3%3Bo%20administrados%20concomitantemente%2C%20n%26%23xE3%3Bo%20h%26%23xE1%3B%20nenhuma%20evid%26%23xEA%3Bncia%20de%20que%20o%20risco%20de%20miopatia%20supere%20a%20soma%20dos%20riscos%20individuais%20de%20cada%20agente%20(veja%20os%20itens%204.%20CONTRAINDICA%26%23xC7%3B%26%23xD5%3BES%20e%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise).%3Cbr%3E%0A-%26%23xC1%3Bcido%20fus%26%23xED%3Bdico%3A%20o%20risco%20de%20miopatia%2Frabdomi%26%23xF3%3Blise%20pode%20aumentar%20com%20a%20administra%26%23xE7%3B%26%23xE3%3Bo%20concomitante%20de%20%26%23xE1%3Bcido%20fus%26%23xED%3Bdico%20(veja%20os%20itens%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise%20e%203.%20CARACTER%26%23xCD%3BSTICAS%20FARMACOL%26%23xD3%3BGICAS%2C%20Farmacocin%26%23xE9%3Btica).%3Cbr%3E%0A-Amiodarona%3A%20o%20risco%20de%20miopatia%2Frabdomi%26%23xF3%3Blise%20%26%23xE9%3B%20aumentado%20pela%20administra%26%23xE7%3B%26%23xE3%3Bo%20concomitante%20de%20amiodarona%20com%20sinvastatina%20(veja%20os%20itens%208.%20POSOLOGIA%20E%20MODO%20DE%20USAR%20e%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise).%3Cbr%3E%0A-Bloqueadores%20do%20canal%20de%20c%26%23xE1%3Blcio%3A%20o%20risco%20de%20miopatia%2Frabdomi%26%23xF3%3Blise%20%26%23xE9%3B%20aumentado%20pela%20administra%26%23xE7%3B%26%23xE3%3Bo%20concomitante%20de%20verapamil%2C%20diltiazem%20ou%20anlodipino%20(veja%20os%20itens%208.%20POSOLOGIA%20E%20MODO%20DE%20USAR%3B%20e%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise).%3Cbr%3E%0A-Lomitapida%3A%20o%20risco%20de%20miopatia%2Frabdomi%26%23xF3%3Blise%20pode%20ser%20aumentado%20pela%20administra%26%23xE7%3B%26%23xE3%3Bo%20concomitante%20com%20lomitapida%20(veja%20os%20itens%208.%20POSOLOGIA%20E%20MODO%20DE%20USAR%20e%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise).%3Cbr%3E%0A-Inibidores%20moderados%20da%20CYP3A4%3A%20os%20pacientes%20que%20tomam%20outros%20medicamentos%20conhecidos%20por%20apresentarem%20efeito%20inibit%26%23xF3%3Brio%20moderado%20sobre%20a%20CYP3A4%20concomitantemente%20com%20a%20sinvastatina%2C%20particularmente%20com%20doses%20mais%20altas%20de%20sinvastatina%2C%20podem%20ter%20um%20maior%20risco%20de%20miopatia%20(veja%20o%20item%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise).%3C%2Fp%3E%0A%3Cp%3E-Inibidores%20da%20prote%26%23xED%3Bna%20transportadora%20OATP1B1%3A%20a%20sinvastatina%20%26%23xE1%3Bcida%20%26%23xE9%3B%20um%20substrato%20da%20prote%26%23xED%3Bna%20transportadora%20OATP1B1.%20A%20administra%26%23xE7%3B%26%23xE3%3Bo%20concomitante%20de%20medicamentos%20inibidores%20da%20prote%26%23xED%3Bna%20transportadora%20OATP1B1%20pode%20levar%20ao%20aumento%20da%20concentra%26%23xE7%3B%26%23xE3%3Bo%20plasm%26%23xE1%3Btica%20de%20sinvastatina%20%26%23xE1%3Bcida%20e%20ao%20aumento%20do%20risco%20de%20miopatia%20(veja%20os%20itens%204.%20CONTRAINDICA%26%23xC7%3B%26%23xD5%3BES%20e%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise).%3C%2Fp%3E%0A%3Cp%3E-Inibidores%20da%20prote%26%23xED%3Bna%20resistente%20ao%20c%26%23xE2%3Bncer%20de%20mama%20(BCPR)%3A%20a%20sinvastatina%20%26%23xE9%3B%20um%20substrato%20do%20transportador%20de%20efluxo%20da%20BCPR.%20A%20administra%26%23xE7%3B%26%23xE3%3Bo%20concomitante%20de%20medicamentos%20inibidores%20da%20BCPR%20(por%20exemplo%2C%20elbasvir%20e%20grazoprevir)%20pode%20levar%20a%20um%20aumento%20das%20concentra%26%23xE7%3B%26%23xF5%3Bes%20plasm%26%23xE1%3Bticas%20da%20sinvastatina%20e%20a%20um%20risco%20aumentado%20de%20miopatia.%20Quando%20a%20sinvastatina%20e%20um%20inibidor%20da%20BCPR%20forem%20coadministrados%2C%20um%20ajuste%20da%20dose%20de%20sinvastatina%20poder%26%23xE1%3B%20ser%20necess%26%23xE1%3Brio%20(veja%20os%20itens%208.%20POSOLOGIA%20E%20MODO%20DE%20USAR%3B%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise%20e%203.%20CARACTER%26%23xCD%3BSTICAS%20FARMACOL%26%23xD3%3BGICAS%2C%20Farmacocin%26%23xE9%3Btica).%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Cp%3E-%26%23xC1%3Bcido%20nicot%26%23xED%3Bnico%20(Niacina)%20(%26%23x2265%3B%201%20g%2Fdia)%3A%20casos%20de%20miopatia%2Frabdomi%26%23xF3%3Blise%20foram%20observados%20com%20a%20sinvastatina%20coadministrada%20com%20doses%20hipolipemiantes%20(%26%23x2265%3B1%20g%2Fdia)%20de%20%26%23xE1%3Bcido%20nicot%26%23xED%3Bnico%20(veja%20o%20item%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise).%3C%2Fp%3E%0A%3Cp%3E-Colchicina%3A%20houve%20relatos%20de%20miopatia%20e%20rabdomi%26%23xF3%3Blise%20com%20a%20administra%26%23xE7%3B%26%23xE3%3Bo%20concomitante%20de%20colchicina%20e%20sinvastatina%20em%20pacientes%20com%20insufici%26%23xEA%3Bncia%20renal.%20Aconselha-se%20o%20monitoramento%20de%20pacientes%20que%20tomam%20esta%20combina%26%23xE7%3B%26%23xE3%3Bo.%3C%2Fp%3E%0A%3Cp%3EOutras%20intera%26%23xE7%3B%26%23xF5%3Bes%3Cbr%3E%0AO%20suco%20de%20grapefruit%20cont%26%23xE9%3Bm%20um%20ou%20mais%20componentes%20que%20inibem%20o%20CYP3A4%20e%20podem%20aumentar%20os%20n%26%23xED%3Bveis%20plasm%26%23xE1%3Bticos%20de%20medicamentos%20metabolizados%20por%20este%20sistema%20enzim%26%23xE1%3Btico.%20O%20efeito%20do%20consumo%20t%26%23xED%3Bpico%20(um%20copo%20de%20250%20mL%20diariamente)%20%26%23xE9%3B%20m%26%23xED%3Bnimo%20(aumento%20de%2013%25%20nos%20n%26%23xED%3Bveis%20plasm%26%23xE1%3Bticos%20da%20atividade%20inibit%26%23xF3%3Bria%20da%20HMG-CoA%20redutase%2C%20conforme%20medido%20pela%20%26%23xE1%3Brea%20sob%20a%20curva%20de%20concentra%26%23xE7%3B%26%23xE3%3Bo-tempo)%20e%20sem%20import%26%23xE2%3Bncia%20cl%26%23xED%3Bnica.%20Entretanto%2C%20uma%20vez%20que%20quantidades%20muito%20grandes%20aumentam%20significativamente%20os%20n%26%23xED%3Bveis%20plasm%26%23xE1%3Bticos%20da%20atividade%20inibit%26%23xF3%3Bria%20da%20HMG-CoA%20redutase%20o%20suco%20de%20grapefruit%20deve%20ser%20evitado%20(veja%20o%20item%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise).%3C%2Fp%3E%0A%3Cp%3E-Derivados%20cumar%26%23xED%3Bnicos%3A%20em%20dois%20estudos%20cl%26%23xED%3Bnicos%2C%20um%20que%20envolveu%20volunt%26%23xE1%3Brios%20normais%20e%20outro%2C%20pacientes%20hipercolesterol%26%23xEA%3Bmicos%2C%20a%20sinvastatina%2C%20na%20dose%2020-40%20mg%2Fdia%2C%20potencializou%20discretamente%20o%20efeito%20de%20anticoagulantes%20cumar%26%23xED%3Bnicos%3A%20o%20tempo%20de%20protrombina%2C%20expresso%20como%20INR%20(Raz%26%23xE3%3Bo%20Internacional%20Normalizada)%2C%20aumentou%20em%20rela%26%23xE7%3B%26%23xE3%3Bo%20aos%20valores%20do%20per%26%23xED%3Bodo%20basal%20de%201%2C7%20para%201%2C8%20e%20de%202%2C6%20para%203%2C4%20nos%20estudos%20com%20volunt%26%23xE1%3Brios%20e%20pacientes%2C%20respectivamente.%20O%20tempo%20de%20protrombina%20dos%20pacientes%20que%20estejam%20tomando%20anticoagulantes%20cumar%26%23xED%3Bnicos%20deve%20ser%20determinado%20antes%20de%20se%20iniciar%20o%20tratamento%20com%20a%20sinvastatina%20e%20sempre%20que%20necess%26%23xE1%3Brio%20durante%20a%20fase%20inicial%20do%20tratamento%2C%20para%20assegurar%20que%20n%26%23xE3%3Bo%20ocorra%20nenhuma%20altera%26%23xE7%3B%26%23xE3%3Bo%20significativa.%20Uma%20vez%20estabilizado%2C%20o%20tempo%20de%20protrombina%20poder%26%23xE1%3B%20ser%20monitorizado%20com%20a%20periodicidade%20usualmente%20recomendada%20para%20pacientes%20em%20tratamento%20com%20anticoagulantes%20cumar%26%23xED%3Bnicos.%20O%20mesmo%20procedimento%20deve%20ser%20repetido%20em%20caso%20de%20modifica%26%23xE7%3B%26%23xE3%3Bo%20da%20dose%20ou%20de%20descontinua%26%23xE7%3B%26%23xE3%3Bo%20da%20sinvastatina.%20O%20tratamento%20com%20a%20sinvastatina%20n%26%23xE3%3Bo%20foi%20associado%20a%20sangramento%20ou%20altera%26%23xE7%3B%26%23xF5%3Bes%20do%20tempo%20de%20protrombina%20em%20pacientes%20que%20n%26%23xE3%3Bo%20estavam%20utilizando%20anticoagulantes.%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Cp%3E7.%20CUIDADOS%20DE%20ARMAZENAMENTO%20DO%20MEDICAMENTO%3Cbr%3E%0AConservar%20em%20temperatura%20ambiente%20(entre%2015%20e%2030%26%23xB0%3BC).%20Proteger%20da%20luz%20e%20umidade.%3Cbr%3E%0APrazo%20de%20validade%3A%2024%20meses%20ap%26%23xF3%3Bs%20a%20data%20de%20fabrica%26%23xE7%3B%26%23xE3%3Bo%20impressa%20na%20embalagem.%3C%2Fp%3E%0A%3Cp%3EN%26%23xFA%3Bmero%20de%20lote%20e%20datas%20de%20fabrica%26%23xE7%3B%26%23xE3%3Bo%20e%20validade%3A%20vide%20embalagem.%3Cbr%3E%0AN%26%23xE3%3Bo%20use%20medicamento%20com%20o%20prazo%20de%20validade%20vencido.%20Guarde-o%20em%20sua%20embalagem%20original.%3C%2Fp%3E%0A%3Cp%3EApar%26%23xEA%3Bncia%3A%3C%2Fp%3E%0A%3Cp%3EPara%2020%20mg%20comprimidos%20revestidos%20com%20formato%20oval%20de%20colora%26%23xE7%3B%26%23xE3%3Bo%20p%26%23xEA%3Bssego%2C%20gravados%20com%20%26%23x201C%3BSST%26%23x201D%3B%20em%20uma%20das%20faces%20e%20%26%23x201C%3B20%26%23x201D%3B%20na%20outra%20face.%3Cbr%3E%0APara%2040%20mg%20comprimidos%20revestidos%20com%20formato%20oval%2C%20de%20colora%26%23xE7%3B%26%23xE3%3Bo%20rosa%2C%20gravados%20com%20%26%23x201C%3BSST%26%23x201D%3B%20em%20uma%20das%20faces%20e%20%26%23x201C%3B40%26%23x201D%3B%20na%20outra%20face.%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Cp%3EAntes%20de%20usar%2C%20observe%20o%20aspecto%20do%20medicamento.%3Cbr%3E%0ATodo%20medicamento%20deve%20ser%20mantido%20fora%20do%20alcance%20das%20crian%26%23xE7%3Bas.%3C%2Fp%3E%0A%3Cp%3E8.%20POSOLOGIA%20E%20MODO%20DE%20USAR%3C%2Fp%3E%0A%3Cp%3EA%20varia%26%23xE7%3B%26%23xE3%3Bo%20posol%26%23xF3%3Bgica%20de%20sinvastatina%20%26%23xE9%3B%20de%205-80%20mg%2Fdia%2C%20administrados%20em%20dose%20%26%23xFA%3Bnica%2C%20%26%23xE0%3B%20noite.%20Ajustes%20posol%26%23xF3%3Bgicos%2C%20se%20necess%26%23xE1%3Brios%2C%20devem%20ser%20feitos%20a%20intervalos%20n%26%23xE3%3Bo%20inferiores%20a%204%20semanas.%3Cbr%3E%0ADevido%20ao%20aumento%20do%20risco%20de%20miopatia%2C%20incluindo%20rabdomi%26%23xF3%3Blise%2C%20particularmente%20durante%20o%20primeiro%20ano%20de%20tratamento%2C%20o%20uso%20da%20dose%2080%20mg%20de%20sinvastatina%20deve%20ser%20restrito%20a%20pacientes%20que%20est%26%23xE3%3Bo%20tomando%20sinvastatina%2080%20mg%20de%20forma%20cont%26%23xED%3Bnua%20(por%2012%20meses%20ou%20mais)%2C%20sem%20evid%26%23xEA%3Bncias%20de%20toxicidade%20muscular%20(veja%20o%20item%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise).%20O%20uso%20de%20sinvastatina%2080%20mg%20n%26%23xE3%3Bo%20deve%20ser%20iniciado%20em%20pacientes%20novos%2C%20incluindo%20que%20j%26%23xE1%3B%20tomam%20doses%20menores%20do%20medicamento.%3Cbr%3E%0APacientes%20que%20est%26%23xE3%3Bo%20atualmente%20tolerando%20a%20dose%20de%2080%20mg%20de%20sinvastatina%20e%20que%20precisam%20iniciar%20um%20medicamento%20que%20%26%23xE9%3B%20contraindicado%20ou%20um%20medicamento%20com%20potencial%20de%20intera%26%23xE7%3B%26%23xE3%3Bo%20medicamentosa%20com%20a%20sinvastativa%20e%20que%20limita%20a%20sua%20dose%20m%26%23xE1%3Bxima%20permitida%2C%20devem%20ser%20mudados%20para%20uma%20estatina%20alternativa%20ou%20regime%20baseado%20em%20estatina%20com%20menor%20potencial%20de%20intera%26%23xE7%3B%26%23xE3%3Bo%20medicamentosa.%3Cbr%3E%0ADevido%20ao%20aumento%20do%20risco%20de%20miopatia%2C%20incluindo%20a%20rabdomi%26%23xF3%3Blise%2C%20associado%20com%20a%20dose%20de%2080%20mg%20de%20sinvastatina%2C%20pacientes%20incapazes%20de%20alcan%26%23xE7%3Bar%20as%20suas%20metas%20de%20colesterol%20LDL%2C%20utilizando%20a%20dose%20de%2040%20mg%20de%20sinvastatina%20n%26%23xE3%3Bo%20devem%20ser%20titulado%20para%20a%20dose%20de%2080%20mg%2C%20mas%20devem%20ser%20colocados%20em%20tratamento(s)%20alternativo(s)%20para%20redu%26%23xE7%3B%26%23xE3%3Bo%20de%20colesterol%20LDL%2C%20que%20proporcione%20redu%26%23xE7%3B%26%23xE3%3Bo%20mais%20intensiva%20do%20colesterol%20LDL.%3C%2Fp%3E%0A%3Cp%3EPacientes%20sob%20alto%20risco%20de%20doen%26%23xE7%3Ba%20coronariana%20ou%20com%20doen%26%23xE7%3Ba%20coronariana%3Cbr%3E%0AA%20dose%20inicial%20usual%20de%20sinvastatina%20%26%23xE9%3B%20de%2040%20mg%2Fdia%2C%20administrada%20em%20dose%20%26%23xFA%3Bnica%2C%20%26%23xE0%3B%20noite%2C%20para%20os%20pacientes%20sob%20alto%20risco%20de%20doen%26%23xE7%3Ba%20coronariana%20(com%20ou%20sem%20hiperlipidemia)%2C%20isto%20%26%23xE9%3B%2C%20pacientes%20com%20diabetes%2C%20hist%26%23xF3%3Brico%20de%20AVC%20ou%20de%20outra%20doen%26%23xE7%3Ba%20vascular%20cerebral%2C%20doen%26%23xE7%3Ba%20vascular%20perif%26%23xE9%3Brica%20ou%20doen%26%23xE7%3Ba%20coronariana.%20O%20tratamento%20pode%20ser%20iniciado%20simultaneamente%20%26%23xE0%3B%20dieta%20e%20aos%20exerc%26%23xED%3Bcios.%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Cp%3EPacientes%20com%20hiperlipidemia%20(n%26%23xE3%3Bo%20inclu%26%23xED%3Bdos%20nas%20categorias%20de%20risco%20j%26%23xE1%3B%20descritas)%3Cbr%3E%0AO%20paciente%20deve%20iniciar%20dieta-padr%26%23xE3%3Bo%20redutora%20de%20colesterol%20antes%20de%20receber%20sinvastatina%2C%20a%20qual%20dever%26%23xE1%3B%20ser%20mantida%20durante%20o%20tratamento%20com%20sinvastatina.%3Cbr%3E%0AA%20dose%20inicial%20usual%20%26%23xE9%3B%20de%2020%20mg%2Fdia%2C%20administrada%20em%20dose%20%26%23xFA%3Bnica%2C%20%26%23xE0%3B%20noite.%20Pacientes%20que%20necessitem%20de%20redu%26%23xE7%3B%26%23xE3%3Bo%20mais%20acentuada%20do%20LDL-C%20(mais%20de%2045%25)%20podem%20iniciar%20o%20tratamento%20com%20a%20dose%20de%2040%20mg%2Fdia%2C%20administrada%20em%20dose%20%26%23xFA%3Bnica%2C%3Cbr%3E%0A%26%23xE0%3Bnoite.%20Pacientes%20com%20hipercolesterolemia%20leve%20a%20moderada%20podem%20iniciar%20o%20tratamento%20com%20a%20dose%20de%2010%20mg%20de%20sinvastatina.%20Ajustes%20posol%26%23xF3%3Bgicos%2C%20se%20necess%26%23xE1%3Brios%2C%20devem%20ser%20feitos%20conforme%20especificado%20acima.%3C%2Fp%3E%0A%3Cp%3EPacientes%20com%20hipercolesterolemia%20familiar%20homozig%26%23xF3%3Btica%3Cbr%3E%0ACom%20base%20nos%20resultados%20de%20um%20estudo%20cl%26%23xED%3Bnico%20controlado%2C%20a%20posologia%20recomendada%20para%20pacientes%20com%20hipercolesterolemia%20familiar%20homozig%26%23xF3%3Btica%20%26%23xE9%3B%20de%2040%20mg%2Fdia%2C%20%26%23xE0%3B%20noite.%20Para%20esses%20pacientes%2C%20sinvastatina%20deve%20ser%20adjuvante%20de%20outros%20tratamentos%20hipolipemiantes%20(por%20exemplo%2C%20af%26%23xE9%3Brese%20de%20LDL)%20ou%20deve%20ser%20utilizado%20quando%20tais%20tratamentos%20n%26%23xE3%3Bo%20estiverem%20dispon%26%23xED%3Bveis%20(veja%20os%20itens%204.%20CONTRAINDICA%26%23xC7%3B%26%23xD5%3BES%20e%205.ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise%3B%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS).%3Cbr%3E%0ASe%20sinvastatina%20for%20utilizada%20concomitantemente%20com%20lomitapida%2C%20a%20dose%20di%26%23xE1%3Bria%20de%20sinvastatina%20n%26%23xE3%3Bo%20deve%20exceder%2040%20mg%20(veja%20os%20itens%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise%20e%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS).%3C%2Fp%3E%0A%3Cp%3ETerapia%20concomitante%3Cbr%3E%0AA%20sinvastatina%20%26%23xE9%3B%20eficaz%20isoladamente%20ou%20em%20combina%26%23xE7%3B%26%23xE3%3Bo%20com%20os%20sequestrantes%20de%20%26%23xE1%3Bcidos%20biliares.%3Cbr%3E%0ASe%20a%20sinvastatina%20for%20utilizada%20concomitantemente%20com%20fibratos%20diferentes%20de%20genfibrozila%20(veja%20o%20item%204.%20CONTRAINDICA%26%23xC7%3B%26%23xD5%3BES)%20ou%20fenofibrato%2C%20a%20dose%20de%20sinvastatina%20n%26%23xE3%3Bo%20deve%20ser%20maior%20do%20que%2010%20mg%2Fdia.%20Se%20a%20sinvastatina%20for%20utilizada%20concomitantemente%20com%20amiodarona%2C%20verapamil%2C%20diltiazem%20ou%20medicamentos%20que%20contenham%20elbasvir%20ou%20grazoprevir%20aa%20dose%20de%20sinvastatina%20n%26%23xE3%3Bo%20deve%20ser%20maior%20do%20que%2020%20mg%2Fdia.%20Em%20pacientes%20tomando%20anlodipino%20concomitantemente%20com%20sinvastatina%2C%20a%20dose%20de%20sinvastatina%20n%26%23xE3%3Bo%20deve%20exceder%2040%20mg%2Fdia%20(veja%20os%20itens%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise%3B%206.%20INTERA%26%23xC7%3B%26%23xD5%3BES%20MEDICAMENTOSAS).%3C%2Fp%3E%0A%3Cp%3EPosologia%20na%20insufici%26%23xEA%3Bncia%20renal%3Cbr%3E%0AUma%20vez%20que%20a%20excre%26%23xE7%3B%26%23xE3%3Bo%20renal%20de%20sinvastatina%20n%26%23xE3%3Bo%20%26%23xE9%3B%20significativa%2C%20n%26%23xE3%3Bo%20devem%20ser%20necess%26%23xE1%3Brias%20modifica%26%23xE7%3B%26%23xF5%3Bes%20posol%26%23xF3%3Bgicas%20para%20pacientes%20com%20insufici%26%23xEA%3Bncia%20renal%20moderada.%3Cbr%3E%0APara%20pacientes%20com%20insufici%26%23xEA%3Bncia%20renal%20grave%20(depura%26%23xE7%3B%26%23xE3%3Bo%20plasm%26%23xE1%3Btica%20de%20creatinina%20%26lt%3B%2030%20mL%2Fmin)%2C%20deve-se%20avaliar%20cuidadosamente%20o%20uso%20de%20doses%20maiores%20do%20que%2010%20mg%2Fdia%3B%20se%20forem%20extremamente%20necess%26%23xE1%3Brias%2C%20dever%26%23xE3%3Bo%20ser%20administradas%20com%20cautela%20(veja%20o%20item%203.%20CARACTER%26%23xCD%3BSTICAS%20FARMACOL%26%23xD3%3BGICAS).%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Cp%3EEste%20medicamento%20n%26%23xE3%3Bo%20deve%20ser%20partido%20ou%20mastigado.%3C%2Fp%3E%0A%3Cp%3E9.%20REA%26%23xC7%3B%26%23xD5%3BES%20ADVERSAS%3Cbr%3E%0AA%20sinvastatina%20%26%23xE9%3B%20geralmente%20bem%20tolerada%3B%20a%20maioria%20das%20experi%26%23xEA%3Bncias%20adversas%20foi%20de%20natureza%20leve%20e%20transit%26%23xF3%3Bria.%20Menos%20de%202%25%20dos%20pacientes%20foram%20descontinuados%20dos%20estudos%20cl%26%23xED%3Bnicos%20controlados%20por%20causa%20de%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20atribu%26%23xED%3Bveis%20a%20sinvastatina.%3Cbr%3E%0AAs%20frequ%26%23xEA%3Bncias%20dos%20seguintes%20eventos%20adversos%2C%20que%20foram%20relatados%20durante%20os%20estudos%20cl%26%23xED%3Bnicos%20e%2Fou%20uso%20p%26%23xF3%3Bs-%20comercializa%26%23xE7%3B%26%23xE3%3Bo%2C%20s%26%23xE3%3Bo%20categorizadas%20com%20base%20em%20uma%20avalia%26%23xE7%3B%26%23xE3%3Bo%20de%20suas%20taxas%20de%20incid%26%23xEA%3Bncia%20nos%20amplos%20estudos%20cl%26%23xED%3Bnicos%2C%20prolongados%2C%20controlados%20com%20placebo%20incluindo%20os%20estudos%20HPS%20e%204S%20com%2020.536%20e%204.444%20pacientes%2C%20respectivamente%20(veja%20o%20item%202.%20RESULTADOS%20DE%20EFIC%26%23xC1%3BCIA).%20Para%20o%20HPS%2C%20foram%20registrados%20apenas%20os%20eventos%20adversos%20graves%20bem%20como%20mialgia%2C%20aumento%20de%20transaminases%20s%26%23xE9%3Bricas%20e%20CK.%20Para%20o%204S%2C%20foram%20registrados%20todos%20os%20eventos%20adversos%20listados%20abaixo.%20Se%20as%20taxas%20de%20incid%26%23xEA%3Bncia%20para%20sinvastatina%20fossem%20menores%20ou%20similares%20%26%23xE0%3Bs%20do%20placebo%20nestes%20estudos%2C%20e%20houvesse%20eventos%20de%20relato%20espont%26%23xE2%3Bneo%20razoavelmente%20com%20rela%26%23xE7%3B%26%23xE3%3Bo%20causal%20similar%2C%20esses%20eventos%20adversos%20seriam%20categorizados%20como%20%26%23x201C%3Braros%26%23x201D%3B.%3Cbr%3E%0ANo%20estudo%20HPS%20(veja%20o%20item%202.%20RESULTADOS%20DE%20EFIC%26%23xC1%3BCIA)%20envolvendo%2020.536%20pacientes%20tratados%20com%2040%20mg%2Fdia%20de%20sinvastatina%20(n%20%3D%2010.269)%20ou%20placebo%20(n%20%3D%2010.267)%2C%20os%20perfis%20de%20seguran%26%23xE7%3Ba%20foram%20compar%26%23xE1%3Bveis%20entre%20os%20pacientes%20tratados%20com%20sinvastatina%20e%20os%20pacientes%20que%20receberam%20placebo%20durante%20uma%20m%26%23xE9%3Bdia%20de%205%20anos%20de%20estudo.%20As%20frequ%26%23xEA%3Bncias%20de%20descontinua%26%23xE7%3B%26%23xE3%3Bo%20por%20eventos%20adversos%20foram%20compar%26%23xE1%3Bveis%20(4%2C8%25%20em%20pacientes%20tratados%20com%20sinvastatina%20em%20compara%26%23xE7%3B%26%23xE3%3Bo%20com%205%2C1%25%20em%20pacientes%20que%20receberam%20placebo).%20A%20incid%26%23xEA%3Bncia%20de%20miopatia%20foi%20%26lt%3B%200%2C1%25%20em%20pacientes%20tratados%20com%20sinvastatina%2040mg.%20N%26%23xED%3Bveis%20elevados%20de%20transaminases%20(%26gt%3B%203X%20LSN%20confirmados%20por%20um%20novo%20teste)%20ocorreram%20em%200%2C21%25%20(n%20%3D%2021)%20dos%20pacientes%20tratados%20com%20sinvastatina%20em%20compara%26%23xE7%3B%26%23xE3%3Bo%20com%200%2C09%25%20(n%20%3D%209)%20dos%20pacientes%20que%20receberam%20placebo.%3Cbr%3E%0ANo%20estudo%204S%20(veja%20o%20item%202.%20RESULTADOS%20DE%20EFIC%26%23xC1%3BCIA)%20envolvendo%204.444%20pacientes%20que%20receberam%2020-40mg%2Fdia%20de%20sinvastatina%20(n%20%3D%202.221)%20ou%20placebo%20(n%20%3D%202.223)%2C%20os%20perfis%20de%20seguran%26%23xE7%3Ba%20e%20tolerabilidade%20foram%20compar%26%23xE1%3Bveis%20entre%20os%20grupos%20de%20tratamento%20durante%20a%20mediana%20de%205%2C4%20anos%20do%20estudo.%3Cbr%3E%0AAs%20frequ%26%23xEA%3Bncias%20de%20eventos%20adversos%20s%26%23xE3%3Bo%20classificadas%20de%20acordo%20com%20as%20seguintes%20categorias%3A%20Muito%20comum%20(%26gt%3B%201%2F10)%2C%20Comum%20(%26%23x2265%3B%201%2F100%2C%20%26lt%3B%201%2F10)%2C%20Incomum%20(%26%23x2265%3B%201%2F1000%2C%20%26lt%3B%201%2F100)%2C%20Raro%20(%26%23x2265%3B%201%2F10.000%2C%20%26lt%3B%201%2F1000)%2C%20Muito%20Raro%20(%26lt%3B%201%2F10.000)%2C%20Desconhecido%20(n%26%23xE3%3Bo%20puderam%20ser%20estimados%20a%20partir%20dos%20dados%20dispon%26%23xED%3Bveis).%3C%2Fp%3E%0A%3Cp%3EDist%26%23xFA%3Brbios%20do%20sangue%20e%20do%20sistema%20linf%26%23xE1%3Btico%3A%3Cbr%3E%0ARaro%3A%20anemia.%3Cbr%3E%0ADist%26%23xFA%3Brbios%20do%20sistema%20nervoso%3A%3Cbr%3E%0ARaro%3A%20cefaleia%2C%20parestesia%2C%20tontura%2C%20neuropatia%20perif%26%23xE9%3Brica.%3Cbr%3E%0AMuito%20raro%3A%20perda%20de%20mem%26%23xF3%3Bria.%3Cbr%3E%0ADist%26%23xFA%3Brbios%20respirat%26%23xF3%3Brios%2C%20tor%26%23xE1%3Bcicos%20e%20do%20mediastino%3A%3Cbr%3E%0ADesconhecido%3A%20doen%26%23xE7%3Ba%20pulmonar%20intersticial.%3Cbr%3E%0ADist%26%23xFA%3Brbios%20gastrintestinais%3A%3Cbr%3E%0ARaro%3A%20constipa%26%23xE7%3B%26%23xE3%3Bo%2C%20dor%20abdominal%2C%20flatul%26%23xEA%3Bncia%2C%20dispepsia%2C%20diarreia%2C%20n%26%23xE1%3Busea%2C%20v%26%23xF4%3Bmito%2C%20pancreatite.%3Cbr%3E%0ADist%26%23xFA%3Brbios%20da%20pele%20e%20do%20tecido%20subcut%26%23xE2%3Bneo%3A%3Cbr%3E%0ARaro%3A%20erup%26%23xE7%3B%26%23xE3%3Bo%20cut%26%23xE2%3Bnea%2C%20prurido%2C%20alopecia.%3Cbr%3E%0ADist%26%23xFA%3Brbios%20musculoesquel%26%23xE9%3Bticos%20e%20do%20tecido%20conjuntivo%3A%3Cbr%3E%0ARaro%3A%20miopatia*%2C%20rabdomi%26%23xF3%3Blise%20(veja%20o%20item%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES)%2C%20mialgia%2C%20c%26%23xE3%3Bibras%20musculares.%20*Em%20um%20estudo%20cl%26%23xED%3Bnico%2C%20a%20miopatia%20ocorreu%20comumente%20em%20pacientes%20tratados%20com%20a%20sinvastatina%2080%20mg%2Fdia%20em%20compara%26%23xE7%3B%26%23xE3%3Bo%20com%20pacientes%20tratados%20com%2020%20mg%2Fdia%20(1%2C0%20%25%20versus%200%2C02%20%25%2C%20respectivamente).%3Cbr%3E%0ADesconhecido%3A%20tendinopatia%2C%20algumas%20vezes%20complicada%20pela%20ruptura%3B%20miopatia%20necrotizante%20imunomediada%20(MNIM).**%3Cbr%3E%0A**Houve%20relatos%20muito%20raros%20de%20miopatia%20necrotizante%20imunomediada%20(MNIM)%2C%20uma%20miopatia%20autoimune%2C%20durante%20ou%20ap%26%23xF3%3Bs%20tratamento%20com%20algumas%20estatinas.%20A%20MNIM%20%26%23xE9%3B%20clinicamente%20caracterizada%20por%3A%20fraqueza%20muscular%20proximal%20persistente%20e%20creatina%20quinase%20s%26%23xE9%3Brica%20elevada%2C%20que%20persistem%20mesmo%20com%20a%20descontinua%26%23xE7%3B%26%23xE3%3Bo%20do%20tratamento%20com%20estatina%3B%20bi%26%23xF3%3Bpsia%20muscular%20mostrando%20miopatia%20necrotizante%20sem%20inflama%26%23xE7%3B%26%23xE3%3Bo%20significativa%3B%20melhoria%20com%20agentes%20imunossupressores%20(veja%20o%20item%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Miopatia%2FRabdomi%26%23xF3%3Blise).%3Cbr%3E%0ADist%26%23xFA%3Brbios%20do%20sistema%20reprodutivo%20e%20da%20mama%3A%3Cbr%3E%0ADesconhecido%3A%20disfun%26%23xE7%3B%26%23xE3%3Bo%20er%26%23xE9%3Btil.%3Cbr%3E%0ADist%26%23xFA%3Brbios%20gerais%20e%20condi%26%23xE7%3B%26%23xF5%3Bes%20no%20local%20de%20administra%26%23xE7%3B%26%23xE3%3Bo%3A%3Cbr%3E%0ARaro%3A%20astenia.%3Cbr%3E%0ADist%26%23xFA%3Brbios%20hepatobiliares%3A%3Cbr%3E%0ARaro%3A%20hepatite%2Ficter%26%23xED%3Bcia%3B%3Cbr%3E%0AMuito%20raro%3A%20insufici%26%23xEA%3Bncia%20hep%26%23xE1%3Btica%20fatal%20e%20n%26%23xE3%3Bo%20fatal.%3Cbr%3E%0ADist%26%23xFA%3Brbios%20psiqui%26%23xE1%3Btricos%3A%3Cbr%3E%0AMuito%20raro%3A%20ins%26%23xF4%3Bnia%3B%3Cbr%3E%0ADesconhecido%3A%20depress%26%23xE3%3Bo.%3Cbr%3E%0AUma%20s%26%23xED%3Bndrome%20aparente%20de%20hipersensibilidade%20tem%20sido%20relatada%20raramente%2C%20a%20qual%20incluiu%20algumas%20das%20caracter%26%23xED%3Bsticas%20a%20seguir%3A%20angioedema%2C%20s%26%23xED%3Bndrome%20semelhante%20a%20l%26%23xFA%3Bpus%2C%20polimialgia%20reum%26%23xE1%3Btica%2C%20dermatomiosite%2C%20vasculite%2C%20trombocitopenia%2C%20eosinofilia%2C%20velocidade%20de%20sedimenta%26%23xE7%3B%26%23xE3%3Bo%20eritrocit%26%23xE1%3Bria%20(VHS)%20aumentada%2C%20artrite%2C%20artralgia%2C%20urtic%26%23xE1%3Bria%2C%20fotossensibilidade%2C%20febre%2C%20rubor%2C%20dispneia%20e%20mal-estar.%3Cbr%3E%0AInvestiga%26%23xE7%3B%26%23xF5%3Bes%3A%3Cbr%3E%0ARaro%3A%20aumentos%20de%20transaminases%20s%26%23xE9%3Bricas%20(alanina%20aminotransferase%2C%20aspartato%20aminotransferase%2C%20%26%23x3B3%3B-glutamil%20transpeptidase)%20(veja%20o%20item%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES%2C%20Efeitos%20hep%26%23xE1%3Bticos)%2C%20n%26%23xED%3Bveis%20elevados%20de%20fosfatase%20alcalina%3B%20aumento%20dos%20n%26%23xED%3Bveis%20s%26%23xE9%3Bricos%20de%20CK%20(veja%20o%20item%205.%20ADVERT%26%23xCA%3BNCIAS%20E%20PRECAU%26%23xC7%3B%26%23xD5%3BES).%3Cbr%3E%0ADesconhecido%3A%20foi%20reportado%20aumento%20dos%20n%26%23xED%3Bveis%20de%20HbA1c%20e%20glicose%20s%26%23xE9%3Brica%20de%20jejum%20com%20estatinas%2C%20incluindo%20sinvastatina.%3Cbr%3E%0AHouve%20raros%20relatos%20p%26%23xF3%3Bs-comercializa%26%23xE7%3B%26%23xE3%3Bo%20de%20disfun%26%23xE7%3B%26%23xE3%3Bo%20cognitiva%20(por%20exemplo%2C%20perda%20de%20mem%26%23xF3%3Bria%2C%20esquecimento%2C%20amn%26%23xE9%3Bsia%2C%20deteriora%26%23xE7%3B%26%23xE3%3Bo%20da%20mem%26%23xF3%3Bria%2C%20confus%26%23xE3%3Bo)%20associados%20com%20o%20uso%20de%20estatinas%2C%20incluindo%20sinvastatina.%20Os%20relatos%20geralmente%20n%26%23xE3%3Bo%20s%26%23xE3%3Bo%20graves%20e%20s%26%23xE3%3Bo%20revers%26%23xED%3Bveis%20com%20a%20descontinua%26%23xE7%3B%26%23xE3%3Bo%20da%20estatina%2C%20com%20tempos%20vari%26%23xE1%3Bveis%20para%20o%20in%26%23xED%3Bcio%20dos%20sintomas%20(de%201%20dia%20a%20anos)%20e%20resolu%26%23xE7%3B%26%23xE3%3Bo%20dos%20sintomas%20(mediana%20de%203%20semanas).%3Cbr%3E%0AOs%20seguintes%20eventos%20adversos%20adicionais%20foram%20relatados%20com%20algumas%20estatinas%3A%3Cbr%3E%0A-dist%26%23xFA%3Brbios%20do%20sono%2C%20incluindo%20pesadelos%3B%3Cbr%3E%0A-disfun%26%23xE7%3B%26%23xE3%3Bo%20sexual%3B%3Cbr%3E%0A-Diabetes%20mellitus%3A%20frequ%26%23xEA%3Bncia%20depende%20da%20presen%26%23xE7%3Ba%20ou%20aus%26%23xEA%3Bncia%20de%20fatores%20de%20risco%20(glicose%20no%20sangue%20em%20jejum%20%26%23x2265%3B%205%2C6%20mmol%2FL%2C%20IMC%26gt%3B%2030%20kg%2Fm2%2C%20altos%20n%26%23xED%3Bveis%20de%20triglicer%26%23xED%3Bdeos%2C%20hist%26%23xF3%3Brico%20de%20hipertens%26%23xE3%3Bo).%3Cbr%3E%0APopula%26%23xE7%3B%26%23xE3%3Bo%20pedi%26%23xE1%3Btrica%3Cbr%3E%0AEm%20um%20estudo%20de%2048%20semanas%20envolvendo%20crian%26%23xE7%3Bas%20e%20adolescentes%20(meninos%20Tanner%20Stage%20II%20e%20acima%20e%20meninas%20com%20pelo%20menos%20um%20ano%20de%20p%26%23xF3%3Bs-menarca)%20entre%2010-17%20anos%20de%20idade%20com%20hipercolesterolemia%20familiar%20heterozig%26%23xF3%3Btica%20(n%20%3D%20175)%2C%20no%20geral%2C%20o%20perfil%20de%20seguran%26%23xE7%3Ba%20e%20tolerabilidade%20do%20grupo%20tratado%20com%20sinvastatina%20foi%20semelhante%20ao%20do%20grupo%20de%20tratados%20com%20placebo.%20Os%20efeitos%20a%20longo%20prazo%20no%20desenvolvimento%20f%26%23xED%3Bsico%2C%20intelectual%20e%20sexual%20s%26%23xE3%3Bo%20desconhecidos.%20N%26%23xE3%3Bo%20h%26%23xE1%3B%20dados%20suficientes%20dispon%26%23xED%3Bveis%20atualmente%20ap%26%23xF3%3Bs%20um%20ano%20de%20tratamento.%3C%2Fp%3E%0A%3Cp%3EEm%20casos%20de%20eventos%20adversos%2C%20notifique%20ao%20Sistema%20de%20Notifica%26%23xE7%3B%26%23xF5%3Bes%20em%20Vigil%26%23xE2%3Bncia%20Sanit%26%23xE1%3Bria%20%26%23x2013%3B%20NOTIVISA%2C%20dispon%26%23xED%3Bvel%20em%20www.anvisa.gov.br%2Fhotsite%2Fnotivisa%2Findex.htm%2C%20ou%20para%20a%20Vigil%26%23xE2%3Bncia%20Sanit%26%23xE1%3Bria%20Estadual%20ou%20Municipal.%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Cp%3E10.%20SUPERDOSE%3C%2Fp%3E%0A%3Cp%3EForam%20relatados%20poucos%20casos%20de%20superdose%3B%20a%20dose%20m%26%23xE1%3Bxima%20ingerida%20foi%20de%203%2C6%20g.%20Todos%20os%20pacientes%20recuperaram-se%20sem%20sequelas.%20N%26%23xE3%3Bo%20h%26%23xE1%3B%20tratamento%20espec%26%23xED%3Bfico%20para%20a%20superdose%3B%20nesses%20casos%2C%20devem%20ser%20adotadas%20medidas%20sintom%26%23xE1%3Bticas%20e%20de%20suporte.%3C%2Fp%3E%0A%3Cp%3EEm%20caso%20de%20intoxica%26%23xE7%3B%26%23xE3%3Bo%20ligue%20para%200800%20722%206001%2C%20se%20voc%26%23xEA%3B%20precisar%20de%20mais%20orienta%26%23xE7%3B%26%23xF5%3Bes.%3C%2Fp%3E%0A%3Cp%3E%26%23xA0%3B%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Ch2%3EData%20da%20bula%3C%2Fh2%3E%0A%3Cp%3E11%2F04%2F2019%3C%2Fp%3E%0A
- Ame
- Não
- ApresentarPrecoDePor
- Sim
- custom_label_0
- campanha
- MedicamentoControlado
- Não
- Cashback
- Não
- Antibiotico
- Não
- Generico
- Sim
Tributos e contexto fiscal
Escolha o estado para ver os tributos deste produto:
Preferência salva neste navegador; confirme o destino da operação.
NCM, CEST e tributos são referências fiscais brasileiras e podem não se aplicar em outros países.
Selecione a UF nesta seção para consultar a estimativa IBPT.
IBS/CBS: o cClassTrib acima vem do enquadramento do NCM; percentuais dependem da operação, regime, data e destino.
Outros produtos em Farmácia
Códigos de barras próximos
Produtos com o mesmo início de código (7896422…), em geral do mesmo fabricante.
PYLORIPAC IBP MEDLEY CAIXA 7 BLISTERS 28 CÁPSULAS DE LANSOPRAZOL
7896422507769
Cloridrato de Sertralina 50mg 30 Comprimidos Revestidos Genérico Medley
7896422507783
Sinvastatina 10 Mg 30 Comprimidos Medley Genérico
7896422507837
SINVASTATINA 20 MG 60 COMPRIMIDOS MEDLEY GENÉRICO
7896422507851
SINVASTATINA 80 MG 10 COMPRIMIDOS MEDLEY GENÉRICO
7896422507875
CLORIDRATO DE METFORMINA 1000 MG 30 COMPRIMIDOS MEDLEY GENÉRICO
7896422507936